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WITNESS SEMINARS: 
MEETINGS AND PUBLICATIONS 1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affiliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome 
Trust continues to fund the Witness Seminar programme via its support for 
the Centre.
The Witness Seminar is a particularly specialized form of oral history, where 
several people associated with a particular set of circumstances or events are 
invited to come together to discuss, debate, and agree or disagree about their 
memories. To date, the History of Twentieth Century Medicine Group has held 
more than 50 such meetings, most of which have been published, as listed on 
pages xi–xix. 
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been 
agreed, suitable participants are identified and invited. This inevitably leads to 
further contacts, and more suggestions of people to invite. As the organization 
of the meeting progresses, a flexible outline plan for the meeting is devised, 
usually with assistance from the meeting’s chairman, and some participants are 
invited to ‘set the ball rolling’ on particular themes, by speaking for a short 
period to initiate and stimulate further discussion.
1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.
viii
Members of the Programme Committee of the  
History of Twentieth Century Medicine Group, 2007–08
Dr Tilli Tansey – Reader in History of Modern Medical Sciences, Wellcome Trust Centre 
for the History of Medicine at UCL (WTCHM) and Chair
Sir Christopher Booth – WTCHM, former Director, Clinical Research Centre,  
Northwick Park Hospital, London
Dr Daphne Christie – Senior Research Assistant, WTCHM, and Organizing Secretary
Dr John Ford – Retired General Practitioner, Tonbridge 
Professor Richard Himsworth – former Director of the Institute of Health,  
University of Cambridge
Professor Mark Jackson – Centre for Medical History, Exeter
Professor John Pickstone – Wellcome Research Professor, University of Manchester
Dr Helga Satzinger – Reader in History of Twentieth Century Biomedicine, WTCHM
Professor Lawrence Weaver – Professor of Child Health, University of Glasgow, and 
Consultant Paediatrician in the Royal Hospital for Sick Children, Glasgow
Each meeting is fully recorded, the tapes are transcribed and the unedited 
transcript is immediately sent to every participant. Each is asked to check his 
or her own contributions and to provide brief biographical details. The editors 
turn the transcript into readable text, and participants’ minor corrections and 
comments are incorporated into that text, while biographical and bibliographical 
details are added as footnotes, as are more substantial comments and additional 
material provided by participants. The final scripts are then sent to every 
contributor, accompanied by forms assigning copyright to the Wellcome Trust. 
Copies of all additional correspondence received during the editorial process 
are deposited with the records of each meeting in Archives and Manuscripts, 
Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
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INTRODUCTION
No therapeutic drug, before or since, has captured the public imagination in the 
way that penicillin did in the years immediately following the Second World 
War. This remarkable drug had been brought to the world by the brilliant work 
of Howard Florey, Ernst Chain, Norman Heatley and their colleagues at the Sir 
William Dunn School of Pathology in Oxford at the start of the war. Thanks 
largely to the vital input of American biological, chemical and commercial 
expertise, sufficient penicillin was produced during the war to influence the 
treatment of battle wounds (and that other common cause of war casualties, 
gonorrhoea) and to provide for widespread civilian use once peace had been 
restored. It was Alexander Fleming who in 1928 had fortuitously discovered the 
remarkable antibacterial properties of a substance produced by a contaminant 
Penicillium mould, and though he failed to realize the full implications, he 
received most of the public adulation: Kevin Brown lists 172 honours showered 
upon him from all over the world between 1943 and his death in 1955.2
Penicillin transformed the treatment of many infections. High on the list of 
notorious microbial felons successfully targeted by the new drug was the golden 
staphylococcus – Staphylococcus aureus – a germ many of us carry harmlessly in our 
noses, armpits or other moist areas of the body, but which can cause devastating 
infection when given the opportunity. The vast array of disease caused by this 
archetypal bacterial pathogen ranges from boils, carbuncles and abscesses, 
through toxin-mediated conditions such as scalded skin syndrome, toxic 
shock and food poisoning, to septicaemia, wound infection and osteomyelitis. 
In the laboratory, the staphylococcus is an unpredictable tease. I can affirm 
from personal experience that, whereas Gram-negative bacilli like Escherichia 
coli generally respond reliably and reproducibly to exposure to antibiotics in 
in vitro tests, no two strains of staphylococci seem to behave the same, and the 
responses of individual strains often appear maddeningly irreproducible. It may 
be no coincidence that Fleming made his celebrated discovery of penicillin while 
engaged in a frustrating study of the properties of staphylococcal variants. 
Fleming, in his acceptance speech for the Nobel Prize in Physiology or Medicine, 
which he shared with Florey and Chain in 1945, warned that inappropriate use 
of penicillin might lead to the development of resistance, something that could 
2 Brown (2004): 213–17.
xxii
be readily generated in laboratory tests.3 However, when resistance to penicillin 
among strains of Staphylococcus aureus did indeed become a major problem in 
hospitals in the 1950s, the cause of the resistance was not the mutational or 
adaptive changes that Fleming had envisaged, but the selection of strains of 
staphylococci able to produce an enzyme – penicillinase (β-lactamase) – that 
had been described as early as 1940.4 It was the prevalence of strains of this type 
that, in the late 1950s and early 1960s, largely stimulated interest in developing 
semi-synthetic penicillins (and related cephalosporins) that were able to 
withstand the enzyme. The first fruit of this research, methicillin, was produced 
at Beecham Research Laboratories in 1959 and marketed the following year. It 
was soon followed by more active compounds, such as cloxacillin and its relatives 
(isoxazolylpenicillins), which had the additional advantage of being absorbed 
orally. These events are well documented in an earlier Witness Seminar.5 
As described during the present Witness Seminar, resistance of Staphylococcus 
aureus to methicillin was detected within a year of the antibiotic appearing on 
the market. This time Fleming’s prediction was closer to being realized, since 
the resistance was not associated with β-lactamase or any other drug-destroying 
enzyme, but was eventually shown to result from a mutational change in 
the proteins attacked by penicillin, which allowed the bacteria to avoid the 
consequences of exposure to the drug. These variant strains became known as 
‘methicillin-resistant Staphylococcus aureus’, or ‘MRSA’. However, methicillin 
has long been superseded by the more active derivatives and is no longer 
marketed. Since these strains nowadays usually exhibit resistance to several 
other commonly used antibacterial agents, the acronym MRSA would be better 
employed, as Professor Gordon Stewart notes in his introductory statement, to 
refer to them as ‘multi-resistant Staphylococcus aureus’. 
Alarmingly, it soon became clear that methicillin resistance extended to all members 
of the expanding β-lactam antibiotic family, and this has remained true as newer 
compounds of this type have been developed. At first the resistance was not perceived 
to be a major problem: it appeared to be uncommon and seemed to require unusual, 
non-physiological conditions in laboratory tests – reduced incubation temperature 
or an abnormally high salt concentration – for full expression of the resistance 
phenotype, leading to dispute about the clinical significance of the phenomenon. 
3 Freely available at http://nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf (visited 
30 January 2008).
4 Abraham and Chain (1940).
5 Tansey and Reynolds (eds) (2000).
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However, during the late 1960s and beyond, the true extent of the problem became 
clear in Britain and many other countries.
MRSA has now been around for close on half a century, but has only lately become 
a cause of deep public anxiety, especially among those faced with admission to 
hospital. The concern has been fuelled by frequently hyperbolic reports in the 
media (sometimes by microbiologists who ought to know better), which have 
mythologized the organism as a ‘superbug’, whereas it is a conventional pathogen 
merely responding to the intense selective pressure of antibiotic usage through a 
classic Darwinian survival process. This is not to diminish its importance. MRSA 
– just like its parent, methicillin-sensitive Staphylococcus aureus – is a formidable 
micro-organism capable of deploying a battery of virulence factors to cause serious, 
even life-threatening, disease. Its special significance lies in the reduced options 
for treatment open to the prescriber. Many preferred choices are excluded by the 
resistance profile (and valuable time lost identifying appropriate alternatives) though, 
contrary to popular belief, there are usually several drugs other than the commonly 
preferred vancomycin to which the organism remains susceptible.
After nearly 50 years, the time is ripe for recording personal experiences of the 
many fascinating twists and turns that the story of MRSA has undergone. Not 
that the story is yet complete, as this Witness Seminar amply demonstrates: the 
expert participants often found themselves tempted to turn the discussion to 
current, rather than historical problems. This is no bad thing, since the present 
will quickly become ‘history’ and it is as useful to have a record of contemporary 
as well as past concerns. Moreover, the ‘story so far’, in all its multi-faceted 
aspects, clearly emerged from a very lively discussion with the sort of passion that 
only those who have to live with the problem during their professional lives can 
provide. That is the great strength of these seminars, which continue to provide 
an invaluable record of key topics in recent medical history. As always, we are 
immensely grateful to Tilli Tansey, Lois Reynolds and their colleagues and to 
Robert Bud who was instrumental in bringing together a representative group 
of highly articulate experts to record for posterity their thoughts, reminiscences 
and comments on an important medical event of our times.
David Greenwood  
University of Nottingham
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Dr Tilli Tansey: Good afternoon, ladies and gentlemen, and welcome to this 
Witness Seminar on the history of MRSA. Our Chairman today is Robert Bud, 
who also chaired an earlier meeting on post-penicillin antibiotics.1 He is a well-
known historian of modern medical sciences at the Science Museum, London, 
and he is about to publish a new book called Penicillin: Triumph and tragedy, 
which I notice today is already on the Amazon website, to be published in 
January 2007.2 So without further ado, I will hand over to Robert.
Dr Robert Bud: Thank you very much, Tilli. It is a great pleasure to welcome 
so many people who have been my mentors and advisers, and people whose 
work I have read and haven’t yet had the chance to meet. I think the key thing 
today is not to feel that you have to be called upon, but rather, spontaneously 
be moved to speak. I am familiar with the possible contributions of a few here, 
so please do contribute. 
We have a series of subject-based headings [in the programme] and I suspect we 
will move rapidly between periods.3 Don’t be embarrassed about that. If you feel 
that you have a contribution about the 1960s or about the 1990s, then don’t feel 
that if the conversation seems to be about the 1960s, that you are not allowed to 
talk about the 1990s. On the other hand, I think that we do want to keep the 
conversation broadly historical, so while the contemporary issues, particularly 
the opportunities and challenges of the year 2006, will be important, and a part 
of the historical debate, I think it will be a shame if these dominate, because 
there are so many other venues where particular contemporary issues are being 
debated. 
In a sense, my contribution to this was above all to discover Gordon Stewart, 
author of the book, The Penicillin Group of Drugs, which was published in 
1965, where the story of the discovery of methicillin-resistant Staphylococcus 
aureus (MRSA) was first outlined.4 I think we are very privileged that Gordon is 
willing to kick off and give a brief introduction.
1 See Tansey and Reynolds (eds) (2000).
2 Bud (2007).
3 Witness Seminar Programme, 11 July 2006: Historical Introduction; Origins and Early History: Discovery/
encounter with MRSA; Mode of transmission; Scottish perspective; Geography of spread; Epidemiology and 
surveillance; Science: Differentiation of pathogenic and carrier strains; Mechanisms of resistance; Genetics, 
organism and host; Pharmaceutical response; Surgery: Changing attitudes to infection; Epidemiology: 
Distribution and clinical pattern of infections; Staph. Reference Laboratories; Hospital response: Nursing; 
Problems of control: chemotherapy; new drugs; Public response/1990s.
4 Stewart (1965).
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Professor Gordon Stewart: Thank you, Robert, I am very glad to have been 
discovered; I thought that I was obsolete. That could still be true, as will be 
apparent in our discussions. 
But I would prefer to remind you that we are here mainly because of non-
obsolescent discoveries, like the new biosynthetic penicillins developed in 1958 
and 1959 by the Beecham group of research workers.5 We are fortunate in having 
Dr Sutherland from that talented team here with us today. Unfortunately, 
others have died since the last seminar in 1998.6 There are many others who 
were invited, but for other reasons cannot be present. We certainly must pay 
tribute to their memory, because without them and all those drugs, especially 
methicillin, there would be no methicillin-resistant Staph. aureus (MRSA), now 
promoted to international status as the notorious multidrug-resistant Staph. 
aureus (also MRSA) and epidemic MRSA (EMRSA). Methicillin itself is also 
obsolete, except as an infallible laboratory identifying marker and label for this 
unusual and terrifying organism. 
5 See Tansey and Reynolds (eds) (2000): 5, 28, 31, 37, 63.
6 Peter Doyle (1921–2004), David M Brown, John Nayler (1927–93) and Eric Knudsen (1921–2001) of 
Beecham; Joseph Anthony Porteus Trafford (Baron Trafford of Falmer from 1987) (1932–89) and Arthur 
Henry Douthwaite (1896–1974) at Guy’s; and my colleague Richard J Holt (1920–2005) at Queen Mary’s 
Hospital. See biographical notes. See also Rolinson (1998).
Figure 1: Dr Frank Batchelor and Dr Peter Doyle, two of the original members 
of the Beecham group of research workers, at the 1998 Witness Seminar,  
‘Post Penicillin Antibiotics’.
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It wasn’t terrifying to begin with. In 1961 when the first strains were isolated, they 
didn’t seem to matter very much.7 Essentially, they were commensal inhabitants 
of nostrils and skin flexures, which spread without doing much harm – until an 
outbreak occurred and spread with amazing rapidity within one hospital.8 There 
were two hospitals in London using methicillin in 1959/60, Guy’s and Queen 
Mary’s, Carshalton, where about 40 children became infected quickly.9 Even so, 
it was mainly a commensal and superficial infection, until we had one fatal case, 
who died with fulminating septicaemia, confirmed at post mortem as a group 
III strain of MRSA. 
Fortunately, we put this strain on file in 1961, followed by a second from an 
outbreak in 1962 with another death. This put a different complexion on it, 
because other people reported similar incidents and put similar strains on file 
and attracted attention under various headings. It wasn’t just the fact that it 
caused a few severe cross-infections. It was also the fact that it was a very new 
kind of organism and many of you who are here today must know much more 
than I do about this, especially Graham Ayliffe, who will be able to tell you more 
about it.10 But what we did find out then was that this was an organism, which 
in colonial characteristics, in molecular structure and in other ways, appeared to 
be very different – Mark Richmond might speak about that. It had a different 
kind of structure altogether. It wasn’t like the ordinary Staph. aureus, it seemed 
to be primitive. 
During the first outbreak, we found that it could revert very quickly to a 
primitive form, rather like L-forms which could become syncytial without a 
cell wall as a boundary. There was no way of saying this could be linked to 
RNA and chromosomes, it grew all over the plates, and in fact Mark Richmond 
commented later that it didn’t seem to be chromosomal. He didn’t at that 
time, I think, say for sure that it was episomal or extrachromosomal. However, 
the Americans and the Japanese – especially Keiichi Hiramatsu in Tokyo and 
Richard Roberts at Cornell, Richard Proctor in Wisconsin and a few others – 
found later in the 1990s that there was a chromosomal factor after all.11 DNA 
was in the picture, as it is in most things. That factor, the mecA and allied genes, 
7 Jevons (1961).
8 Stewart and Holt (1963).
9 Knox (1960); Stewart et al. (1960).
10 See page 7.
11 Hanifah and Hiramatsu (1994); Roberts et al., Tri-State MRSA Collaborative Study Group (2000).
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is now known to be responsible for the virulence, especially in septicaemic and 
surgical infections, because these are the biggest problems.12 There’s no point 
going into the detail of all that now, although the detail is fascinating and we 
will hear more about it later. 
In other ways, the challenge is largely ecological. The staphylococcus is an 
inhabitant of skin flexures and found in different situations, in hospitals, 
especially in theatres, and often in the noses of doctors, nurses and others. 
It took a long time before people would admit that this was something that 
should be dealt with. S D Elek and others at St George’s Hospital Medical 
School, London, were very quick on the draw there, and they tried to devise 
ways of preventing the spread and, to some extent, were successful.13 But MRSA 
continued to spread in a series of small outbreaks, firstly in Europe and then 
in South Africa, Egypt and a few other countries. And then a strange thing 
happened. In 1964, Jerzy Borowski in Bialystok, eastern Poland, found that 
this was a strain that had existed before any methicillin was used.14 We had been 
using methicillin, but he hadn’t, nor had some of the Russians nearby, although 
shortly after that they got hold of some, goodness knows how. Then we found 
that the same kind of resistance, complete with fatal cases, was occurring in 
situations with methicillin and the newer penicillins, like the isoxazolyls and so 
on, that had not been in use. So this was a new clue that’s been followed through 
and shows that we are now dealing with something that is chromosomal, but 
also environmental and is extra chromosomal, but not closely related to therapy, 
as further forms of resistance are.15 The overseeing of multi-resistance is hard 
enough, and is very widespread, but fortunately, we have vancomycin, complete 
with a new acronym, VRSA (vancomycin-resistant Staphylococcus aureus), as 
well. The only drugs that seem to be controlling this – and we knew this back 
12 Hurlimann-Dalel et al. (1992). 
13 See, for example, Stern and Elek (1955); Elek and Conen (1957); Elek and Fleming (1960). Elek also 
contributed the Elek-Ouchterlony gel diffusion method for detection of anti-alpha haemolysin and anti-
leucocidin. Elek (1948a and b); Ouchterlony (1948).
14 Borowski et al. (1964, 1967); Borowski (1988a and b).
15 Professor Gordon Stewart wrote: ‘After publication of the success of methicillin in 1960, it was used 
more extensively and more freely in major centres in the US than anywhere else through the 1970s. Tens of 
thousands of strains of Staph. aureus were tested, but there were very few isolations of MRSA, no reports of 
indigenous outbreaks until the 1980s and no major incidents until the 1990s when strains with the mecA 
gene and other markers of virulence were identified in strains isolated from severe and fatal cases.’ Note on 
draft transcript, 8 December 2007.
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in 1960 – were the quinoline-related amides, such as quinacillin, and, more 
recently, daptomycin.16 Professor Emmerson might say something about that. 
There are other drugs in use, including, oddly enough, some new twisted 
structures linking a quinoxolidone structure to penicillins and small peptides.17 
Now, both of these have turned up historically, but there were many other 
things that we had in mind when designing this Witness Seminar, a follow-up 
to the earlier meeting in 1998, also supported by the Wellcome Trust, when 
MRSA was not such a problem, although spreading rapidly.18 The meeting 
today is a sequel to that, which Robert Bud steered so well then and now. You 
are the witnesses to speak about these different aspects. We are hoping to cover 
all the main topics, and that’s saying something, including ecological, genetic, 
microbiological, and administrative issues – not least administrative, because, to 
a large extent, the problem is one of full hospitals, over-full bed lists, transfer of 
cases between wards and this kind of thing. The human story is made very sad 
by all the incidents that are linked to these. 
Bud: Thank you very much, Gordon. I think we have some people here who 
have been engaged with MRSA since the very first experience of it. Graham 
Ayliffe has very kindly agreed to kick off for us, while people are thinking about 
what they can say.
Professor Graham Ayliffe: We ought to start by saying a few words about 
the situation before methicillin appeared. Superbugs have long been a cause 
of hospital infection. Hospital gangrene, pyaemia and erysipelas caused by 
haemolytic streptococci and Staph. aureus were responsible for many hospital 
outbreaks in the nineteenth century and had a high mortality. When penicillin 
came along we thought this was the end of staphylococcus as an important 
cause of hospital infection. But, as you all know, resistant strains soon appeared 
and Mary Barber described them at the Hammersmith Hospital, London, in 
the 1940s.19 There were other reports in the US, and particularly in Australia.20 
16 See, for example, Sato et al. (1967); Gedney and Lacey (1982); Maple et al. (1991); Sheldrick 
et al. (1995).
17 Wasserman (2006).
18 See Tansey and Reynolds (eds) (2000).
19 Mary Barber found that 38 per cent of strains of Staphylococcus aureus were penicillin-resistant in 1947, 
increasing the following year. See Barber (1947).
20 See Rountree and Barbour (1950, 1951). 
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What was very important at this time was the introduction of staphylococcal 
‘phage-typing, which enabled us to investigate these outbreaks.21 And then the 
particular virulent strain of 80/81 appeared, I think, first of all in Australia, 
described by Phyllis Rountree.22 This strain caused a lot of superficial and severe 
sepsis, mainly in maternity units, causing severe sepsis in babies, furunculosis 
and carbuncles in staff and abscesses in nursing mothers. Then, this tended to 
disappear over the 1950s.
21 Blair and Williams (1961); Hartstein et al. (1995). See also Cox et al. (1995). See Glossary, 
page 125; see also Figure 2. 
22 Rountree and Freeman (1955). See Appendix 2, page 82. 
Figure 2: Bacteriophage-typing, c. 2003: three Petri dishes showing different 
strains of S. aureus tested at 100 × Routine Test Dilution (RTD), giving varying 
patterns of lysis with 27 ‘phages (including 23 ‘phages of the International Typing 
Set and 4 experimental ‘phages), as shown in the reference grid. From slides 
provided by Dr Angela kearns.
 group I (TSST-1)
 group II (ETA & ETB)
 group III (SEA without TSST-1)
 group V (SEB)
 miscellaneous (95 with SEC)
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But in surgical wards there were other problem epidemic strains. These were 
‘phage group III strains, not so virulent as the 80/81, and really were the start 
of most of our present problems with resistant strains.23 They were virtually all 
resistant to tetracycline, but there were strains acquiring increasing resistance to 
erythromycin, novobiocin, neomycin, etc.24 We ended up having some strains 
which were resistant to most of the available antibiotics. 
Before going on, I should mention the large amount of work done in the 1940s 
to the 1960s, which formed the basis of all our knowledge of staphylococcal 
cross-infection and prevention. Among these, Robert Williams, Reggie Shooter 
and Robert Blowers were prominent and most of this story is summarized in 
a comprehensive book.25 There were others, such as Owen Lidwell, Edward 
23 Professor Graham Ayliffe wrote: ‘Staphylococcal bacteriophages are viruses which lyse [destroy] specific 
strains of Staphylococcus aureus. A set of different bacteriophages [see Appendix 2] is applied to strains of 
staphylococci and varying patterns of lysis are obtained with different strains, e.g. 80/81, 6/7/53/75/77.’ 
E-mail to Mrs Lois Reynolds, 3 December 2007. See Shooter et al. (1958); Williams (1959); Parker and 
Jevons (1963); Parker et al. (1974).
24 Shanson (1981).
25 Williams et al. (1960, 1966).
Figure 3: Directors of the PHLS at R E O Williams’ retirement in 1985.  
Seated: Sir Graham Wilson (1941–63); standing L to R: Dr R E O Williams (Staphylococcus 
and Streptococcus Reference Laboratory, 1949–60; PHLS, 1973–81); Dr J E M Whitehead 
(1981–85); Dr Joe Smith (1985–92). 
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Lowbury, Tom Parker and Bill Noble, who were very much involved in these early 
days in describing the carriage sites (noses, perineum) and the heavy dispersers of 
staphylococci; all these studies were done before the emergence of MRSA.26 
Initially, I was involved at Bristol in the mid-1950s with William Gillespie 
on the control of wound outbreaks and although isolation was well accepted 
at this stage, we were concerned with preventing infection in wards where no 
isolation was possible.27 Topical antiseptics and antibiotics, such as neomycin 
and chlorhexidine, were applied to noses and wounds, plus some environmental 
improvements, such as sterilization of blankets, etc. We found in those days 
that a single measure by itself was very unlikely to be successful; also if you 
removed an infected patient from the open ward, the outbreak tended to go 
away. But by 1960, although we had some measure of control, this was a period 
of disenchantment with antibiotics, and in those days only these highly toxic 
antibiotics (vancomycin and ristocetin) were available to treat these highly-
resistant strains. With the introduction of methicillin in 1960 – marketed as 
‘Celbenin’ – many believed that this was the end of the resistant staphylococcus 
and Ernst Chain was the one who said ‘no more resistance problems, methicillin 
is the answer’.28 Mary Barber was one of those who disagreed with him, quite 
rightly, that this wasn’t the answer to the problem.29 Patricia Jevons, working 
at the Central Public Health Laboratory in Colindale, as we have already 
26 For further details, see Tansey and Reynolds (eds) (2000).
27 Professor Graham Ayliffe wrote: ‘In the Bristol Royal Infirmary [Gillespie et al. (1961)] at that time, noses 
and the perineum were recognized as important carriage sites, but major sources were usually the dangerous 
spreaders, who became known as dispersers. These dispersers were associated with heavily discharging 
wounds, pneumonia or generalized dermatitis and were identified by Ronald Hare and others [Hare and 
Thomas (1956)]. Bill Noble and R Davies made the important discovery that staphylococci were spread 
on skin scales [Davies and Noble (1962)]. We often found that spread could occur from hidden sources 
such as bedsores and outbreaks usually ceased when a disperser was removed from the ward.’ Note on draft 
transcript, 9 January 2007.
28 Ernst Chain quote, personal communication to Mary Barber, recalled by Professor Graham Ayliffe. See 
also Knudsen and Rolinson (1960); Rolinson et al. (1960).
29 Dr Mary Barber was influential in formulating an antibiotic policy for the Hammersmith Hospital in 
1958, along with representatives of a Joint Committee of the Medical Research Council Antibiotics Clinical 
Trials Committee and the staff of the Hammersmith Hospital: Professor L P Garrod (Chair), A A C Dutton, 
P C Elmes, W Hayes, P Hugh-Jones, E J L Lowbury, J G Scadding, R Schackman and J P M Tizard. 
For their regime, see Barber et al. (1960): 12. Other guidelines on antibiotic use have been published by 
committees of the Hospital Infection Society, British Society for Antimicrobial Chemotherapy and the 
Infection Control Nurses Association in 1986, 1990, 1998 and 2006.
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Figure 4: Advertisement for ‘Celbenin’ (methicillin), 1960.
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mentioned, looked at 5000 strains, and found a methicillin-resistant strain in 
one hospital.30 I think this didn’t worry people too much, because it was really 
still quite a rare event. 
At that time, many of the investigations were done by Mary Barber. I was working 
with her from about 1960 and we were joined by Pamela Waterworth after 
Professor Garrod retired.31 Mary Barber studied a number of strains of naturally 
occurring MRSA, mainly obtained in this country, but also from Yves Chabbert 
in Paris and Kirsten Rosendal in Denmark.32 She found that they were most 
closely related to ‘phage group III strains from all these countries. They were all 
resistant to penicillin and tetracycline, but they had an unusual heterogeneous 
resistance. In the presence of low concentrations of methicillin, a heavy growth 
was obtained where there was a heavy inoculum on the plate, whereas individual 
colonies were inhibited on other parts of the medium. Mary Barber showed that 
the addition of an electrolyte of sodium chloride – 5 per cent – actually enabled 
these colonies to grow normally. It seemed likely that methicillin interfered with 
cell wall synthesis. D I Annear in Australia showed that growing these MRSA 
at 30°C would also provide a normal growth.33 We, and others, also found that 
these strains produced high levels of penicillinase, but methicillin was really 
quite resistant to penicillinase. The methicillin-resistant strains produced in the 
laboratory were different, and these naturally occurring strains were virulent, 
both in animals, and, as Professor Stewart said, in surgical patients.
Both Jerzy Borowski from Poland and Ozdem Äng from Turkey were working at 
the Hammersmith Hospital, London, at the time, and they returned home and 
started looking for MRSA. As Professor Stewart said, they both found them, 
and MRSA was also found in India this time.34 So this indicated that methicillin 
resistance wasn’t related necessarily to the clinical use of methicillin. These strains 
were also multi-resistant, which was also something that needed an explanation, 
although this further indicated that MRSA was in existence before methicillin 
was introduced, but did not explain the multi-resistance of these early strains. 
Clinical infections were increasingly reported during the 1960s, usually in large 
hospitals, mainly in Europe, Denmark, Switzerland, but strangely enough at 
30 Jevons (1961).
31 Barber (1961).
32 Barber (1964a). 
33 Annear (1968).
34 Pal and Ray (1964).
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that time, not so often in the US.35 Other penicillinase-resistant penicillins, and 
the cephalosporins, were introduced during that decade. Unfortunately, Mary 
Barber died in a road accident in 1965 and this was at an early stage of her work 
on this subject.
Bud: Is there somebody else? I know that Professor Hamilton-Miller was 
involved very early on.
Professor Jeremy Hamilton-Miller: I was at Guy’s in 1960 and, as Professor 
Stewart has just said, we were doing one of the first clinical trials there, and he 
was doing his at Carshalton [Queen Mary’s Hospital for Children].36 Professor 
Robert Knox was a consultant to Beecham’s and so we got some of the early 
specimens. I can recall the excitement of the clinical trial that was being done 
on methicillin by Arthur Douthwaite, Anthony Trafford and others.37 They had 
this magic white powder, we didn’t know its structure and we weren’t told what 
its pharmacokinetics were, we were just given the phials and told to inject it 
every six hours, a far cry from modern clinical trials, I can assure you.38 But 
35 Professor Graham Ayliffe wrote: ‘Clinical infections were increasingly reported during the 1960s. A 
prevalence survey carried out by the Hospital Infection Research Laboratory [Ayliffe (1973)] of noses 
of patients in general hospitals of the West Midlands showed an increase from 0.14 per cent of 1478 
patients in 1967 to 2.7 per cent of 2321 patients in 1970. Tom Parker from Colindale at the first major 
International Conference on Hospital Infection in Atlanta in 1970 [Parker (1971)] reported that 5 per 
cent of staphylococcal isolates in Britain were resistant and Kirsten Rosendal in Denmark reported that 
40 per cent of staphylococcal isolates from blood cultures were MRSA [Rosendal (1971)]. The increase 
in methicillin resistance was not related to an increase in usage of penase-resistant penicillins, which were 
introduced during this decade, but all showed cross-resistance with methicillin.’ Note on draft transcript, 
4 December 2007. 
36 Stewart et al. (1960).
37 Douthwaite and Trafford (1960). See Figure 4.
38 Professor Jeremy Hamilton-Miller wrote: ‘Here are some parameters, if you wish to include them: half-life: 
0.5–1 h[our]; peak level after 1g IM [intramuscular injection] ≥ 10mg/L[itre]; 40 per cent serum bound; 
C > MIC [simulated peak plasma concentration (C) to the literature value of the minimum inhibitory 
concentration (MIC)] for 3–4 hours following 1g IM.’ Note on draft transcript, 1 December 2007. Professor 
Gordon Stewart wrote: ‘I worked closely with Dr John Farquharson, an organic chemist who was the first 
Director of Research at Beecham’s. We knew that we were handling derivatives of 6-APA with insertions of 
amino- and methyl-groups which altered antimicrobial activity. The formula for BRL1241, methicillin, was 
divulged to me in confidence after we had used it to arrest an MRSA septicaemia in December 1959. The 
difference between the D(-) and L(+) epimers of BRL1060, ampicillin, was recognized by myself before the 
therapeutic trial. Although local or individual circumstances may sometimes justify exceptions, safety in 
trials should take precedence over commercial secrecy and patents.’ Note on draft transcript, 8 December 
2007. See also Stewart (1965): 120; note 144. 
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the surgeons were absolutely delighted, because patients had been dying of 
staphylococcal sepsis at the time.
I believe the first MRSA isolated was from Guildford in 1959. It was given the 
number 13136 by the people at Colindale and there were two letters published 
in the British Medical Journal, the first by Jevons, and the second by Knox.39 
The one by Jevons is always quoted, although they were actually side by side, 
because ‘J’ comes before ‘K’ in the alphabet, which I always thought was a bit 
unfair on Robert Knox. We didn’t find any MRSA at Guy’s, unlike Stewart’s 
team at Carshalton.40 I sometimes wonder about this: looking back at those 
days, we didn’t actually know that you had to reduce the temperature to 30°C 
or add salt. At that time, as Graham [Ayliffe] pointed out, that wasn’t actually 
made clear until Bob Sutherland and Mary Barber showed these requirements.41 
I wonder if those figures that Patricia Jevons came out with – that 0.05 per cent 
of strains that they looked at retrospectively were methicillin-resistant – might 
actually have been a bit higher. You certainly do miss them if you grow them at 
37°C under normal laboratory conditions. There was a tremendous controversy 
as to whether these MRSAs were hyperproducers of β-lactamase and Knox and 
Smith did quite a lot of work on that.42 I think we all came to the conclusion, 
as did Mark Richmond and his team, that this wasn’t the case. Although 
methicillin in high concentration is labile, it is not at the concentrations attained 
therapeutically.43 
Because of the heterogeneous nature of MRSA, there was considerable discussion 
as to whether you could use high doses of the cephalosporins. At one stage there 
was quite a lot of support for using cefamandole, the cephalosporin which is 
most active against Staphylococcus aureus.44 As Professor Stewart has said, the 
problem virtually disappeared, until we got to the EMRSA (epidemic MRSA) 
story, which is a bit different. 
Professor Michael Emmerson: I would like to add to Graham Ayliffe’s and 
Gordon Stewart’s points. There was a bit of a smokescreen at that time, because 
39 Anon. (1961); Jevons (1961); Knox (1961); Rolinson (1998). 
40 Stewart et al. (1960).
41 Sutherland and Rolinson (1964); Barber (1964). See also page 12.
42 Knox and Smith (1963).
43 Hamilton-Miller and Ramsay (1967).
44 Eykyn et al. (1973).
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we were still coping with ‘phage 80/81 and we wanted to know what the virulence 
or pathogenic markers were. Phyllis Rountree was in London at the time and 
was looking at cadmium and mercury resistance. I was a senior house officer 
at University College Hospital (UCH), London, with David Shanson, and Dr 
Joan Stokes employed us to take swabs from members of staff who came into the 
hospital, so we were surrounded by large numbers of nasal swabs, looking for 
tetracycline resistance. Like Jeremy [Hamilton-Miller], we didn’t know about 
the effects of temperature and salt etc., so we were looking for cadmium and 
mercury markers and the carriage rate among medical students, nurses and the 
like. We weren’t concerned with methicillin, because the numbers were so small 
at the time, we still wanted to know why ‘phage 80/81 killed young people, 
particularly young men going for clean operations without risk factors. And 
then, of course, some of these were tetracycline-resistant and not penicillin-
resistant, and so we were still very confused at that time. I think that may be 
why our eyes were off the ball, so to speak, round about the mid-1960s.
Professor Ian Phillips: I was appointed as an assistant lecturer in the Department 
of Microbiology at St Thomas’ in 1963, and one of the first jobs that I was 
given was to look at stored clinical isolates of staphylococci from within the 
hospital, by the method that has been mentioned by Graham [Ayliffe], Mary 
Barber’s salt plates.45 Eventually I trawled 15 isolates between 1961, when our 
collection started, and 1963 when I did the investigation. The interesting thing 
is that we had missed all of them in our ordinary susceptibility testing, which 
again prompts me to wonder whether, say, the original Beecham screens on 
staphylococci had missed isolates as did Patricia Jevons’. So, we had missed 
them in the laboratory. But interestingly, we had also missed them clinically, 
so there was never any question from the clinicians that what was being used 
was failing. Looking back, they were proper infections. Indeed, I remember one 
patient who had an osteomyelitis, which surprised me. I am not quite sure what 
the epidemiology of that one could have been, but that’s what it was. So, yes, we 
missed them and I wonder how far back they really go, apropos of what Gordon 
was saying. Were they selected by methicillin, or were there strains before?46
45 Barber (1964b).
46 Professor Gordon Stewart wrote: ‘Studies in the UK, US and Poland suggested that strains with natural 
resistance existed before methicillin was used in volunteers or clinically. Surprisingly, all of them formed 
constitutive penicillinase, were resistant also to tetracyclines and showed differences in cellular and colonial 
morphology.’ Note on draft transcript, 8 December 2007. See comments by Duckworth (page 22), Phillips 
(page 24) and Richmond (page 35).
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Dr Joe Selkon: I started work at the Hammersmith Hospital [London] in 1954. 
After initially working on Mycobacterium tuberculosis, including a four-year 
spell in India, I thought I had better learn about general microbiology and so 
I attached myself to Mary Barber’s tuition on the control of hospital-acquired 
infection. This was a most important education, for she taught us a fundamental 
lesson that went back to Florence Nightingale: the first requirement of a hospital 
is that it does no harm.47 I then went to work in the General Hospital, Newcastle 
upon Tyne, in 1963 and was amazed at the number of staphylococcal infections 
occurring in our surgical patients and the complete absence of adequate extract-
ventilated rooms for the isolation of patients who had multi-drug resistant 
staphylococcal infections.48 I therefore spent three or four years building isolation 
rooms attached to the wards, with extract ventilation as suggested by the work 
of Williams and Shooter.49 However, by 1968 we were in serious trouble, for 
in that year we isolated staphylococci resistant to methicillin from 37 different 
patients. Despite everything we did in following the standard requirements 
as suggested by Williams and Shooter, the situation deteriorated further and 
MRSA were increasingly isolated from surgical wounds – from 37 in 1968; 104 
in 1969; 127 in 1970; 177 in 1972; to 134 in 1973. The bacteriophage type 
75/80 predominated, being present in 84 per cent of the 177 MRSA strains 
isolated in 1972.50 Quite clearly, our hospital did not meet the requirements of 
a place that does no harm. The health authority understood our predicament 
and agreed to build a separate isolation unit of 12 beds. We started studying 
the epidemiology of methicillin-resistant staphylococcal strains throughout 
the hospital and found, surprisingly, that MRSA were circulating within the 
medical wards where no infections were occurring. However, when those 
patients were transferred into surgical wards, they went down with an MRSA 
infection after surgery and started an epidemic there. We therefore initially 
used our isolation ward to clear the presence of MRSA from our medical wards 
and screened new patients for surgery. Slowly, over two years, we succeeded in 
reducing the isolation of MRSA from all patients in this 1000-bed hospital, and 
over the following five years to 14 (0.53%) of the 26 586 admissions.51 In the 
47 Nightingale (1863): Preface. See also Reynolds and Tansey (eds) (2007b):196.
48 See Kinmonth et al. (1958). For details of the clean air theatre introduced for orthopaedic surgery in 
1960, see Reynolds and Tansey (eds) (2007a).
49 Shooter et al. (1958).
50 Selkon et al. (1980).
51 Ingham (2004).
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ten subsequent years to 1994 there were seldom more than three patients with 
MRSA infections in any one year [see Figure 5].
Unfortunately, in 1995 the Newcastle upon Tyne health authority [Trust for the 
Newcastle General Hospital] decided to use the isolation wards to treat AIDS 
patients only, since they believed MRSA were ‘no longer a problem’.52 Within 
a number of years the MRSA figures were back to those we started off with. 
I mention this as an historical picture of what happened when we used the 
appropriate facilities and the failure to adhere to these fundamental principles 
of isolation by the administration of the health service after 1994.53
Professor Sir Mark Richmond: One or two small points: I got involved when I 
returned from Denmark on 1 January 1960 to be confronted with the arrival of 
methicillin. I was interested in penicillinase and staphylococcal resistance. One 
person who hasn’t been mentioned, who I think was tremendously important but 
very much behind the scenes, was Tom Parker and his colleagues at Colindale 
[PHLS’s Staphylococcal and Streptococcal Reference Laboratory]. For a while, 
he and I spent quite a long time trying to work out whether methicillin resistance 
was actually ‘phage-affected. Because, as you know, the typing patterns in 
staphylococci reflect, to a certain extent, the sensitivity to ‘phages, but more often 
52 Professor Ian Phillips wrote: ‘It is worth noting that MRSA remained uncommon in many hospitals 
despite a lack of isolation facilities and the application only of routine infection-control procedures, until 
the advent of EMRSA. At that stage, incidence jumped from 0.2 per cent to 11 per cent of hospital isolates 
in St Thomas’ Hospital. See Phillips (1991).’ Note on draft transcript, 6 January 2007.
53 Selkon et al. (1980); Ingham (2004).
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Figure 5: Number of patients with MRSA admitted annually to the isolation 
ward at Newcastle General Hospital, 1979–94.  Adapted from Ingham (2004). 
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than not it’s the resistance patterns from ‘phage resistance. It all came to nothing, 
and nothing was ever published. But Parker, Pat Jevons and Liz Asheshov, who 
were there at the time, did a tremendous amount of work on that aspect of it.54 
One other point arising from what Graham Ayliffe said. When I was in Bristol, 
William Gillespie was the Professor of Clinical Bacteriology there, who had a lot 
of experience of treating bacterial infections both in the war and after. He always 
used to rib me, because I was so interested in resistance due to penicillinase: ‘Oh 
well, if you want to get rid of staphylococcal infections, the way you do it is to 
arrange your patients in the wards’. He saw then that the environment in which 
the patient was located was a very clear way for dealing with staphylococcal 
infections. Antibiotics could be useful, but the main thing was to give the 
patients space: isolate them and have sufficient space between the beds.
Dr David Shanson: In Europe and many parts of the UK in the 1970s there 
was generally a decline in multiple antibiotic-resistant Staph. aureus problems, 
and people weren’t quite sure why this was. Some people postulated that the 
decreasing use of tetracycline was possibly one aspect. I used to call the 1970s 
the decade of ‘complacency’, as far as Staph. aureus problems were concerned 
and the vast majority of sporadic Staph. aureus strains were sensitive to methicillin 
during that decade.55 
54 See also note 21. 
55 Shanson (1981): 19–21.
Figure 6: Dr Tom Parker, 1982. 
Director of the Cross Infection Reference Laboratory, PHLS, 1960–78.
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The other point about that decade [1970s] is that enormous attention was given 
to Gram-negative gentamicin-resistant bacteria causing outbreaks of hospital 
infection. I think the eye was off the ball, in terms of multiple-resistant Staph. 
aureus, until 1976, when there were hospital outbreaks of gentamicin-resistant 
Staph. aureus for the first time all over the world, including Bristol where David 
Speller reported an outbreak.56 We at the London Hospital Group reported for 
the first time an outbreak of Staph. aureus due to a methicillin- and gentamicin-
resistant strain which was also multiple resistant.57 We managed to control that 
outbreak with a package of measures that many people today would regard as 
way over the top, including the closure of wards, formaldehyde fumigation of 
closed wards and intensive care units, and the use of a temporary isolation ward 
to cohort the patients, since there were no isolation facilities. Dr Richard Marples, 
who was at the PHLS Colindale, mentioned that our particular ‘phage type Staph. 
aureus outbreak strain was never seen again, so I think we did a reasonable job.58
Dr Norman Simmons: I would like to view the situation with the eyes of a 
young man in 1961. I was working at Edgware General Hospital with Bill 
Brumfitt. At the time there was no MRSA. All I can remember is a hell of a lot 
of patients getting infected. The PHLS ‘Survey of Infection’ in 1960 showed a 
10 per cent post-operative infection rate, and if they had an infection with an 
organism sensitive to an antibiotic, you gave it to them and they got better.59 But 
there were a lot that had an infection with an organism that wasn’t sensitive to 
an antibiotic. They were getting resistance to tetracycline, as well as penicillin, 
and then the patient got worse and sometimes they died. It’s interesting to see 
that by 1980 the infection rate was said to be 18 per cent, but these comparisons 
aren’t fair, because the patients had different operations. Now, because I don’t 
see Bill Brumfitt here, I want to quote something that he told me that Fleming 
said to him: ‘You know, the staphylococcus is a very clever organism. No matter 
what antibiotic we find, it will get resistant to it’. 
Now what did I think of the organism, staphylococcus, and the antibiotic 
[methicillin] at that time? I thought simply: ‘Here’s an antibiotic, we can 
treat the patients with it, and they will get better’. There was a belief that in 
becoming resistant to methicillin, the organism somehow lost its pathogenicity. 
56 Speller et al. (1976).
57 Shanson et al. (1976).
58 Dr R Marples, personal communication to Dr David Shanson.
59 PHLS (1960).
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That was the hope and I did exactly the same sort of work that Mary Barber 
did.60 Unfortunately, she published it just about a week before we finished. You 
remember that horrible feeling when you have done two years’ work and their 
stuff appears in print before yours. We made organisms resistant to methicillin; 
they were completely unstable. We got the natural ones and the resistance was 
stable, and the stable ones were pathogenic in animals. MRSA then became the 
name of one sort of infection, although there are several sorts of MRSA. Then 
it became an industry. At first there was the mythology, and now it’s become an 
industry, as if somehow these organisms aren’t staphylococci at all. People talk 
about them as if they don’t spread in the same way as other staphylococci; as 
if they don’t do the same things, and yet they do all the things that happened 
before methicillin appeared, probably before 1960. 
If you look at the infection rate in the days of the 1930s and 1940s, it was the same. 
There were many infections. The most important effect of methicillin was that it 
put an end to the tremendous amount of research and enthusiasm for infection-
control measures which were vigorous and effective at the time, because when 
people were infected with this nasty organism, you could treat them. Who the hell 
wanted to put them in an isolation facility? People stopped washing their hands, 
and doing all the things that they have realized they should be doing now. 
Dr Ian Gould: Forgive me, I am too young to reminisce, but perhaps there are 
one or two contemporary issues which certainly run true with me. Joe Selkon 
and Mike Emmerson mentioned two points which I might comment on. Joe was 
talking about how hospitals should do no harm. I am reminded of something I read 
recently.61 Of course, coming from Aberdeen I know a bit about Alexander Ogston, 
the Regius Professor of Surgery there, who discovered the clinical significance of 
Staphylococcus aureus in the late 1870s.62 I think it is well documented that at the 
entrance to his wards in the hospital there were signs saying ‘Prepare to meet thy 
maker’, or something to that effect. Soon after he discovered Staphylococcus aureus, 
he got involved in Listerian antisepsis and he was soon able to take down those signs 
from the ward.63 There’s certainly a contemporary ring about that these days when 
we look at the public anxiety, if not to some extent the reality of the very virulent 
clones of MRSA that we see, not only in our hospitals but in the community.
60 Barber (1961).
61 Bulloch (1929).
62 Ogston (1881).
63 Lyell (1989).
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That brings me to Mike Emmerson’s point about why ‘phage type 80/81 was 
killing young people and causing some very serious infections. I think it has 
been quite well established now that that strain still exists in the form of a so-
called sequence-type 30 Asian-Pacific MRSA clone, a close relative of ‘phage 
type 80/81. It has at least one toxin, which probably is also shared with 80/81, 
called the Panton-Valentine leukocidin, discovered at the London Hospital, I 
believe, in the mid-1930s.64 There are two aspects where things have come full 
circle and are very relevant today, as they were earlier.
Dr Bill Newsom: I have four quick points: Patricia Jevons in her paper, you 
might remember, said the patients who grew the staph didn’t actually have any 
methicillin, and they had only ever used methicillin in the hospital once on 
a completely unrelated person.65 The second is pathogenicity. I will remind 
you that the first recorded US case was a lab technician who jabbed his finger 
with a strain that had been sent to them in 1967 from France to be examined, 
and he had required vancomycin, so he was poorly. The first time we saw it in 
Papworth Hospital was soon after we started testing for it, and certainly we had 
one patient who transferred it to three more patients. The first patient came 
from Ipswich. We rang up Ipswich and they said, ‘Ah, I think we are just starting 
these tests’. They rang back and said, ‘Well, actually we have had an outbreak in 
the orthopaedic ward for some time.’ They clearly hadn’t realized they had got 
it. Finally, it was the last speaker’s dad [J Cameron Gould, a microbiologist in 
Edinburgh], who found penicillin in the ward air in Edinburgh.66
Professor Mark Casewell: I want to go back to what Graham [Ayliffe] was 
saying about the studies done in the late 1950s–early 1960s by the Williams–
64 Panton and Valentine (1932). See Glossary, page 128–9. 
65 Jevons (1961).
66 Dr Ian Gould wrote: ‘My father, J C Gould, found that the majority of patients and staff of a large general 
hospital who were carriers of Staph. aureus were found to be colonized with penicillin-resistant strains and 
non-treated patients also became rapidly colonized with these organisms. This suggested selective pressure 
in the hospital environment. The report showed that penicillin was present in the environment of the 
hospital and in highest concentration where it was being used. Droplet nuclei and agitated dust particles 
containing penicillin were found in the air and penicillin was recovered from fomites and noses of patients 
and staff in these areas. Examination of a factory handling penicillin showed a similar contamination of the 
environment with the antibiotic and carriage of penicillin-resistant strains amongst staff. It was concluded 
that environmental penicillin is an important selective agent leading to the colonization of hospital carriers 
and patients with penicillin-resistant strains of S. aureus.’ E-mail to Mrs Lois Reynolds, 7 December 2007. 
See Gould (1958); Anon. (1958b). 
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Shooter–Lidwell group.67 I was a medical student at Bart’s at that time, and we 
dutifully had our noses swabbed from time to time, with little idea about what 
it was all about. They were, of course, pursuing ‘hospital’ staphylococci such 
as the ‘phage type 80/81. In those studies, conducted on certain wards, they 
were collecting prospectively all staphylococci from all patients, from all staff and 
from air samples. This yielded an enormous number of isolates, and they sent 
them from time to time to the Staphylococcal Reference Laboratory in Colindale 
to be ‘phage-typed. They could then put together the pieces of the puzzle.68 In 
these papers, which are rarely cited these days, you can find the evidence that 
indicates the need for single wards; the pivotal roles were the importance of nasal 
carriage; the contribution of airborne transmission and of nurses to the spread 
of staphylococci.69 They were able to quantify the percentage of infections that 
came from other patients, from the staff, and so on. The answers to so many of 
the questions that are asked today about the ‘modern’ MRSA are to be found in 
those papers. I reviewed these when we were in trouble with the MRSA outbreak 
at the London Hospital in the 1980s, to demonstrate the need for surveillance, 
treatment of nasal carriers and patient isolation.70 Today, the implications of these 
studies for MRSA, such as the need for adequate isolation facilities and/or single 
wards, seem lost in history. I think if nothing else comes out of this meeting, 
we should highlight these unique studies, which couldn’t possibly get resourced 
today, that describe the epidemiology of hospital staphylococci of the 1960s, 
which forms the basis for the successful control of the current MRSA problems, 
as happens, for example, in the Netherlands with their policy of actively seeking 
out MRSA, isolation of positive patients and energetic eradication of carriage. 
Dr Georgia Duckworth: Like Ian Gould, I can’t bear witness to what was going 
on in our hospitals in the 1960s, but I think the focus so far has been very much 
on England, and I think it’s important to say that the MRSAs in the 1960s 
67 For example, Williams and Shooter (eds) (1963); Williams et al. (1966): 77–115; Williams (1963); 
Lidwell et al. (1970).
68 For example, Lidwell et al. (1966, 1971). 
69 Professor Mark Casewell wrote: ‘For example, in a multi-centre survey by the PHLS of the nasal acquisition 
of hospital staphylococci for 4100 medical patients in the late 1950s, there was an acquisition rate of 9.4 
per 100 patient weeks. But when adult patients were nursed in modern single rooms in the newly opened 
Coppett’s Wood Hospital [now part of the Royal Free Hospital, University College Hospitals, London], the 
nasal acquisition rate reduced to only 1.0 per patient weeks.’ Note on draft transcript, 12 December 2007. 
Casewell and Hill (1986).
70 Casewell (1986).
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were widespread in other countries too. I remember papers from Switzerland 
and other European countries, including one from Denmark around 1969, 
which stated that around 40 per cent of all their Staph. aureus strains were 
MRSA.71 The Scandinavian countries now have very low rates (as shown on in 
those international maps produced by the European Antimicrobial Resistance 
Surveillance System) [<1–5% in Figure 7], and we would love to be like them.72
So what happened? I think David [Shanson] has already alluded to the lull in the 
1970s. Why did that happen? I think that’s very poorly understood. Certainly 
the strains in the 1960s were very different from the ones that started arriving 
in the 1980s, like the one Mark [Casewell] mentioned at the London Hospital, 
which was very much like an Australian strain. But again, the first of the so-
called epidemic MRSAs in the 1980s (Epidemic MRSA-1 or EMRSA-1), just 
71 Rosendal (1971); Shanson (1981). 
72 The European Antimicrobial Resistance Surveillance System (EARSS), funded by the European 
Commission, is an international network of national surveillance systems which collects antimicrobial 
susceptibility data for public health professionals. For further details, see www.rivm.nl/earss/result/
Monitoring_reports/Annual_reports.jsp (visited 5 December 2007).
Figure 7: Staphylococcus aureus: proportion of invasive isolates resistant 
to oxacillin (MRSA) in 2005 by the European Antimicrobial Resistance 
Surveillance System (EARSS). 
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imperceptibly went and was replaced by other epidemic strains, EMRSA-15 
and -16.73 Why do these changes occur, the lulls, and different strains coming 
to the fore?
Selkon: Can I bring us up to date on the evolutionary history of MRSA? 
Mark Enright and his colleagues have recently published a study funded by 
the Wellcome Trust which helps to bring the past and present understanding 
of the pathogenicity of Staphylococcus aureus together.74 During the 1950s the 
most pathogenic strains of Staph. aureus, especially for young people, were 
bacteriophage types 80/81 and this was claimed to be due to their ability to 
produce the Panton-Valentine leucocidin (PVL). D Ashley Robinson and his 
colleagues have shown that the gene cassette [a collection of genes] responsible 
for the production of the PVL were now present in most of the epidemic MRSA 
clones and especially those re-emerging as community-acquired strains. Thus 
our old enemy returns in a new guise to haunt us.75
Phillips: I want to comment on this paradoxical behaviour of MRSA and, 
indeed, other staphylococci. First, we have had Gordon Stewart telling us about 
a major outbreak, while a number of us have commented that we missed the 
thing as it went by. We were conscious of no cross-infection, and, indeed, of 
no particular clinical problem. Staphylococci are like that, but, like Georgia, I 
do scratch my head and say: ‘What on earth accounts for this?’ What accounts 
for the fact that the clean-living Scandinavians eventually reached 46 per cent 
MRSA in their staphylococcal isolates, and then nothing the second-time 
round, when the real epidemic strains come along?76 I think we, too, ought to 
be careful when we are talking about virulence and a property that I have tried 
to call ‘epidemigenicity’. It isn’t virulence, it’s the ability to spread, and I think 
it’s important to distinguish [the two]. I think those early strains were no more 
virulent than any other staphylococcus. And they weren’t particularly able to 
spread, as far as I am concerned. Gordon Stewart may disagree with me, but 
73 Cox et al. (1995); Cooke and Marples (1987); Marples and Cooke (1988). See Appendix 1 with details 
of EMRSA-1 through -17.
74 Enright et al. (2002). 
75 Dr Angela Kearns wrote: ‘The paper by Robinson (which I co-authored) has been slightly mis-quoted, so 
the text should read: “have shown that the two genes which encode PVL were present in the epidemic 80/81 
Meticillin-sensitive Staph. aureus (MSSA) clone and this strain has re-emerged as community-acquired 
MRSA following the acquisition of the mecA gene”.’ Note on draft transcript, 3 January 2008. Robinson 
et al. (2005).
76 Rosendal (1971).
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ours certainly didn’t spread; they were sporadic, they cropped up here and there, 
and apparently were the same – all ‘phage group III – and were all resistant only 
to penicillin, streptomycin and tetracycline.77 Whenever anyone typed them, 
they all looked the same, but they behaved differently, as staphylococci often 
do, in different contexts.78
Professor Curtis Gemmell: Can I perhaps go back to the 1960s? I was a young 
PhD student and joined a very small group in Glasgow who were interested in 
looking at the virulence of staphylococci, and at that time the interest there was 
the search for the toxins of Staph. aureus that might be important in developing 
a vaccine. In fact we, in-house, developed purified staphylococcal α-haemolysin, 
coagulase and also a homologous strain of Staph. aureus and we thought that 
was the answer to producing a vaccine against Staph. aureus. It didn’t really go 
very far; it did protect rabbits, but only against the whole of this strain. But in 
the 1960s, the change was the introduction of methicillin resistance, but people 
were probably side-tracked looking at why these 80/81s, and the clones thereof, 
were more virulent, and causing more serious infections. 
If I can just say one more thing, so that when I do come back into the 
conversation, my real interest in MRSA started only ten years ago in 1996 
when we were asked to set up the first Scottish MRSA Reference Laboratory in 
Glasgow, but we will come back to that later.
Stewart: In answer to that point, the staphylococcus begins in this way. You get 
currents of increase, and this was very marked in those early days, because in 
the 1950s, to which various people have made reference, there was a devastating 
outbreak of penicillin-resistant staphylococci due to type 52/52A and various 
others and then they disappeared. When methicillin resistance appeared in the 
1960s, all the original pathogenic strains belonged to group III ‘phage type 
75/77 and so on, and then they began to disappear again. 
In my review at the beginning of the meeting, I missed out some important 
people whose names come up incidentally in what’s been said.79 For example, 
Knud Riewerts Eriksen in Copenhagen was one of the first to observe that these 
77 Cookson and Phillips (1990); Phillips (2007).
78 Professor Gordon Stewart wrote: ‘There are cellular and morphological differences in highly-resistant 
strains of MRSA and also a property of regressing to a more primitive, syncytial [without cell walls] growth. 
See Kagan et al. (1964).’ Note on draft transcript, 8 December 2007.
79 See pages 4–7. 
Superbugs and Superdrugs: A history of MRSA
26
strains became quite prevalent as soon as methicillin began to be used in the 
university hospital in Copenhagen.80 And, his strains were the same as ours, as 
were those isolated by Yves Chabbert at the Pasteur Institute, Paris.81 They were 
never sent to the US, which was quite strange. For something like 20 years, 
right through the 1970s, there was a continuous watch in the US, and nothing 
turned up, and there was no problem until we had the group III strains turning 
up with similar virulence in the 1990s.82 There was a carriage problem, but 
not a problem of severe infections. Some hospitals, some countries, missed out 
altogether, others were very badly affected. 
Bud: I thought perhaps we should get a perspective from another country, I 
didn’t know whether Dale Smith could say anything about how the US engaged 
in this from the mid-1960s.
80 Professor Gordon Stewart wrote: ‘Mainly of ‘phage group III and this still applies.’ Note on draft transcript, 
10 January 2007. See Faber et al. (1960); Eriksen (1964); Rosendal et al. (1977).  
81 Chabbert et al. (1964).
82 For a list of the EMRSA strains, see Appendix 1.
Figure 8: Nasal carriage of tetracycline-resistant Staphylococcus aureus (including 
MRSA) in a large general hospital, 1968–78. 
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Professor Dale Smith: Well, you are now calling on a historian, not an eyewitness. 
The emphasis on the US was bifurcated. The epidemiology was being worked 
out by people looking at the massive epidemics of staphylococcus of the mid-
1950s in neonatal nurseries and after surgery, and they were concerned with 
infection control much more than they were concerned with resistance or typing. 
It was looking at procedures and what was breaking down because of this. In 
the laboratories of some of the leading medical schools people were working 
on resistance and toxins. I know Dr Spink at Minnesota was working with 
toxins at that point.83 The focus though, I think, was not on anything that was 
different, so much as on what had happened to surgical and obstetric training 
that resulted in the spreading hospital epidemics that were documented by the 
CDC [Centers for Disease Control in Atlanta] in the classical staphylococcus 
report of 1958.84
Stewart: Yes, Professor Smith, where you come from there is quite a problem 
in the spread into the community now, because some of the accounts which are 
most alarming now, come not from hospital spread but from the community, 
often via drug addicts in San Francisco.
Smith: We have a significant problem in several states. There’s a bad problem 
in Texas, in California and it’s spreading in other places into the community 
as well.
Professor Alan Glynn: On the question of spread and infectivity, I don’t know 
much about MRSA. But when I was a student at UCH, over 50 years ago, 
Ashley Miles, the mentor of Robert Williams, used to show us the photograph 
of a bench of bishops and though they weren’t actually picking their noses, at 
least half of them had their fingers very near.
Professor Brian Spratt: I would like to talk a little about the epidemiology. 
If you look at the Staph. aureus population, it’s very diverse, but there are a 
number of very prevalent strains, and when methicillin resistance first arose, we 
know that the mecA gene moved into one of those strains, which was prevalent 
at the time and this was Mark Enright’s work when he was in my lab.85 If you 
83 Professor Gordon Stewart wrote: ‘Wesley Spink foresaw the importance of enterotoxins and leucocidins [see 
page 30]. These infections, like those in the CDC report, were the ones that cleared with the advent of methicillin.’ 
Note on draft transcript, 8 December 2007. See, for example, Spink (1951, 1962); Wise et al. (1956).
84 US Department of Health Education and Welfare (1958). See also Ministry of Health (1959); CDC 
(1977): 13. 
85 Enright et al. (2002).
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look at the very early strains during the 1960s, they are essentially all the same. 
What happened then was that the mecA gene moved into these other prevalent 
strains to produce a whole set of new successful strains with the mecA gene in 
them, and that I suspect correlates with the problems that we started to have 
with the epidemic MRSA. Now why is it that the mecA gene, moving into other 
successful Staph. aureus strains, gave rise to the EMRSA problem? I don’t know, 
but presumably it is something to do with those strains being particularly well 
adapted to transmission within hospitals. 
The other thing is that we have talked about the hospital problem and the 
emerging problem in the community, and it was also said that ‘phage type 80/81 
has been mentioned, and ‘phage type 80/81 as we now know from various 
studies has got this PVL toxin. What Mark Enright showed quite recently in 
that paper in the Lancet that was alluded to, was that ‘phage type 80/81 had now 
picked up the mecA gene and has become MRSA, so we now have a community 
MRSA, which has many of the properties of the old ‘phage type 80/81 in causing 
necrotizing pneumonia and other serious conditions in the community.86
Shanson: Two points: first the community strains we see in the UK are not 
like the community strains in the US at the present time, as far as I am aware. 
Our experience is that they are not generally multiply resistant like the US 
strains and they are different types. I am not sure that anybody has shown 
in a British strain an 80/81 type genetic basis, and they are not usually PVL-
toxin producers. 
Coming back to Scandinavia and the reason that there seems to be less MRSA 
there than elsewhere in Europe during the last three decades, I know Rosendal 
and others in Scandinavia have been very keen on surveillance and strict infection 
control measures. The Dutch are also aggressive on ‘search and destroy’ policies, 
and I think the whole culture nationally is different from what we have seen 
for various reasons in the UK.87 I am also aware that even in recent years: the 
British EMRSA-16 epidemic strain was transported by a patient from England 
to Greenland and caused a major outbreak in a hospital there, in spite of the 
fact that it was in danger of becoming endemic there, the aggressive actions 
by infection control authorities there wiped out that EMRSA-16 from that 
hospital, though it involved draconian measures.
86 Robinson et al. (2005).
87 Spicer (1984); Cox et al. (1995); Gould (2005). See also Department of Health (2003). 
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Newsom: One thing that I wonder about is how much we encouraged the 
methicillin-resistant strains in the beginning, because if you look in the 1960 
issue of the Lancet announcing methicillin [Figure 4, page 11], there is also a 
paper from St George’s Hospital, describing its use as an aerosol in the nursery. 
While I wasn’t aware that there were problems later on in St George’s Hospital, 
London, I did have a friend who was a medical student in Melbourne at the 
time when methicillin was being sprayed around the surgical wards, and sure 
enough ten years later Melbourne was an absolute hotbed of MRSA. So I just 
wonder to what extent aerosolized antibiotic contributed.
Simmons: May I suggest that the staphylococci are behaving in exactly the same 
way that staphylococci have always behaved, in that some are more spreadable 
than others, for a reason we don’t know, and some are more capable of causing 
disease than others, often for reasons we don’t know, although with some of them 
we think we may do.88 If you look at the way staphylococci became resistant to 
penicillin, it took a period of time, then it was resistant. Tetracycline: it took 
a period of time, then it got resistant. Methicillin: there were some resistant 
ones, but it didn’t get resistant so quickly. That, I think, was a critical difference 
in the behaviour of the staphylococcus. Some of the staphylococci had the 
characteristics of spreadability, which they added to pathogenicity or virulence. 
Some didn’t.
There’s not just one MRSA: there are lots of MRSAs. The staphylococcus is just 
picking up these things, including the characteristic of resistance to this one 
antibiotic, or the methicillin family of antibiotics and adding it to its library of 
pathogenicity factors which contribute to its ability to cause illness in modern 
society. The staphylococcus finds the same environmental niches in which it 
can rest and spring out on the unsuspecting patient who has had some nasty 
infection, or whose immune system is suppressed, and kills him more easily. 
But the organism is behaving as it always has behaved. If you look at the 1940s, 
1950s, 1960s, it suddenly got resistant to the antibiotics in use. The thing 
about MRSA is the comparatively long delay until the emergence of widespread 
resistance. It didn’t change the behaviour of the staphylococcus, it changed the 
behaviour of man, the people who were trying to treat it. If resistance had 
occurred within five years, we would have carried on isolating patients and 
doing all the things that we had done before that. But the methicillin actually 
suppressed our memory banks. There were people before that who were giants 
at that time – Reggie Shooter, Robert Williams – people that we respected and 
88 Parker et al. (1974).
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who knew what could be done. How many people now could get their local 
authority to build a bathroom, and make surgeons shower, and then do air 
counts on them? They showed showers increased our counts. And yet they are 
still trying to get patients to shower before they have their operations.
Bud: As a historian I noticed very much at the time how people like Williams 
felt very beleaguered and were seeing bad practice all around them. So they were 
advocating the best practice, but there seems to have been an awful lot of bad 
practice, even then.
Dr Angela kearns: If I can just come back to the 80/81 story, because I find it 
quite fascinating. I am now working in the Staph Reference Unit [Colindale] 
and we are looking at PVL in many different strains of staphylococci. It’s found 
in a very diverse range of strains, as I mentioned before, but, of course, the 
80/81 does have some significance for us, and, yes, we are seeing PVL-positive 
community MRSA, which have descended directly from the 80/81 MSSA 
strain. Also the US strain which was referred to earlier, is classically the so-called 
USA300 or what we call the ST8 strain, which we do see in this country as 
well. We are seeing some evidence of international spread of these PVL-positive 
strains with some great concern, but what we don’t see is large outbreaks as yet, 
they are very much sporadic. It may be a ‘watch and wait’ situation, but that’s 
the evidence as we see it at the moment.89
Professor Brian Duerden: I can only go back to the very late 1960s as a student 
and starting in all of this. But we have said a lot about the changing pattern, or 
not-so-changing pattern, of the staphylococcus, and we have hinted from time to 
time about the people that are involved. To pick up on what Norman Simmons 
said a short while ago, the emergence of MRSA had a big impact upon the 
medical staff, and what we saw in the late 1980s and through into the 1990s, as 
MRSA started to come back as a real clinical problem, just coincided with when 
the subject of infection was basically dropping out of the medical curriculum 
in many medical schools. Many of us here, as members of the Association of 
Professors of Medical Microbiology at the time, actually tried to survey what 
was happening in the reduction of teaching about microbiology and the use of 
89 Professor Graham Ayliffe wrote: ‘In 1976/7, Edward Lowbury and Harold Lilly reported an outbreak of 
severe staphylococcal sepsis in the Birmingham burns unit, affecting patients and staff [Lilly et al. (1979)]. 
This was caused by a methicillin-sensitive strain, ‘phage type 95, with characteristics resembling type 80/81. 
Towards the end of the epidemic, the relatively avirulent endemic strain of MRSA in the unit developed a 
similar enhanced ability to cause severe infections. It seemed likely that a virulence factor was transferred to 
the MRSA possibly by transduction.’ Note on draft transcript, 9 January 2007. 
Superbugs and Superdrugs: A history of MRSA
31
antibiotics and infection control in our medical schools.90 This was compounded 
by the General Medical Council coming out with guidance on medical education 
that omitted the word infection. We are still waiting to try to get that back in 
their recommendations. At that time when there was a neglect, then the organism 
was rearing its head again as a very significant pathogen. 
The other people who were involved were the patients, and it is a very changing 
and very different patient population. I was interested to pick up, again I think it 
was Joe Selkon who said, in looking at patients in the 1960s that it was medical 
patients who came in with it and yet it was the surgical patients who were then 
the problem. Now many of the patients who are getting MRSA infections are 
medical patients, but they are desperately ill. It was the same sort of patients 
who were coming in with it then, but the things that are being done to them in 
our hospitals are effectively similar to what was being done with them on the 
surgical side then. So it’s medical patients that are getting it, but the message is 
exactly the same as it was, as you described it.91 
Dr Bilwanath Chattopadhyay: During the last four years of the 1960s I was a 
junior doctor in microbiology. Then I was fortunate enough to be appointed 
senior registrar to Professor Reggie Shooter, and to Professor Francis O’Grady, 
at St Bartholomew’s Hospital, London. Now, somehow, we did not come 
across any problem in those days with MRSA, and no one can tell us that 
we missed MRSAs, because Francis O’Grady was there, David Greenwood 
as well. What happened was that I found that they were actually ruthless in 
recommending isolation and infection control procedures in any patient 
with serious staphylococcal and streptococcal sepsis. There was absolutely no 
excuse for not following infection control guidelines. Similarly, they also put 
tremendous emphasis on air-borne spread, which I think these days we are not 
taking much notice of. Then I joined Whipps’ Cross as a consultant in the 
beginning of 1974. As David Shanson said, I had my honeymoon period and 
there was not much problem at that time, but then within two years I wanted 
to appoint the first infection-control nurse. My clinical colleagues thought I 
was a mad microbiologist, someone who wanted to take money away from 
the nursing budget. But again I was very lucky, because at that time one of 
the ward’s senior nurses was no less than Christine Hancock (who later on 
became the Chief Executive of our Trust, followed by the General Secretary of 
90 General Medical Council, Education Committee (1993).
91 See page 16. 
Superbugs and Superdrugs: A history of MRSA
32
the Royal College of Nursing). Christine Hancock, as Director of Nursing, with 
a newly appointed surgeon, Mr Nigel Offen, after a lot of difficulties approved 
the appointment of our infection-control nurse, and, dare I say, some of the 
senior clinicians were horrified to notice that that infection-control nurse was 
inspecting their aseptic practice. 
Gould: I think it was Ian Phillips who asked why the Danes hadn’t had a second 
phase of MRSA. Maybe I could be a little controversial and say it’s because 
they learnt their lesson the first time round. Whereas I am afraid, many of 
our colleagues (as has already been hinted at by David Shanson) over the last 
20 or 30 years, have been remarkably complacent about MRSA and, I think, 
continue to be complacent, even to this day. I find it very difficult to find 
kindred spirits when one wants to take an aggressive stance on MRSA. Our 
colleagues in Scandinavia find this absolutely incredible, what is going on in the 
National Health Service, today with the huge amount of public concern and the 
huge amount of resource, allegedly, put into infection control. There seems to 
be a complete inability to learn from the papers that Mark Casewell has already 
hinted at about the epidemiology of Staphylococcus aureus and how it spreads, 
and the importance of identifying cases and carriers, and isolating them properly, 
while taking cognisance of the problems of environmental contamination etc., 
etc. I could go on, but I will leave it at that at the moment. 
Professor David Greenwood: When Bill Chattopadhyay remembers me at 
Bart’s in the 1960s, I was a technician in the bacteriology lab, and, as Bill will 
remember, one of the reasons why we didn’t find methicillin-resistant Staph. 
aureus is that we used a very antiquated method of sensitivity testing that was 
inherited from Paul Garrod: the test organism was spread on a blood agar plate 
with a glass spreader, holes were made in the agar with a cork borer and liquid 
antibiotics were pipetted into the holes.92 As has been alluded to earlier, if you 
want to detect MRSA reliably, you not only need a better method than this, you 
have to use special conditions – reducing the incubation temperature to 30°C 
or adding a high, non-physiological concentration of salt to the agar. Moreover, 
there was a view prevalent at the time that a good way to keep MRSA at bay was 
not to test Staph. aureus under these strange conditions; after all, it was argued, 
patients weren’t incubated at 30°C or given increased salt.
Shanson: I think there is perhaps one difference which the Blowers–Williams era 
didn’t describe in relation to epidemic MRSA strains, and that is the astonishing 
92 See his Biographical note on pages 114–15.
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latency that’s often seen, whereby you can screen contacts of an index case and 
they are negative, but six months later they are positive in various sites, and 
that causes difficulties in the management of individuals and in the control of 
outbreaks. In the mid-1980s, we described the use of an isolation ward at St 
Stephen’s Hospital, London, and although it was one of a number of measures, 
so you couldn’t say the isolation ward per se helped to control the outbreak, there 
was no doubt that it was useful in dealing with these negative contacts as well as 
infected patients.93 So that when a ward was closed, cleared of surgical patients 
in that ward having the MRSA epidemic strain, and the other patients in that 
ward were screened and were negative, we decided to also put the negative 
contacts in the isolation ward. This was a purpose-built ward, and indeed two of 
the screened-negative patients subsequently became positive. It does show the 
difficulties in dealing with epidemic MRSA strains, more perhaps than with the 
previous 1960s and 1970s antibiotic-resistant Staph. aureus strains, apart from 
perhaps the 80/81 strain which was very spreadable.
Duckworth: A query and also a point. Firstly the query: in the Staph. aureus 
story in the 1950s, much of it was concentrated on paediatric wards, particularly 
babies – and Graham mentioned that some of the early MRSAs occurred in 
paediatrics – and we also heard about the aerosolization of methicillin in the 
93 Shanson et al. (1985). 
Figure 9: Two scanning electron micrographs, c. 1969, showing damage to the normally smooth 
cell walls of Staphylococcus aureus caused by penicillin. L: normal cells; R: cells exposed to 
penicillin (ampicillin). Source: Greenwood and O’Grady (1969): 1077.
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nursery at St George’s Hospital. But MRSA infections more recently haven’t been 
heavily focused on children. Bacteraemia rates have certainly been going up in 
children’s wards, but nothing like the situation elsewhere in the hospital. Now, 
is that related to current strains? Or is it that practice has changed, for instance, 
that children now are often effectively isolated in their incubators? Moving on 
to my other point, this relates to what Brian Duerden was saying about neglect 
in medical education. It wasn’t just the neglect in medical education, it was the 
neglect that was happening with senior management in our hospitals around 
the late 1980s. Many of us were using the ‘search and destroy’ approach then 
and I get very, very upset when we keep being told that we ought to do what the 
Dutch are now doing – ‘search and destroy’. A lot of us in England were using 
this approach. 
There were two things happening: firstly, the strains changed. We got these 
new EMRSA-15s and -16s, a major new onslaught on many of our hospitals, as 
these strains appeared to be more transmissible. It might have been to do with 
the epidemicity that Ian Gould alluded to.94 But secondly, at the same time as 
this was happening, our ability to influence our chief executives also seemed 
to be spiralling downwards. Because of the financial pressures on hospitals, we 
were no longer able to shut wards etc. The influence of the Infection Control 
Doctor seemed to be waning. 
Bud: What years are you talking about there?
Duckworth: I think this was towards the late 1980s. My colleagues will be 
able to confirm that. We established an isolation ward at the London Hospital 
in the early 1980s, and that has been maintained ever since, although the case 
for maintaining it has to be made periodically to hospital management. It was 
possible to establish an isolation ward then, but very difficult to set one up in 
the current climate. It was the sort of thing that you could do in that period. 
You certainly can’t do that sort of thing now.
Hamilton-Miller: I would like to make two very brief points: John Pearman 
in Perth, Australia, managed to keep his hospital completely clear of MRSA, 
despite the fact that other parts of Australia were absolutely teeming with it. 
What he did was to admit every patient to an isolation ward before they got into 
hospital. The second thing I would like to say is that when the EMRSA-1 came 
out in 1980, we at the Royal Free Hospital, London, had the dubious distinction 
94 Professor Ian Phillips wrote: ‘As did I, but I called it epidemigenicity (v. supra), emphasising it as a property 
of the organism, independent of its environment.’ Note on draft transcript, 6 January 2007. See page 24. 
Superbugs and Superdrugs: A history of MRSA
35
of being one of the first places that it appeared. There was a patient who was 
going home on intermittent dialysis, which I thought was rather strange. We 
were able to get rid of the EMRSA-1 and subsequent strains, until we got to -15 
and -16, where we just drew a complete blank. This reinforces the point that 
it’s the nature of the organism, because our infection control systems have been 
very robust throughout the last 25 years.
Richmond: Can I change focus slightly. Arising out of all this, I do wonder 
whether something about the policies in relation to the funding of research in 
this area has not had quite a lot to do with the phenomenon that we now have. 
So much more work has been funded on the basic genetics, the mode of action, 
why antibiotics work, how organisms are resistant, and very little, or relatively 
little, it seems to me, in the area of how epidemics form, how the organism 
survives in this situation or that situation. I think it is absolutely incontrovertible 
that antibiotic use does influence the incidence of resistant organisms, but the 
coupling is very, very complex. I don’t want to get off the subject, but I was 
always very interested in E S [Andy] Anderson’s papers on salmonella, where 
you got enormous outbreaks of resistant salmonella type 29 and various others, 
and they then disappeared, even though antibiotic use didn’t apparently alter 
substantially.95 It seemed to me that this must point in the direction that it was 
something to do with the organism in relation to the host and the environment. 
In my experience, and maybe we will come on to this a bit later, the Medical 
Research Council in the 1960s and 1970s was broadly rather uninterested in that. 
They were all absolutely obsessed with the molecular basis of this phenomenon, 
the molecular basis of colonization and things like that were really very, very 
difficult to tackle in the way that the purists of E. coli K12 liked. I think there 
has been a very substantial shortage of funding in the area of epidemiology of 
infections. Now, maybe people didn’t want to do the research, or couldn’t do it. I 
know the research councils were responsive to a degree, but I think that there was 
also something of a positive policy to concentrate on the molecular side.96
Bud: Can we take Professor Richmond’s intervention as a chance to make sure 
that in the last half hour before tea we do talk about the patterns of research, 
and also, so to speak, about changing the science of MRSA. I think that the line 
that you have taken us on following other people is something that we should 
spend a little time talking about.
95 Anderson (1968). See also Anderson (1966).
96 
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Stewart: Mark, I wonder if you remember responding to a question raised on 
the nature of resistance to antimicrobials at a symposium in the US in 1967? 
You said: ‘The realization that most Gram-negative and some Gram-positive 
bacteria carry extrachromosomal elements, such as episomes or plasmids, must 
have a profound effect on our concept of speciation’.97 Now this was a most 
important point, which foresaw some of the complex mechanisms identified 
by Bill Hayes and others later, but did not anticipate the present problems 
with virulent strains of MRSA that depend on the mecA gene and related 
chromosomal elements identified in recent years in the US, Japan and elsewhere. 
The same genes were found as those in subcultures of the group III strains filed 
in Colindale during the original outbreaks in the London area, and eventually 
all over the world. Haemolytic streptococci, pneumococci and staphylococci 
possess a muramic acid–peptide kind of cell wall.98 It doesn’t apply to a lot of 
other organisms, which are also highly mutable. 
This was 1967, but if we go back a bit to, say, 1942, when I was a house physician 
in the Glasgow Royal Infirmary, the problem then was not, as in Lister’s day 
and now, staphylococcus. The problem then was the haemolytic streptococcus, 
because Glasgow was an incendiary place, full of shipyards, furnaces, steel works, 
and the big problem was burns, with streptococcal cross-infection. There was a 
team working in Glasgow Royal Infirmary’s burns unit using crude penicillin, 
prepared in the Dunn School of Pathology, Oxford.99 Their target organism 
was not staphylococcus, it was haemolytic streptococcus. That was my first 
encounter with penicillin, when I was shown those plates where this crude 
penicillin was inhibiting haemolytic streptococci. And then, with war wounds 
in view, staphylococci entered the picture, used in the armed services. And then 
the same sequence began to be recycled in staphylococci. One organism [strain] 
would come in a wave and then disappear. And in answer to the question: ‘Why 
has there never been an epidemic of MRSA in Britain?’ the answer is there is no 
97 Symposium on epidemiology of drug-resistant infections. Stewart G T (Convenor) Antimicrobial Agents 
v. Chemotherapy, 1967. American Society for Microbiology, 245. Richmond quote on page 293. 
98 For the characteristics of muramic acid-peptides, see Stewart (1965): 89, 92–3. 
99 Professor Gordon Stewart wrote: ‘Crude yellow penicillin made in the Sir William Dunn School of 
Pathology, Oxford, was used in the Oxford Burns Unit for application to burned and grafted areas of skin 
by a team of Arthur Clark (surgeon), Leonard Colebrook (bacteriologist), Thomas Gibson (plastic surgeon), 
Peter Medawar (biologist and Nobel prize winner) and Maurice Thomson (house surgeon). During the 
same period, penicillin was cultured in gin bottles by Dr C A Green in the Royal Naval Medical School, 
Clevedon, Somerset, and tested in cooperating naval units.’ Note on draft transcript, 10 January 2007.
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room for an epidemic, because it is endemic. There’s room for an epidemic in 
France, in Denmark, and elsewhere, and especially just now in the US, but not 
here, because we have had it all the time and it has become endemic, it’s become 
accepted, and, as somebody has said, we cannot administratively deal with that 
under the present organization. That’s quite true.
Bud: Professor Richmond, would you like to respond?
Richmond: No, all that is right. I think the point to reinforce is that these 
organisms are pretty clever. I sometimes wonder why it is that this organism 
continues to be recognizable as Staphylococcus aureus in view of the amount of 
genetic exchange that goes on.
Selkon: The most dangerous organism we have is the Department of Health. 
This has become very clear to me. From about the early 1990s, we were being 
forced into accepting excessive surgical admissions to reduce waiting lists, or to 
have our finances cut. I once tried to close a ward at the John Radcliffe. The 
Chief Executive said: ‘Certainly we will do that, but you realize that it will cost 
us £500 000 if we don’t meet our expected patient put-through rate: think of the 
hospital, please’. And I foolishly conceded. But the fact is that there was great 
pressure put on the medical profession and I am sure many others here will agree 
that they did not have the support which normally one would expect from the 
top echelons of the nursing and medical administrative staff, to be able to insist 
that our protection policies were adhered to. This was very difficult to accept.
Newsom: Just to go back to Georgia [Duckworth] and the type 80/81 and the 
babies. We had a big outbreak in the Westminster [Hospital] in 1959, I guess, 
and this started from a midwife with an infected finger. The babies, of course, 
were all kept in the nursery, so there was a seed bed for them, unlike today. 
The second thing is that the babies gave the germs to their mothers and 16 
breast abscesses appeared. At that time if you looked for serious staphylococcal 
infection in the community, if you asked had they had a new baby, they very 
often had. So I think the babies were a definite seed bed for it all. I think the 
germ could be nasty to the grown-ups as well. 
Spratt: The Chairman said we might talk a little bit about some of the scientific 
aspects and Mark Richmond has already mentioned that a lot of money was 
going into mechanisms of resistance in the 1960s and 1970s. I thought I might 
just look at the history of what we know about the basic mechanism of resistance 
to methicillin in Staph. aureus. 
Superbugs and Superdrugs: A history of MRSA
38
Soon after the discovery of MRSA, as Mark has alluded to, there were some 
curious properties about the instability of methicillin resistance, and the 
possibility was raised that perhaps it was on a plasmid and maybe β-lactamase 
was somehow involved. I think it was probably Keith Dyke in Oxford in the 
mid-1960s, who, I think, showed convincingly that you can get rid of the 
β-lactamase plasmid, but you don’t get rid of methicillin resistance.100 I think 
that pretty clearly showed that the mechanism had nothing to do with the 
β-lactamase plasmid. And really there was not a lot that had progressed in terms 
of the mechanism of methicillin resistance throughout the 1960s and 1970s. 
There were some suggestions that perhaps it was something to do with the 
cell wall. It became gradually clear that resistance was due to a chromosomal 
gene, but there was a very poor understanding of this, throughout the whole 
of the 1960s, about the precise mechanism of action of methicillin, or of 
penicillin and the β-lactam antibiotics in general. It wasn’t until 1975 when 
it was possible to identify in cell wall synthesis, in peptidoglycan synthesis, the 
individual enzymes that were inhibited by penicillin.101 It then became possible 
to look at the interaction of penicillin with each of the individual enzymes 
in cell wall synthesis that were inhibited by penicillin, which became known 
as penicillin-binding proteins (PBP), and it became clear towards the late 
1970s that although resistance to penicillin in most bacteria was due to the 
β-lactamases, there were some examples where resistance was due to alteration 
in the target enzymes, alteration to PBPs, and particularly, for example, in the 
pneumococcus, where all resistance to penicillin is due to alterations in the 
PBPs. Alex Tomasz was particularly involved in this.102 But in terms of MRSA, 
the breakthrough with understanding the mechanism of MRSA was actually in 
Cambridge, and it was Derek Brown and Peter Reynolds who in 1980 looked at 
the PBPs of methicillin-susceptible and methicillin-resistant Staph. aureus and 
showed that there was what appeared to be a new penicillin binding protein 
which was highly resistant to inhibition by methicillin and other β-lactam 
antibiotics.103 They hedged their bets slightly, they weren’t quite clear whether 
it was a large amount of one of the existing PBPs, or a new PBP. But then 
work, particularly from Barry Hartman and Alex Tomasz in the next few years 
showed very clearly that MRSA were resistant because they had somehow got 
100 Dyke (1969).
101 Spratt (1975).
102 Hakenbeck et al. (1980).
103 Brown and Reynolds (1980).
Superbugs and Superdrugs: A history of MRSA
39
hold of an extra PBP, which was resistant to essentially all β-lactam antibiotics.104 
That’s probably still a unique mechanism of resistance to penicillin. Slightly 
mysterious, where did this resistant PBP gene, which is called PBP2´ [known 
as 2 prime], come from? Of course, it’s encoded by the mecA gene, and it was 
Song in Matsuhashi’s lab who managed to clone the mecA gene and showed 
that MRSA strains, or the first MRSA strains had quite a large piece of DNA 
which included the mecA gene and a number of other genes, including some 
encoding other drug resistances. Song and Matsuhashi suggested that the mecA 
gene had somehow come in and this penicillin binding protein gene had fused 
with the β-lactamase gene to produce a PBP which is under the control of 
a β-lactamase.105 That is more or less where we are with MRSA. An unusual 
mechanism, a new PBP coming in, resistant to β-lactams. We still don’t really 
know where it came from. There are some suggestions where it came from, but 
I don’t find them terribly convincing.
Simmons: Going back to Professor Richmond, who asked how people behaved 
towards funding research. One of my colleagues, the late David Williams, had 
a research project in 1961, all written up, ready for application for a research 
grant into the transmission of staphylococcal infection, and it was all favourably 
received, but when methicillin came out within a year, it was rejected, because 
it wasn’t a problem any more. Secondly, the incidence: everyone is saying that 
children were very important. In 1960 the incidence of staphylococcal post-
operative sepsis in gallbladder operations was 14.9 per cent, in breast operations 
it was 12.7 per cent, in varicose veins, hardly a paediatric disease, it was 9 per 
cent. So the idea that Staph. infection occurred only in children is in the eye 
of the beholder. Now, MRSA doesn’t exist in a little capsule, at the moment 
anyway, it exists principally in our hospitals, and what has changed there is the 
system of patient management. The present system of patient management is 
designed to bring about a reduction of waiting times, which is perceived to be 
the most important issue. If the prevention of infection was the most important 
issue, we would control the infection. It’s a question of priorities. 
Dr Elizabeth Price: Bill Newsom mentioned that outbreaks of Staph. aureus 
were not uncommonly reported from neonatal units in the 1950s. One of the 
reasons that these do not seem to occur to such a large extent now is that infants 
are usually ‘roomed-in’ with their mothers. This means that the baby remains 
104 Hartman and Tomasz (1984).
105 Song et al. (1987).
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at the side of the mother’s bed, rather than going to a large nursery with the 
possibility of coming into contact with other infants, their mothers and members 
of staff, all of whom could transfer infecting organisms, including staphylococci. 
Another reason is that most mothers and babies leave the maternity unit because 
they are discharged very rapidly. As a result there is less chance for an infant to 
acquire infecting organisms in hospital. 
Joe Selkon mentioned the relevance of poor ventilation in hospitals in the 1960s. 
Well, that situation may be even worse now and I am talking about the late 1990s 
onwards. In hospitals with natural ventilation, we are not allowed to open windows 
more than 10cm [100mm] because of the possibility that patients might fall out 
or attempt suicide by jumping out. This is an NHS Estates Health Technical 
Memorandum requirement.106 I think we are ending up with sweaty patients and 
perspiring doctors, and that is a great way of transferring organisms. I would like 
to see more research on organisms and the environment, particularly looking at 
humidity and heat. We have lots of computers and heat-producing equipment 
as well as poor ventilation in our hospitals. Maybe in our research we should be 
looking at the hospital environment and its effect on infecting organisms.
Shanson: I would like to ask a research question following some personal 
observations while working for the last four years in a children’s hospital. Most 
weeks there are two or three new MRSAs detected, but they usually don’t spread 
and the patients are promptly isolated anyway. But over the last two years 
there was one particular strain seen where we experienced extreme difficulty in 
controlling its spread. We gave the strain the name of the index patient.107 This 
strain had a very characteristic multi-resistant pattern, and it particularly affected 
immuno-compromised children with skin lesions. Later it also infected other 
children without skin lesions. It was noted how persistent this organism was in 
single rooms, even those which had been cleaned once, twice or occasionally 
three times. It sometimes needed hydrogen peroxide treatment to eradicate it 
106 Health Building Notes and Health Technical Memoranda were published by NHS Estates until its duties 
were transferred to the Department of Health Delivery Group on 30 September 2005. Health Technical 
Memorandum no. 55 covered the requirements for windows as part of a series on building components, 
which originally appeared in 1989, with a second edition in 1998. 
107 Dr David Shanson wrote: ‘This outbreak problem with a difficult spreading strain in the children’s 
hospital was not published, although further characterization of the isolates was carried out at the 
Staphylococcal Reference Laboratory at the HPA Laboratories at Colindale.’ E-mail to Mrs Lois Reynolds, 
5 December 2007.
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from the environment.108 So it seemed that this particular very virulent strain 
resisted drying and I wonder whether anybody is doing research to look at the 
most spreadable strains, if you like, in terms of their resistance to drying, and 
whether they also compare it with the other strains at a genetic level in relation 
to drying. 
Gould: Norman Simmons correctly said that the focus of MRSA in the UK is 
still the hospital, and yet paradoxically the greatest single barrier to hospitals 
controlling MRSA at the moment is that there is now a large, dormant, 
asymptomatic population of MRSA-carriers in the community, who have picked 
up their MRSA in the hospital. Now, we recognize that within the UK overall, 
probably between 5 and 7 per cent of hospital admissions are asymptomatically 
colonized with MRSA. Just to bring you bang up to date, a recent health 
technology assessment (HTA) from Scotland has costed a national programme 
of admission screening for everybody and isolation and decolonization based 
on mathematical models which originally emanated from Ben Cooper and his 
colleagues in London.109 The HTA reckoned that per annum an average-size 
teaching hospital with 700 or 800 beds would have to spend £17 million on this 
process, but within five years would have brought the underlying MRSA rate 
down from 7 per cent to 1.4 per cent. But, of course, the possibilities of getting 
such funding in the present circumstances must be open to extreme doubt.
Gemmell: I am currently the Director of the Scottish MRSA Reference 
Laboratory and one of the things that we are doing at the moment in our 
research is that we are looking for genes of virulence among MRSA strains 
and particularly strains from bacteraemia. We have looked at something like 
200 strains over the last two to three years and one thing we are detecting is 
that there are strains out there, on the MRSA, in which the virulence factor is 
quite a potent one, such as TSST1, the toxic shock syndrome toxin. We were 
finding some that produced the β-haemolysin, an old-fashioned toxin which 
was historically always associated with animal strains, and we are also seeing 
occasionally PVL toxin and also epidermolytic toxins and it’s called the scalded 
skin syndrome toxin. So the toxins are there among the MRSA, but they are 
very spread out among different sub-clones.
Ayliffe: Can I comment on grants? There used to be a MRC research committee 
which had a fair amount of money available, a vast sum was spent on a multicentre 
108 See, for example, French et al. (2004).
109 Cooper et al. (2003). For the October 2007 version, see Ritchie et al. (2007).
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trial for hip replacement surgery in the 1980s.110 Then, suddenly at the end 
of that, the MRC stated that, ‘We don’t need it any more’. Individuals had 
to send in their own research grant applications for projects of two or three 
years, which was quite different from putting a lot of money into a large 
research scheme.
Bud: Do you remember when that was?
Ayliffe: I think the early trial was in about 1980, and it must have been some 
time after that. 
Chattopadhyay: We have heard about preoperative screening. With a reasonable 
amount of funding, we opened the first of our MRSA wards in 1989, and we 
could manage to control that outbreak at that time, and there was a dedicated 
SHO/Registrar for that unit. Second, because of the problems in orthopaedics 
in the mid-1990s, we had three wards: one was the designated MRSA ward, 
one was the very clean ward for prosthetic implants and the third was for other 
categories of patients. That was very successful until the authorities decided that 
there were too many beds in orthopaedics, so they closed one of the wards, and 
the whole thing fell apart. Over the last nearly ten years, we have an isolation 
ward – not just an MRSA ward – with 17 beds, nine cubicles and two bays with 
four patients in each, where we admit MRSA-positive patients plus Clostridium 
difficile and so on. Patients with open pulmonary tuberculosis are admitted to 
an isolation cubicle with en-suite facility. It is not the solution to the problem, 
because there are several disadvantages: one is the mixing of disciplines, which 
the consultants don’t like. They don’t like their surgical patients to be mixed with 
the care of an elderly medical patient with a large leg ulcer, carrying MRSA. 
Secondly, it is not feasible to transfer the MRSA-positive patients from intensive 
care unit (ICU) or orthopaedic patients on traction, or from paediatric units. 
Thirdly, it is very expensive to run with regards to cost of drugs used and also bed 
occupancy and nursing staff ratios to patients. It is very difficult to recruit nursing 
staff, because they don’t find it very rewarding to be a specialist nurse in infection 
control; they would rather do surgery – vascular, orthopaedics or something. 
And lastly, the junior doctors tend to forget the outliers [patients not admitted 
to their designated wards], a patient on that isolation unit. So the patient may 
not be visited by the team. There were advantages as well from the point of 
view of quality of isolation and the control of infection, which was excellent. 
110 Lidwell et al. (1982, 1984). For a Cochrane Review of antibiotic prophylaxis, see Gillespie and 
Walenkamp (2001). 
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Training was excellent, obviously with developmental expertise. But this is not 
the solution, because I can tell you from my experience that it is very expensive 
to run. You cannot have a bed occupancy in that ward of 80 or 90 per cent. If 
your incidence of MRSA goes down, you can’t fill in those beds, and you are 
under tremendous pressure from the administration to admit patients into that 
ward, when there is not a single bed available anywhere in the hospital. Likewise, 
whenever there are more than 17 patients with MRSA infection/colonization, all 
of them could not be accommodated in the isolation ward. 
Duerden: To pick up your point again about research and research funding 
and the pattern of research: we heard from Brian Spratt of the excellent work 
that has been funded on the mechanisms of resistance and the work of Mark 
Enright, who described the genetics, but very little money has gone in over 
the past 15–20 years at the applied end of this, at the interface between good 
research science and clinical applicability and infection control. There has 
been very little funding there; it’s about two weeks since I was talking to some 
colleagues at the MRC – fortunately they are actually realizing that this had 
happened and the question they were asking was whether this had an impact. 
Well, the obvious answer was ‘Yes’: a huge impact, because over the same period 
it was coupled with the various research assessment exercises (RAE).111 I have no 
problem with wanting to assess the effectiveness and the quality of university 
research, and research in the medical schools, but it did go quite against what 
had been the traditional pattern in medical schools of the clinical academic, who 
was both an academic and doing clinically applied work in the hospitals. Again, 
I look around the room and think of the number of clinical academics who 
are represented here. I would be hard pressed to actually balance their number 
with currently active clinical academic microbiologists, who should have been 
their successors. It’s a diminishing number and these are the people who should 
have been carrying on the work of Shooter and Blowers and colleagues then, 
and the people who are here. This has not been an area that has been attractive 
to the major funders and we are seeing the results of that now. I hope that the 
recognition might turn round this issue, but we have got to find the people who 
are capable of doing the work now.
Duckworth: I would like to comment on Bill Chattopadhyay’s point – the 
litany of all the disadvantages of an isolation ward. We faced them all in David 
Williams’ department when we were setting up the isolation ward at the London 
111 The Research Assessment Exercise was first undertaken in 1986. For further details, see www.rss.org.uk/
main.asp?page=1224 (visited 30 January 2008).
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Hospital in the early 1980s. Sometimes it seemed an extraordinarily uphill 
struggle, with surgeons not wanting their patients transferred there etc. But 
I really thought we had won the day when one of the general surgeons came 
up to me and said that he wished all his patients got MRSA because they 
received so much better care on that ward. We had orthopaedic patients in 
traction there, we even had some ICU and paediatric patients. It was just an 
ordinary ward, nothing specially built. It had cohort areas and some single 
rooms. When we didn’t have enough MRSA patients to fill it, we were able to 
put patients with other infectious diseases in the side rooms. Infection control 
practice got so good on that ward, that we did not get spread of MRSA to 
the patients being isolated for TB or chickenpox or other infections in the 
side rooms.
I would also like to comment on Bill’s point about expense, because I was 
involved in an Health Technology Assessment (HTA), which included a 
systematic review of the effectiveness of isolation in the control of MRSA and 
some mathematical modelling. The modelling showed that even if the isolation 
ward was not big enough for the size of the problem in the hospital at that 
particular time, it still had an impact on ultimate numbers of infections.
Richmond: Just one comment on this funding business, a personal comment. 
When I moved to Bristol in 1968, I put a large grant application in to the MRC 
to work on staphylococcus and it was turned down. The message came through 
that we will fund you if you put in for a grant to work on E. coli.
Selkon: The cost of looking after 200 patients with MRSA in a Belgian hospital 
is put down at £2.6 million.112 When we talk about costs, it’s not just the costs 
of what you have to do, it’s the costs you will incur if you don’t do it, in terms 
of isolation of source cases. Very seldom do you have a chance to have a proper 
debate upon the total costs involved with the disease and the costs for running 
an isolation unit. 
There is another point I want to make in terms of what has just been said. We 
must realize – and we will see this in the paper from Oxford published in the 
British Medical Journal this week, which shows that we have a major problem 
of patients coming back into hospital with MRSA bacteraemia during their 
hospital stay or on readmission after they have been discharged.113 The mortality 
112 Dr Joe Selkon wrote: ‘For cost comparison, see Abramson and Sexton (1999).’ Letter to Mrs Lois 
Reynolds, 25 June 2007. See also Pirson et al. (2005).
113 Wyllie et al. (2006).
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rate in these patients was 29 per cent. Let’s get our game together and look at 
hard facts, then you will see that the cost of isolation is, in fact, relatively smaller 
than the real cost, if we have to pay damages on human life, as you would in a 
motorbike accident.
Simmons: Why are the Dutch better than we are at this? Well, I think they have 
learnt that the time to stick your finger in the dyke is before the flood.
Gould: A point on cost, following on from what Joe Selkon said: I am afraid that 
in this day and age most hospitals are actually bankrupt and it’s impossible to get 
an extra penny to spend on infection control. Even with the promise that you 
will repay a thousand-fold in the following year, the money just won’t come.
Dr Stephanie Dancer: I have had a wonderful afternoon so far, and I am sure 
it’s going to continue. It’s been fantastic to hear so many relevant observations 
from the times of the staphylococcal pioneers, whom I hold in great respect. 
In answer to Mike Emmerson, who had suffered the indignity of a swab 
shoved up his nose in the 1960s. I had that too in the 1980s undertaken by 
Professor Shooter, and I didn’t know why at that stage either. In the late 1980s 
I defected across the Thames to Guy’s, where I did a thesis on toxin-producing 
staphylococci, and at that point in time MRSA wasn’t big business, it was toxin-
producing Staph. aureus. Little did I know that the work that I did then on the 
epidemiology of Staph. aureus would be so relevant to the present time, where 
I am a consultant at a busy teaching hospital in Glasgow and fighting MRSA 
every day, two positive bacteraemias a day, and, in order to juggle patients about, 
cohorting positive patients on the ward, because we have no isolation facilities 
and indeed no spare beds at all. 
My final point, said with a huge amount of passion, is that I have just spent the 
last two years trying desperately to get some money together to look at hospital 
cleaning, because it’s something about which I feel very strongly. I went through 
all of the usual sources, and jumped through all the hoops and got through to 
the final stages with at least three legitimate funding bodies, only to be turned 
down for various interesting reasons. I finally accepted the offer of money from 
the health union, UNISON, to set up some cleaning trials in a surgical unit of 
my hospital, where MRSA is endemic. That trial is going to start next week.114
114 Dr Stephanie Dancer wrote: ‘The trial finished in August 2007, and the first paper, “Monitoring 
environmental cleanliness on two surgical wards”, has just been submitted for publication; the second will be 
entitled, “What is the impact of targeted cleaning on methicillin-resistant Staphylococcus aureus (MRSA) in a 
hospital?”. See White et al. (2007, 2008); Dancer (2008).’ E-mail to Mrs Lois Reynolds, 16 January 2008.
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Bud: If you would just like to turn over your exam papers [to page two of the 
Witness Seminar Programme], there are a series of issues which I am sure we will 
cover this afternoon. We need to cover something more about the pharmaceutical 
response and we are really very fortunate that Robert Sutherland, a member of the 
Beecham team from the early days, is with us. We need to talk, I think, a bit more 
about surgery and the changing attitudes to infection. I hope that we will talk 
a little bit more about epidemiology and the hospital response, and then finally 
something about the public response in the 1990s. So, I think there is a series 
of issues on the second page [of the programme], which will provoke a valuable 
response. We should begin with Robert Sutherland, who will get us to think 
about the pharmaceutical response to the challenge of resistant organisms.
Dr Robert Sutherland: I feel a bit intimidated, being the sole representative 
of the pharmaceutical industry here today, along with leading academics. At 
the previous Witness Seminar on ‘Post Penicillin Antibiotics’ in 1998, I think 
due credit was given to the role of Professor Sir Ernst Chain in leading to the 
development of the discovery of 6-aminopenicillanic acid (6-APA) and, of course, 
the development of semisynthetic penicillins.115 When the Beecham workers 
went to work in Professor Chain’s fermentation laboratories in Rome, it was not 
with the intention of discovering the penicillin nucleus, but the fermentation of 
p-aminobenzyl penicillins that could be chemically modified. And, of course, 
the story of the observation of the discrepancy between the chemical assay and 
the biological assay is pretty well known.116 I think it is serendipity in a sense, in 
the same way that Fleming’s discovery of penicillin was a piece of serendipity. 
But, of course, what is interesting is that other companies, Merck and, I think, 
Eli Lilly had also made the same observation, but it was the Beecham workers 
Rolinson, Bachelor, Doyle, and Nayler, who explained the difference between 
the assays and which led to the isolation of 6-APA at Brockham Park, Surrey.117 
Professor Chain was a very enthusiastic consultant and did drive a lot of the 
research in the early days. 
The first penicillin to reach the market was the semisynthetic penicillin, 
phenoxyethyl penicillin, Broxil, which was just a modified penicillin-V, and 
115 See Tansey and Reynolds (eds) (2000); Rolinson and Geddes (2007). See also Abraham (1983). A collection 
of Chain’s papers, CMAC/PP/EBC, is held in Archives and Manuscripts, Wellcome Library, London.
116 Ballio et al. (1959). See also Lazell (1975). 
117 Dr Robert Sutherland wrote: ‘I believe it is important to clarify that the isolation of 6-APA was made at 
Brockham Park and not in Rome.’ Note on draft transcript, 23 January 2007. See Figures 1 and 10.
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caused some excitement among the commercial colleagues, but very little among 
the scientists. But it was the discovery in 1959, not long after the isolation of 
6-APA, of methicillin, with the brand name ‘Celbenin’, a 6-dimethoxyphenyl 
penicillin, and its stability to β-lactamase and consequently its activity against 
β-lactamase-producing staphylococci, which caused great interest, because the 
potential to treat these penicillin-resistant strains of staphylococci or multi-
antibiotic-resistant strains of staphylococci was very exciting. In the early days, 
of course, the papers were talking about ‘Celbenin’-resistance to staphylococci, 
before the approved name became methicillin. But, I now see in a recent paper 
in the Journal of Hospital Infection that we are talking about meticillin-resistant 
staphylococci.118 So, in a sense, we are going round in a big circle. Whether 
meticillin will catch on, instead of methicillin, will be quite interesting. I think 
it was Graham Ayliffe who said: ‘Of course, nowadays methicillin is off the 
market, no longer sold and younger members of the medical profession won’t 
know about it, so they will probably be very happy with meticillin.’
However, after the discovery of methicillin, intensive work was done, obviously, 
on β-lactamase-stable penicillins. In the Beecham Laboratories, several hundred 
strains of Staph. aureus were tested for susceptibility to methicillin in the early 
days and, as I replied to Ian Phillips, I don’t think any resistant strains were 
missed because it was traditional to test these staphylococci at two inocula, a 
large, undiluted inoculum, and a diluted inoculum, analogous to the testing of 
118 See, for example, Coia et al. (2006). Meticillin is the accepted spelling used in the WHO’s 2006 
International Pharmacopoeia (4th edn) guidelines.
Figure 10: The structure of the penicillin nucleus (6-APA) and the methicillin side 
chain. Source: Tansey and Reynolds (eds) (2000): 62–3.
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benzylpenicillin against Staphylococcus aureus, where β-lactamase is the problem. 
So, I don’t think we missed any strains. 
We did notice the heterogenous resistance early on. I think that it was described 
in the first paper in the British Medical Journal; we did look at it. What I found 
of interest, was when we were doing further work, where we subcultured 
β–lactamase-producing MSSA in the presence of methicillin, we could select 
resistant cultures with this heterogenous resistance. What was interesting to 
us I think, was that when you subcultured these strains back into antibiotic-
free medium, the strains retained this minority population of resistant cells, 
whereas when the same kind of test was done on other antibiotics – tetracycline, 
streptomycin – the cultures reverted to full susceptibility in the absence of the 
antibiotic. Very briefly, after the discovery and development of methicillin, we 
then went on to other β–lactamase-stable penicillins. The first was oxacillin, 
which we at Brockham Park concluded was not really sufficiently stable 
to staphylococcal β-lactamase, nor were the oral absorption characteristics 
sufficiently favourable, but this compound was taken up by Bristol Laboratories 
[Syracuse, NY] with whom we had a licensing agreement, and was very successful 
in the US. Next in the isoxazolyl series was cloxacillin, which we felt had the 
degree of activity and β-lactamase stability that was required, and was well 
absorbed orally and by injection. And, of course, that was eventually followed 
by flucloxacillin. We did examine many compounds and we could not find 
any that we felt showed real improvement on flucloxacillin or cloxacillin. The 
chemists thought that they had that area sewn up, but, of course, when Boots 
produced quinacillin, this was a great blow to their pride.119 As an anecdote, we 
had a visit in 1967 when the testing of methicillin-resistant staphylococci, of 
course, was a problem, certainly the inoculum size was very important and the 
observation that incorporation of 5 per cent sodium chloride in the agar made 
it so much easier. We had a visit in 1967 from Dr Douglas Annear from the 
Royal Hospital in Perth [Australia]. He was showing us his results on the effect 
of temperature on the detection of the methicillin resistance. The higher the 
temperature the less resistant the organism became up to 43°C. And, of course, 
at 30°C, resistance is much more readily detected. He then astonished George 
Rolinson and me by announcing that (if my memory plays me right) he had 
been either to the NIMR at Mill Hill, or to Colindale, where he showed these 
results to some unspecified person who told him that they couldn’t be correct, 
because somebody else would have reported them a bit earlier. So, not exactly a 
119 Boots’ quinacillin was introduced in 1963. See Richards et al. (1963).
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prophet in his own country. In our work at Brockham Park we never found any 
compounds active against methicillin-resistant staphylococci, apart from one of 
Professor Chain’s compounds. 
This story started with Professor Chain, so I will finish with him. He and his 
workers at Imperial College isolated the antibacterial agent which he called 
pseudomonic acid from a strain of Pseudomonas fluorescens, well known to 
produce antibacterial activity. I think it had been reported by Garre in the 1880s. 
Professor Chain isolated the material and he was very enthusiastic, until one day 
he seemed very depressed about the whole subject of pseudomonic acid, now 
known as mupirocin.120 When we inquired why, he said: ‘Well, of course, it’s a 
shame that the compound is so toxic, with haemolytic activity against red blood 
cells’. What he was confusing was the high serum binding of the compound, 
which was a disadvantage, but the main problem was that, although mupirocin 
was well absorbed in the body, orally and by injection, it was extensively degraded 
to inactive monic acid. So, it had no potential as an oral or parenteral agent in 
the early 1970s. Much later in the 1980s, somebody had the idea of suggesting 
it as a topical agent, and I believe that topical mupirocin ointment is now used 
for the treatment of the nasal carriage of MRSA. So, the wheel has gone around, 
starting with Professor Chain and finishing with him. 
Emmerson: About this time Beecham’s released mupirocin (formerly called 
pseudomonic acid) in a polyethylene glycol base.121 We in north London had 
a problem with a major outbreak of MRSA infections on a urology ward 
and, since mupirocin was a bit experimental, thank goodness I was a fully 
paid up member of the Medical Protection Society at the time. Through our 
surveillance, we found that the main culprit causing the outbreak in a core ward 
of the hospital was the single remaining urologist. I was a bit nervous about 
sending him off for the usual three weeks of cetrimide and convalescence in 
the Swiss mountains, because I thought that if my prostate played up, I would 
have despatched my only hope. So, we swabbed him and found that his nasal 
carriage sites and axilla yielded pure growths of the outbreak strain. We had 
this gel and, of course, we had to tell him that if you put it up your nose it 
will melt (as it is in a polyethylene glycol base similar to antifreeze). I couldn’t 
send him off work so we had him on pseudomonic acid, so to speak, for 36 
hours, which miraculously cleared him of the MRSA colonization, and we were 
120 Chain and Mellows (1977). See also Fuller et al. (1971).
121 See note 128.
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able to keep him on this treatment, while we coped with the rest of the other 
colonized/infected nine patients. A few years later I moved from north London 
to Belfast; we had a major problem with neonates, and with a slightly different 
preparation, so we started treating the ultra-low birthweight neonates with the 
same compound. We had to be careful to make sure that no pseudomonic acid 
was carried over into the recovery growth medium, otherwise this would have 
biased our results. We overcame this problem by using some activated charcoal 
and sheep red cells etc. At that outbreak, too, we were able to manage, but it was 
at a time when, as Robert [Sutherland] says, pseudomonic acid was absorbed 
into the blood stream, broken down into monic acid very quickly, and caused 
none of the side-effects of hexachlorophane or some of the other compounds. 
Also we were guessing on the dose, and when Mark Casewell came around and 
started doing dose response curves, we realized that we were being rather zealous 
in our management, but at least it broke the two early major outbreaks.122
Duckworth: I am surprised Mark hasn’t put his hand up, so I’ll comment! 
At about the same time that Mike Emmerson was referring to, we were also 
doing work on mupirocin (or pseudomonic acid) under Mark Casewell at the 
London Hospital. We started using it as part of the control programme. We 
had just opened an isolation ward and were screening around four wards a 
week. This was an enormous ‘search and destroy’ operation.123 Mupirocin made 
a tremendous difference to our control efforts, as, prior to that, any staff who 
were found to be colonized were off work for ages. We tried clearing nasal 
carriage with chlorhexidine creams (even using the high concentration cream, 
which I think was the vaginal preparation), but were not successfully clearing 
carriage quickly. Then along came mupirocin and not only did it clear carriage 
of MRSA, but it cleared it so fast that it was no longer necessary to send simple 
nasal carriers off work. After all, it had already taken a couple of days to find 
out that they were positive, so another day for clearance of carriage would make 
little difference to the risk of exposure on the ward. So, it had a dramatic impact 
on control at that time.
Ayliffe: May I mention a controlled trial that Edward Lowbury did in the 
Birmingham Burns Unit?124 Most of the burns patients there in the 1970s were 
colonized by MRSA and there were virtually no clinical infections at all. He 
122 Casewell and Hill (1989, 1991).
123 Duckworth et al. (1988). For work with mupirocin, see Casewell et al. (1984); Hill et al. (1988).
124 Lowbury et al. (1977). See also discussion on page 30.
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treated carriers with flucloxacillin for four days. Surprisingly, the MRSA were 
actually removed from half the burns, and none were removed from the controls. 
So, the explanation was rather difficult, and it was suggested that when burns 
had got all their dressings on, the temperature at the burn surface was probably 
37°C. Further clinical studies on this observation were not made.
Gould: Two contemporary points about mupirocin: in common with many other 
antibiotics, there is certainly a shortage in the UK, if not a world shortage, and 
one wonders, as its use expands, and it undoubtedly will, whether production 
will be upgraded. But as I say, this is a recurring problem with many antibiotics 
these days. But the other note, maybe more cautious, is that a Cochrane Review 
two or three years ago concluded that there was no good evidence that mupirocin 
should be used routinely in attempting to decolonize patients with MRSA.125 
This is, perhaps, a somewhat surprising finding, because I think everyone in this 
room will have anecdotal evidence of the success of mupirocin.
Casewell: Yes, I was surprised that mupirocin initially received such a poor 
reception.126 I presented the results of our in vitro work and the first clinical trial 
to the Interscience Conference on Antimicrobial Agents and Chemotherapy 
(ICAAC) in the US in 1987, but there was very little interest from the 
Americans.127 They seemed less aware that the spread of MRSA might have to do 
with nasal carriage. Coming to the present time, again I was surprised that the 
Cochrane method of reviewing research and producing guidelines for MRSA 
control recently came up with very dubious conclusions about the use of this 
compound.128 I think that view will be revised in future and casts doubts on this 
Department of Health-inspired mechanism of interpreting scientific literature. 
In terms of the supply of mupirocin, it was pretty hard in the 1980s to persuade 
the company [Beecham Pharmaceuticals] that this was a potentially exciting 
and marketable topical agent that had come at just the right moment for MRSA 
125 Loveday et al. (2006).
126 Professor Mark Casewell wrote: ‘It was the impression that they didn’t think nasal carriage was pivotal 
in the control of epidemic staphylococcal spread and were therefore (disappointingly for me) excited by 
the prospects of using mupirocin for the elimination of nasal carriage of MRSA.’ Note on draft transcript, 
12 December 2007.
127 Program and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, 
abstract no. 173, by the American Society for Microbiology, 4–7 October 1987, in New York, NY.
128 Loveday et al. (2006). For a WHO review of recommendations by expert policy groups, see Avorn et al. 
(2001).
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control. In 1984, when we had an outbreak of MRSA at the London Hospital, 
Beecham’s came to my lab and wanted to market it for infected skin lesions, 
for the dermatologists. I asked them whether they had heard of MRSA? The 
representative said: ‘No’, so I explained that we were witnessing one of the 
first outbreaks of MRSA in the UK, and I suggested that, used intranasally, it 
might treat carriers, a great advance as we were all desperate to find something 
to clear nasal carriers. Then they did take an interest. It is available now in the 
US, although they may still need to go to the early literature to appreciate the 
pivotal role of nasal carriage in the spread of MRSA.
Selkon: I am surprised that we actively treat burns patients for Staph. aureus 
colonization. I was trained in the opposite direction by a plastic surgeon of great 
experience in Newcastle who said: ‘Leave the Staph. alone, it helps the graft to 
stick’. I worried about this, so I went to Ted Lowbury in Birmingham, put the 
case to him, and he pondered for a while and said: ‘I think there is something in 
that, I wouldn’t treat a Staph. on a burn unless there was actual pyrexial evidence 
of infection’. I have always followed that advice and I think we have to be very 
careful when we prescribe antibiotics for organisms, on the surface, unless we 
do so with good evidence that it is necessary to do so. They may not be playing 
a pathogenic role.129
Stewart: If you forgive me making a comment, that’s what I referred to when 
I talked about the work in the burns unit in Glasgow, because there were all 
kinds of injuries and burns from war factories and so on. Staph. was not a 
problem, it was the superficial burns, the haemolytic strep that was a problem, 
but the Staph. was not, and I think people there – Leonard Colebrook, Peter 
Medawar, Tom Gibson and others – were perhaps subconsciously observing 
that haemolytic streptococcus was a major problem.130 Now, if you think about 
that and translate it into the world of the maternity ward, the main cause of 
maternal mortality was sepsis due to predominantly haemolytic streptococci; 
it was never a staphylococcal infection, although many of those women were 
carriers of pathogenic staphylococci in the vagina or elsewhere. What really 
made a difference then was something that we don’t have now: a committee was 
appointed, but unlike contemporary committees it wasn’t part of a multiple 
129 Professor Gordon Stewart wrote: ‘It is important, therefore, to check polymorph response, erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) in clinical assessment of superficial infection, and to 
check the phenotype and genotype of the Staph. aureus in the lesion and nose of the patient and attendants.’ 
Note on draft transcript, 8 December 2007.
130 See, for example, Lowbury (1983); Simpson (1988); Clark et al. (1943). 
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committee resistant to organization, it was a single executive committee and 
maternal mortality dropped from being quite high and a problem, very quickly, 
within a few years in the 1950s.131
Simmons: I would like to stress something that Dr Sutherland said. Methicillin 
was discovered in 1959 – the Jevons paper was published in 1961 – and it was 
in general use by 1961. I am told that there are over 90 agents effective against 
methicillin-resistant staphylococci that have not been pursued, because it would 
take at least ten years to bring them to general use. Question: are we right to 
apply the same regulations to the use of a new antibiotic and its production for 
general use, as we do to the use of other drugs which are used for much longer 
than an antibiotic would be?
Ayliffe: May I comment on what Joe said? I wasn’t actually suggesting that 
cloxacillin was being used for the treatment of the staphylococcus. It was used 
for streptococci and it was an accidental finding that MRSA were removed and 
followed up with a trial.132
Professor Gary French: May I comment on antimicrobial resistance and new drugs 
for MRSA? Not only are these organisms methicillin resistant, but they are often 
– not always but often – multiply antibiotic resistant. One of the reasons is that 
the chromosomal area where the mecA gene is inserted has other sites where other 
variance genes can be inserted, making them stable. These organisms also rapidly 
become resistant to quinolones by chromosomal mutation. About 90 per cent of 
MRSA strains are now resistant to quinolones, while methicillin-sensitive Staph. 
aureus (MSSA) generally remains fully sensitive to quinolones. Thus ‘multiresistant’ 
Staph. aureus is a better phrase than ‘methicillin-resistant’ Staph. aureus and their 
spread is probably encouraged by antimicrobial therapy in hospitals.
Most of the antibiotics used against Staph. aureus are not as good as methicillin/
flucloxacillin. Flucloxacillin is a great drug: it penetrates the cells and tissues 
well, is highly bactericidal and is one of the great drugs of the twentieth century.
Many of the other agents that we have for Staph. aureus appear not to be so 
effective (although older agents have not been trialled against MRSA). Once 
methicillin resistance emerged, we were forced back on older drugs, especially 
vancomycin, a drug which is only available parenterally [using a muscle, vein 
131 The local sanitary authority was to send a medical officer of health to be a member of the control of 
infection committee set up by hospital management committees and local hospital boards. Ministry of 
Health (1956): 8. See also Barber et al. (1960).  
132 Lowbury et al. (1977).
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or any pathway in to the body other than by mouth], is potentially toxic, only 
slowly bactericidal and has relatively poor tissue penetration. For 30 years there 
was no resistance to this drug in Staph. aureus, probably partly because it was 
hardly ever used, because it was so toxic.133 It was called Mississippi Mud, because 
of the impurities present and it required a further purification process before 
most people would be prepared to use it, but with the emergence of MRSA, 
vancomycin began to be used much more widely. 
Teicoplanin, the other glycopeptide, is much less toxic and serum assays were 
not made available [by the manufacturer to doctors] for it to emphasize its 
safety. Ironically, because many doctors were frightened of vancomycin toxicity, 
they were also wary of teicoplanin, and tended to underdose because they could 
not perform assays. As a result, the early literature has many reports of failures 
with teicoplanin and this may be part of the reason why teicoplanin was never 
licensed in the US. Although teicoplanin works very well, it is not used nearly 
so much as vancomycin.134 
In the mid-1980s vancomycin usage increased dramatically for the treatment 
of MRSA, methicillin-resistant coagulase-negative staphylococci and as an oral 
agent for Clostridium difficile diarrhoea.135 Inevitably, about the same time reports 
133 Professor Harold Lambert suggested in the 1998 Witness Seminar that vancomycin was, at that time, 
the accepted reserve drug [Tansey and Reynolds (eds) (2000): 54]. For other antibiotic policies of the time, 
see Williams et al. (1960): 218.
134 Professor Gary French wrote: ‘Inevitably, around the same time reports began to appear of vancomycin 
resistance in enterococci [Woodford et al. (1995)]. This was high level resistance to both vancomycin and 
teicoplanin – hence glycopeptide-resistant enterococci, (GRE), also called vancomycin-resistant enterococci 
(VRE), which is encoded by a transposon on a transferable plasmid. GRE have since become more common, 
especially in the US. In Europe, GRE are found in the bowels of animals fed the glycopeptide avoparcin 
as a food supplement and in faeces of normal people in the community [Bates (1997)]. The evidence is 
incomplete, but it is widely accepted that the use of avoparcin in animal husbandry is associated with the 
emergence of GRE in animal faeces that may enter the food chain and colonize humans [Witte (2000)]. 
There has been continuing concern about the possible transfer of glycopeptide resistance from GRE to 
MRSA. Transfer to S. aureus was first done experimentally on the skin of nude mice by Bill Noble at St 
Thomas’ Hospital [Noble et al. (1992)]. However, the first report of a clinical isolate of fully vancomycin-
resistant MRSA did not occur until ten years later [Sievert et al. (2002)] and there have been only a handful 
of such isolates since then, all from the US. Thus, transfer of high level vancomycin resistance from GRE 
to MRSA is fortunately a rare phenomenon, despite the millions of opportunities there must have been for 
these organisms to interact in hospitalized patients.’ Note on draft transcript, 4 December 2007.
135 Kirst et al. (1998).
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began to appear of vancomycin resistance in enterococci.136 This was high-level 
vancomycin resistance on a transmissible plasmid and we were very concerned 
about the transfer of this plasmid into MRSA. There must have been millions of 
opportunities for the vancomycin-resistant enterococci to interact with MRSA, 
but vancomycin resistance transfer has hardly ever happened.137 Bill Noble in St 
Thomas’ Hospital first did it in the lab on the skin of naked mice. There’s some 
debate about whether he should have done this, but he made a transfer in the 
lab, some ten years before it actually happened clinically.138 
As you know, around the 1970s many pharmaceutical companies stopped 
pursuing antimicrobial therapy. It can take ten or 15 years to get a drug on the 
market and by then the organisms might well have changed entirely. Already by 
the 1970s there were something like 13 different classes of antibiotics that are 
naturally active against MSSA, including the excellent flucloxacillin. There was 
therefore no clinical or commercial pressure to develop new agents for Gram-
positive infections. However, by the late 1980s, multi-drug-resistant MRSA, 
enterococci and pneumococci had unexpectedly emerged and treatment was 
dramatically compromised. No agents for Gram-positive infections were in 
development, but by chance DuPont had discovered the oxazolidinones in 
the 1970s. 
These are entirely artificial compounds that had in-vitro activity against Gram-
positive bacteria, but were not developed for human use because of serious 
animal toxicity.139 
The Upjohn Company revived oxazolidinone research in the 1990s and 
discovered new derivatives that retained good antibacterial activity but without 
animal toxicity.140 The first of these to be developed for clinical use was linezolid 
which is active against most clinically important Gram-positive bacteria and 
is now one of the standard treatments for serious MRSA infections.141 The 
oxazolidonones are available orally as well as parenterally and are the first new 
antibacterial class to be introduced into clinical use for 30 years. In one of the 
136 Reviewed by Woodford et al. (1995).
137 See note 138.
138 Noble et al. (1992).
139 Slee et al. (1987).
140 Ford et al. (1996).
141 Gemmell et al. (2006).
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labs in the Upjohn research centre at the Kalamazoo was a small group of people 
headed by a scientist called Chuck Ford. They investigated these compounds 
before it was clear that they were needed, because they were inherently 
interesting. Every year he went to the Board and said something like: ‘We need 
more money for this interesting research’, and they were given it without much 
need to prove commercial usefulness. Eventually they emerged with linezolid, 
the first member of a new class of antimicrobials for 30 years. Meanwhile, just 
at the time the MRSA crises were recognized. 
Nevertheless, the problem outlined by Norman [Simmons] remains: it is so 
expensive, so difficult and so commercially dangerous to produce new antibiotics, 
that a continuing supply of effective agents is unlikely. As we generate more 
and more resistant strains, we run into trouble because the pharmaceutical 
companies may not come to rescue us. That’s just another reason not to generate 
new resistances and to try to bring them under control.142
Gemmell: I would just like to add a bit to the story about Upjohn. In 1982 
I was sent two phials of powder, both Upjohn names, but one was linezolid 
and one was eperezolid, and, in fact, because of superior in-vitro activity the 
company went with linezolid. But it was 1982 when the first white powder 
studies were done.
Selkon: I forgot to complete the story a moment ago, in saying that despite 
the reassurance from Edward Lowbury, I was rather worried at the potential 
of not treating Staph. colonization in our burns unit and we looked for them 
very carefully. Whenever a patient was pyrexial, we did grow streps, we did 
grow Klebsiella, we did grow Pseudomonas, but we have never ever had a Staph. 
septicaemia. I would very much like to know if anybody dealing with burns has 
in fact had a Staph. septicaemia.
Sutherland: In reply to Dr Simmon’s plea for accelerated testing of antibiotics, 
I have great sympathy, but if I recall right, the early penicillins were in the 
pre-thalidomide theory period and toxicity was not really appreciated. I must 
say, when I look back at Brockham Park in the early 1960s, we were testing 
something like two new penicillins a week in human volunteers. Members 
of staff were paid three guineas [£3.3s.0d; £3.15], plus a hearty breakfast, to 
142 Dr Geoff Scott wrote: ‘Several successful studies to control resistant organisms by limiting antibiotics 
were published in the early days. For example, Mary Barber and her colleagues (1960) showed that penicillin 
resistance in staphylococci could be reduced by restricting penicillins.’ Note on draft transcript, 14 January 
2008. See also Appendix 2, page 82.
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give five or six samples of blood – no follow-up, no group medical attention 
afterwards. Penicillin is a very safe molecule.143 I am not sure I would suggest 
that for other antibiotic molecules. 
Stewart: I wonder in this respect if the methodology has some gaps. I would be 
interested to know what some of the experts like Dr Sutherland would say about 
this. If you take the usual method of testing, it is gravimetric, it’s micrograms 
per ml [µg/ml]. This means that you can spot differences in molecular weight. 
If you remember the sequence of BRL syntheses, methicillin was number 1241. 
There was a number before that called 1060 (or was it 1061?), in which I had 
taken an interest because of the known activity of an additional amino group 
in the side chain. This didn’t, at first, appear to hold too much promise when 
assayed by the gravimetric method. But, when assayed chromatographically, it 
turned out that there were two epimers: one was highly active, that was the D(-) 
epimer, which is what you would expect in something which is an oligopeptide 
which penicillins are, and the L(+) was not active by comparison. The reason 
that Beecham’s very wisely went to ampicillin was by a differential calculation of 
the amount of activity that was contributed by the active D(-) epimer.144 
Now a similar thing has occurred to me with regard to vancomycin, and some of 
the others like daptomycin, in that category. Vancomycin has a molecular weight 
of about 1800, penicillin G has a molecular weight of about 220, methicillin has 
a molecular weight of about 230 or 240, and so on, and ampicillin similar. Now, 
if you then assay by the µg/ml, do a micrograms per molar comparison, and 
then compare that with the gravimetric one, then you find, of course, that the 
penicillin molecule – like the ampicillin molecule, like the methicillin molecule 
– is very much more active than the vancomycin molecule, or the daptomycin 
molecule, or some others that are much heavier. So in terms of the assay, the 
number of molecules which are active could appear to be too small to be any use 
in the assay. You could reject that in terms of toxicity. So you need a differential 
143 Professor Gordon Stewart wrote: ‘This fact is often forgotten because of fear of allergy, which was largely 
overcome by cessation of topical therapy and removal of macromolecular residues of manufacture or storage 
of natural penicillin and ampicillin that have allergenic and therapeutic activity in the nanometric range, 
but are safe at gramme per day levels though if given as potassium salts in high doses, toxicity can be caused 
by the medication. Blood levels, counts and renal function should be tested when antimicrobials are used in 
high or continuous dosage, to facilitate and regulate high dose therapy for “resistant” infections. Used this 
way, isoxazolyl penicillins could be a safer option than vancomycin in treating refractory MRSA or other 
amphoteric, high molecular weight antigenic glycopeptides.’ Note on draft transcript, 8 December 2007.
144 See note 38. Ampicillin was known as BRL1341.
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which will be calculated in terms of the molar strength. Would you have any 
observation from that, Robert [Sutherland][From the floor: I would need notice 
of that question]. Well, it was your company that I had the arguments with.
Richmond: From my experience in the pharmaceutical industry fairly recently, 
most people measure things in terms of nanomols, so I don’t know that that 
argument holds up. 
Can I make a comment about the pharmaceutical industry and its search for 
antibacterials? It seems to me an interesting change has come over the world; it’s 
something that I have been quite heavily involved with for the last two or three 
years – or more, five years. The major companies have actually abandoned their 
work in anti-infectives. I suppose the most spectacular was Roche who decided 
that they wouldn’t pursue a follower for Rocefin, when it was making them well 
over $1 billion a year. But what they have done, of course, is to fund a very large 
number of small start-up companies, particularly in the US, but a few in this 
country, with a view to using the originality and excitement of the people that 
run those companies to find new molecules, at which point they will buy them. 
I think we are seeing part of the evolution of ‘big Pharma’, which is the setting 
up of their out-of-house research activities, but under control, and it’s been 
particularly noticeable in the area of anti-infectives.
Stewart: Is this what you would call ‘in-sourcing’ or ‘out-sourcing’?
Richmond: Well, they have put in the money and it’s risk capital.
Newsom: Can I just go back to vancomycin for a minute? I have the original 
vancomycin data sheet, which tells me that it is a substance which is 82 per cent 
pure, and vancomycin I think was licensed by the FDA, it must have been in 
desperation, within 18 months of the fungus first being isolated. So that was a 
‘needs must’ situation.
Stewart: And justifiably, too. 
Newsom: Yes, well, they thought so.
Stewart: Yes, it is a product of a different genus and a different line of thinking, and 
there is room for exploration there. One of the difficulties is that opportunities for 
patents with molecules are limited and are explored very widely for other reasons, 
for example the hydroxyquinolines and the quinoline group generally. This is 
what I think obstructed quinacillin, which was an obvious lead to follow. There is 
now some evidence that new forms of quinolines might be more active.
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Gould: In terms of fast tracking new agents, I think the US FDA has done that 
recently for anti-retroviral drugs. But until two or three years ago, probably, 
it was highly arguable whether there was a perceived need. There was great 
debate, and still is in some quarters, about the relative pathogenicity of MRSA 
vs MSSA.145 While two or three meta-analyses definitely now ascribe at least 
double the mortality to serious MRSA infection, compared with MSSA, there 
are certainly going to be strain differences and complications to do with the 
underlying risk factors in patients. But, I think, recent evidence does confirm that 
even with rapid institution of appropriate therapy against MRSA infections, the 
outcome still is inferior. I think Gary’s point about flucloxacillin and oxacillin 
really being superb drugs that have not yet been equalled for MRSA, with the 
possible exception of linezolid, the jury is still out. We have to do a lot more 
public relations with pharmaceutical companies, if we are really to convince 
them of the need for new drugs.
Stewart: Well, this is why the National Research Development Corporation 
(NRDC) was formed, and in its day it was very successful. I don’t think we 
would have had cephalosporins without the NRDC.146 
145 Gould (1958); Anon (1958b). See also Whitby et al. (2001); Salgado et al. (2003); Shorr (2007).
146 For the background of the NRDC’s worldwide patenting and licensing scheme and the royalties generated 
by the cephalosporins, see the papers and correspondence of Sir Edward Penley Abraham (1913–99), GB 
0161, held at the Bodleian Library, Oxford; Keith (1981). See also Tansey and Reynolds (eds) (2000): 
38–43.
Figure 11: Stages of vancomycin development, 1956–81. L: ‘Mississippi mud’, early sample 
of compound 05865; M: vancomycin purified with picric acid precipitation; R: vancomycin 
hydrochloride. Griffith (1981): S202.
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Hamilton-Miller: I know for a fact that Schering dropped everninomycin, 
which was a very good anti-MRSA drug, because they didn’t think there was 
enough market for it.147 I am sure this sort of thing also happened at other drug 
companies. Concerning the oxazolidinones: DuPont were originally working 
on agrochemicals, with no interest in medicine. By chance, they picked a useless 
agrochemical compound off the shelf, found it was an active antibacterial and 
developed the series.148
Bud: Shall we move on then towards another section and I think we have 
persuaded John West to say a few words to kick off this section on changing 
attitudes to infection.
Professor John West: I was asked to say something about antibiotics and 
surgery, and first I should say that I think I am here under false pretences. I am 
a clinical physiologist with an interest in the history of medicine, but I don’t 
know much about MRSA. But perhaps I can tell you an anecdote about my 
father, an orthopaedic surgeon trained in Liverpool in about 1935, and then 
returned to Adelaide, Australia, where we come from. (Incidentally, I just might 
mention that Howard Florey also came from Adelaide, because we have already 
heard about Fleming and Chain.) When my father got back to Adelaide with 
his orthopaedic degree, he had a very frosty reception from the general surgeons, 
who claimed that they could do anything that an orthopaedic surgeon could. But 
then two important things happened: one was the outbreak of the Second World 
War. My father was sent to a hospital in Palestine, where he looked after a lot of 
Australians who had been fighting in North Africa, and had lots of terrible bone 
injuries. The other important thing was that penicillin came along. Penicillin, 
according to my father, absolutely made all the difference to orthopaedic surgery. 
There was no way you could do things to bones that orthopaedic surgeons 
wanted to do without penicillin. It completely revolutionized that area, and I 
presume it is still an important factor. Incidentally it is interesting that although 
the general surgeons, as I said were rather arrogant in the late 1930s, it turns 
out now – at least in our institution – that the orthopaedic surgeons are the 
top dogs, and the general surgeons are actually relatively minor. I think that 
as far as orthopaedic surgery is concerned, the introduction of antibiotics was 
absolutely critical.149 
147 Dr Geoff Scott wrote: ‘Everninomycin caused reversible renal failure in about 1:15 volunteers, which was 
one major reason the development was discontinued.’ Note on draft transcript, 14 January 2008. 
148 See Daly et al. (1988); Gregory et al. (1990). 
149 See Reynolds and Tansey (eds) (2007a).
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Bud: Do people want to talk about the attitude of surgeons when they started 
encountering antibiotic-resistant bacteria, and cleanliness?
From the audience: Ogston became famous for operating on knock-knees. He 
had to change from being an ophthalmic surgeon into an orthopaedic surgeon 
and he later became Surgeon to the Queen. So, there you are, it’s very important, 
they all went on.150 
Shanson: My experience during the last 30 years in many hospitals suggests that 
most surgeons generally didn’t think much of MRSA. Patients were colonized, 
or often only had mild wound sepsis, and the surgeons weren’t very impressed 
when you asked them to isolate their patients. I once had a difficult urologist 
problem. During one week at St Stephen’s Hospital [now part of the Chelsea 
and Westminster Hospital, London], several urological patients developed deep-
wound sepsis, within a short time of operation.151 There was another hospital 
in north London where this urological surgeon worked and the microbiologist 
phoned me and said have you got any problem with Mr X’s patients, because this 
hospital also had a lot of deep-wound sepsis in his patients, and that was within 
a fortnight of our experience.152 The urological surgeon didn’t think much of 
MRSA, he didn’t think he was doing much harm, but I had to investigate him and 
stop him operating. He applied various antiseptics to his skin before I swabbed 
him, but we none the less isolated the epidemic MRSA strain from him. He was 
initially resistant to treatment and had an eczematous skin lesion on his hand. We 
had to change his dermatologist to get his skin better and after various treatments 
he became MRSA-negative and started to operate again. I got some advice from 
Graham Ayliffe, at the Hospital Infection Research Laboratory in Birmingham, 
on various impermeable gowns for him to use. Unfortunately about eight months 
later, the same MRSA strain came back again with a new outbreak of theatre-
acquired wound sepsis involving only his patients. This time, he was afraid for 
his livelihood, and I had to get the ‘three wise men’ of the hospital and the house 
governor to stop him operating again. Eventually we got his cooperation, and 
finally managed to clear him permanently of MRSA carriage. 
Phillips: Another anecdote about surgeons. My experience over the years is that 
they respond to a dramatic event. This particular dramatic event was our first 
couple of EMRSAs in cardiac patients. I had been giving a talk in Vienna, 
150 See also Newsom (2004). 
151 Shanson and McSwiggan (1980).
152 See Professor Michael Emmerson’s description on page 49.
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saying that we didn’t have MRSA and I came back to find two patients in 
adjacent beds, one of whom had an aortic aneurysm infected with MRSA. 
The old tradition was that you put sawdust around these unfortunate people, 
for fairly obvious reasons. His aorta duly ruptured into his oesophagus. The 
surgeons then believed and supported us. And, they spread the word.
Dr Geoffrey Scott: I am sorry I have remained curiously silent for so long, but 
I just wanted to reiterate what Stephanie had said a bit earlier on that this is an 
extraordinary meeting. It’s a great pleasure to be here and listen to everybody’s 
witness to what happened. I read that in the 1950s when penicillin-resistant 
Staphylococcus aureus emerged that there were reports of outbreaks of surgical 
sepsis of about 25 per cent in many hospitals, to the extent that the MRC started 
to look into this.153 They went around the hospitals, and of course they found 
that there were very high rates of post-surgical infection with penicillin-resistant 
Staph. aureus in all of the hospitals. They went to the surgeons and asked, ‘How 
many infections do you think you have?’ and they all said, ‘Nil’. And, as I teach 
the medical students, the reason for that is that they liked to examine patients 
with lumps and bumps and operate on them, but they are not really terribly 
interested in outcome and left post-operative care to their juniors. Of course, if 
they look inwardly at their outcomes, then perhaps reflecting on patients who 
had had a bad outcome would make life quite difficult to deal with. After all, 
they are the people who are actually going to do things to patients and for that 
they have my highest respect. 
Nowadays, surgeons, of course, do the most extraordinary things to patients in 
terms of the risks to them and to older and older patients as well. People become 
more and more susceptible to infection. Surgeons work in a sea of multi-resistant 
organisms, not only the Gram-positives, but also the Gram-negatives, some of 
which are very resistant. And yet, even in a hospital like UCH next door, given 
that there’s a certain amount of MRSA floating around, moving around, if you 
go to any one individual surgeon and say, ‘Do you feel that this is a problem?’, 
or to a physician within, say, a medical committee, they don’t perceive it to be 
a problem. This is because if you take any individual person, they will, perhaps, 
see one infected patient every three months. If you have a sufficient number 
of consultants, the amount of work is divided up rather in such a way that the 
number of cases is not so great as to have a big influence on their brains. That is 
difficult for infection control people, because they are seeing all the cases every 
day. I tend to have a very jaundiced view of the outcome of work within our 
153 MRC, Cross Infection Committee (1951). For an earlier MRC report, see Hill (1934). 
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hospital, because I see the patients for whom the treatment has gone wrong, who 
have problems, who have infections and so on. And it was ever thus. So, I think 
the attitudes of the people within this room might be rather subtly different.
Duckworth: I concur with what Ian Phillips said about a dramatic event having 
an incredible capacity to focus the mind. In the early days of the London 
Hospital outbreak, it affected cardiothoracic surgery – chest walls just fell 
apart post-operatively, so that you saw everything you shouldn’t see inside the 
chest. That certainly got our surgical colleagues on board pretty fast. Turning 
to the recent surgical site infection data, many hospitals participate routinely 
in surgical site infection surveillance, and some of it is mandatory, for instance 
in orthopaedics.154 Now the overall infection figures are very worrying from the 
point of view of MRSA, but, as you would expect, Staph. aureus accounts for 
the majority of these post-operative infections, but around 60 per cent of the 
Staph. aureus infections are due to MRSA. 
Simmons: I retired in about the mid-1990s. I had one surgeon who had TB and 
didn’t want to stop operating, but we persuaded him in a few short sentences. I 
never had a problem with any other surgeon, physician, administrator, manager 
of any sort, not doing what I thought was necessary to end an outbreak. Never 
a one. If I said a ward had to close, it closed, and we told him [the surgeon] 
it was shut. If I said the patients needed isolating, they were isolated. I never 
deferred to the management in terms of the prevention of infection. That’s 
my job. I have a responsibility to patients, that’s what I regarded it as. But I 
never for one minute had a surgeon who refused to do what I told them to 
do in respect of infection. If he wanted to operate, I never interfered with his 
operating technique, and he wouldn’t interfere with my responsibility. 
French: I agree with two or three points which have been made about surgeons 
paying attention to infection. There is now evidence from meta-analyses to 
show that patients with MRSA infections do worse than those with MSSA, 
when other factors are controlled for.155 This is certainly true anecdotally, and 
our surgeons – especially those in cardiac, vascular and orthopaedic (implant) 
surgery – are now frightened of MRSA infection. I think this is the first time 
surgeons have been scared of bacteria for 40 years. 
154 Health Protection Agency (2007c).
155 Whitby et al. (2001); Cosgrove et al. (2003); Engemann et al. (2003).
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Surgeons are also very concerned about litigation. At the present time MRSA 
is nearly always acquired in hospital, and the lawyers know this. The surgeons 
quite rightly are very concerned about the legal aspects. A patient who comes 
into hospital for a routine operation, acquires MRSA and suffers serious post-
operative sepsis, is likely to take the hospital and surgeon to court for negligence. 
A similar infection with MSSA may not be challenged because MSSA is more 
likely to be acquired in the community. MRSA are regarded as being hospital-
acquired, and therefore preventable.
Chattopadhyay: I must be the odd man out to be defending the surgeons. I must 
say that the culture is changing, and it is changing fast. There are several reasons 
for it, we have already heard from Gary [French] that they are under the spotlight. 
First, their post-operative infection rate; second, their post-operative mortality; 
and third, post-operative adverse events, like taking patients back to the theatre 
again; and finally, re-admission. Surgeons are very serious about these issues and 
I understand that the league table is there, for cardiac surgeons, for everyone to 
see, and is in the public domain. But what we also found very helpful was to have 
an active surgeon, Mr Ravi Kunzru, on our [Whipps Cross] Hospital Infections 
Control Committee.156 In this case it was an orthopaedic surgeon who was really 
brilliant, and he used to take these bad messages back to his colleagues, and we 
got nothing but support from this orthopaedic surgeon and I think unless we can 
take them on board, we are unlikely to achieve what we are aiming for.
Stewart: With certain reservations, I would also like to throw in a favourable word 
for surgeons. For one thing, and I mention one name in particular, Mr Harold H 
Nixon, a surgeon (unfortunately, now dead) of Great Ormond Street, London, 
who also had beds at Queen Mary’s Hospital for Children [Carshalton].157 He 
was the first surgeon who saw the need – I was working with him at the time 
– to use the new penicillins on surgical cases, and the first convincing case was 
one of a child who had undergone neurosurgical procedures and others followed 
later.158 This was what first convinced people clinically that there was a strong 
case for using methicillin. The surgeons had been dragging their feet until then. 
Now that was important. But, if you think back again about the surgeons, when 
Ogston discovered Staph. aureus, c. 1865, there was no evidence that other 
156 See Reynolds and Tansey (eds) (2007a).
157 Nixon and O’Donnell (1961).
158 Stewart et al. (1960); Callaghan et al. (1961). 
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surgeons paid a lot of attention to this, except that he himself was a surgeon.159 
Two years later in Glasgow Royal Infirmary, Lord Joseph Lister discovered cross-
infection due to staphylococci, and used Ogston’s work, and that was what came 
through as cross-infection in surgical wards. In surgical wards, with cases of 
fractures and so on, you got cross-infection and staphylococcal osteomyelitis and 
bacteraemia, septicaemia, whereas in burns units there were superficial infections, 
streptococcal infections, different things; staphylococci were in their own niche. 
So surgeons have had a key role in all this and I would say that today the main 
problem in MRSA is with the surgical side, and it’s essential that surgeons are 
kept in the picture all the way. My experience is that if that is done, then they 
are immensely helpful. But there are difficulties now, because many surgeons are 
not in control of their own wards, they can’t open them, they can’t close them, 
sometimes they can’t admit patients. Sometimes if they do admit patients, the 
patient is transferred without their being consulted. I have kept tabs on half a 
dozen such cases, very severe, and one fatal, in the past two or three years, and I 
have been myself consulted about that. There is a strong administrative pressure, 
which defeats clinical independence. This has to be recognized. 
Bud: I think that leads us very nicely to the questions of epidemiology and 
I think Professor Spratt could lead off on this topic. Well, would we like to 
talk about it from a different angle then, about the Staphylococcal Reference 
Laboratories, because we have two people here, Dr Pitt from England and 
Professor Gemmell from Scotland.
Duckworth: What the general epidemiology has been showing is that rates 
of MRSA have risen dramatically, from less than 2 per cent of Staph. aureus 
bacteraemias in the early 1990s to around 40 per cent at the turn of the 
millennium.160 However, focusing on MRSA as a proportion of all Staph. aureus 
bacteraemias hides the fact that methicillin-susceptible Staph. aureus (MSSA) 
bacteraemias have been rising as well. I think a lot of this focus on MRSA takes 
our eye off the ball as regards methicillin-sensitive Staph. aureus. 
Coming back to what’s been happening recently (I can really only speak about 
English data), the control of MRSA is extremely high profile. It is very high on 
the Government’s agenda. Unlike the situation Joe was rueing earlier, it is now 
very much the Government who is driving action to reduce MRSA. I think it is 
quite sad that action has had to come from the Government and not from our 
159 Ogston (1984).
160 Duckworth and Charlett (2005).
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colleagues. Many of our colleagues got very blasé about MRSA. There was much 
complacency, an attitude of ‘we have to live with MRSA’. The mortality associated 
with MRSA was not being recognized. Joe [Selkon] alluded to a recent paper from 
Oxford, which indicated high mortality, and if you look at the Office for National 
Statistics (ONS) data, they show that mention of MRSA on death certificates 
has increased in parallel with the rise in MRSA bacteraemias.161 We are currently 
undertaking a study with ONS to examine this in more depth. But coming 
back to my point about the Government driving action, what this has meant 
is that reporting of MRSA bacteraemias became mandatory from April 2001.162 
Subsequently, reduction of MRSA bacteraemias has become one of the NHS’ 
top 20 targets (a 50 per cent reduction by 2008). The Trust’s Chief Executive 
has to sign off the Trust’s MRSA data monthly and this data is being scrutinized 
closely, not only by the Department of Health, but also by the Prime Minister’s 
Delivery Unit. If a trust looks as if it is not on course to meet its target, that 
information immediately flows along the performance management pathway, to 
the Strategic Health Authority (or monitor for Foundation Trusts). Trusts that are 
not improving are visited by Department of Health review teams to assess action 
within the Trust and develop an action plan. So, as you can see, MRSA control 
is extremely high profile. The impact of this so far on the data is that MRSA 
bacteraemias appear to have plateaued since reporting became mandatory, but 
this is against a background of ever-rising rates before then. So, although Ministers 
etc. are unhappy that further national reductions are not yet visible, in my book 
a plateau gives cause for optimism against the increases we were seeing year on 
year before. There is nothing to indicate that levels would have automatically 
plateaued, as the story from some other countries has been that MRSA levels can 
go on rising, well beyond 40 per cent of all Staph. aureus bacteraemias.
Bud: Do you or anybody else want to comment on what happened to transform 
the political response from what we saw earlier, what people have been talking 
about, which is an ambivalent attitude within the profession towards this very 
strong political response?
Scott: A lot of this was driven by high-profile political people being lobbied by 
ordinary people in the country, saying that their loved ones, their dear ones, 
had died from hospital-associated infection. I was the first Press Officer for the 
161 Wyllie et al. (2006). The ONS data is reviewed in Griffiths et al. (2004).
162 Every NHS Trust in England and Wales must record and report levels of hospital-acquired infection after 
April 2001. Health, Department of (2000, 2001, 2004). For the most recent targets, see Department of 
Health (2008); Figure 12.
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Hospital Infection Society, and at the time that we had our first international 
meeting, I can’t quite remember when it was now – 1987, thank you, David 
[Shanson] – I didn’t know anything about being a press officer and I said, ‘What 
do you want me to show?’ They said: ‘We want you to show that there is a 
Hospital Infection Society’. Of course, nobody knew anything about hospital 
infection at that time. I would say that we had quite a successful campaign, but 
in fact what I learnt was that the only news is bad news. We had some very, very 
interesting statements like [those from] Richard Marples, our great leader of 
our Staphylococcal Reference Lab, saying that the only way to get rid of MRSA 
would be to burn the hospitals down.163 There is one nice quote, and I think it was 
Peter Davey, who said that the surgeons were the reason for MRSA and all these 
surgical infections. We were pushing quite hard to get some recognition and the 
newspapers were picking up on stories all the time, but in fact it rebounded on 
us in a way, because when people started to get MRSA sepsis and perhaps even 
succumb from it, that became very serious public and political news. Of course, 
MPs are lobbied, and if relatives of MPs get this infection, then they go to the 
163 See, for example, Marples (1981); Marples and Richardson (1982); Richardson and Marples (1982).
Figure 12: Staphylococcus aureus bacteraemia reports received under the voluntary and 
mandatory surveillance schemes in England, 1990–2006. Mandatory surveillance started  
in April 2001. Source Health Protection Agency. . 
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Secretary of State for Health and say, ‘Well, what are you going to do about it?’ 
Of course, in this Government they set targets, as Georgia [Duckworth] has 
said, they set a target for us to reduce our MRSA. But, as Ian Phillips said, we 
do not know the scientific determinants for the spread of this organism. We 
do not know, because we have not done the proper research to find what it is 
that makes this organism tick, and I don’t mean MRSA, I mean Staphylococcus 
aureus. Gary [French] is right to say that MRSA is probably worse for you than 
MSSA [methicillin-sensitive Staph. aureus], but that is the status today, and if we 
had virulent penicillin-tetracycline-resistant Staph. aureus floating around our 
hospitals – ‘phage type 80/81 as in the 1970s – I could promise you that some 
of our patients would be doing exceedingly badly, if they picked that up.164 There 
are so many linked factors in the evolution of this organism within our hospital 
practice, that it’s almost impossible to get our brains around them. So, I would 
say that a target has been set, but it’s rather like King Canute being asked to 
hold back the waves. He didn’t know quite how to do it, he hadn’t been given 
guidance on the moon, and astronomy, and actually how to change the waves 
and so on, and similarly, we have been set a target for MRSA rates and nobody 
really knows what it is that we have to do to reduce the burden of the bug in our 
hospitals. I think that’s a very important thing for us to consider as a group.
Selkon: It is very pleasing to hear that the Prime Minister’s office is considering, 
involved and worried about MRSA: good intentions. But until we have the great 
pressure removed from our hospitals to get the waiting lists down, we have got 
to keep on running at up to 102 per cent bed occupancy in our surgical wards. 
The present newly arrived efficiency expert appointed to our hospital has now 
decided that the operating theatres were only used for 87 per cent of the time 
available and this is to be increased to 93 per cent, and the number of pathology 
investigations should be reduced. Perhaps if we reduced the number of wound 
swabs, the prevalence of MRSA infection will also be reduced. Until the load on 
the hospitals to undertake non-essential surgery is reduced, I don’t see how we 
can, with our inadequate isolation facilities, achieve safety for our patients.
French: I agree with Geoff [Scott] in this. When patients die with MRSA sepsis, 
their grieving relatives notice that the wards are crowded, dirty and understaffed 
and are rightly outraged. Things are changing dramatically, but until recently, 
standards of cleanliness and hygienic practice in some hospitals have been 
poor. Microbiologists did not draw a line in the sand over this because it has 
164 See, for example, Robinson et al. (2005).
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been difficult scientifically to prove a clear association between environmental 
contamination and infection and managers took advantage of this to cut costs. 
R E O Williams said that Staph. aureus was his favourite organism, because it 
had designed hospitals. All the standard hygienic practices in hospitals that we 
are supposed to ensure is done – smooth floors, cleaning, damp mopping, hand 
washing, sterile uniforms, separate operating theatres, changing bedclothes, 
filtering the air – everything is directed primarily at the control of Staph. 
aureus.165 We need to continue to maintain hospital hygiene.166 
I have to add that the microbiologists didn’t help, because there was a big 
debate – very interesting historically – as to whether MRSA was important. 
Many people felt that we were wrong to take MRSA more seriously than MSSA 
and that a great MRSA industry has arisen that was totally unrelated to the 
importance of the organism in their hospitals. For some hospitals this may have 
been true.167 When the 1998 Guidance on the control of MRSA came out, there 
was a bitter exchange of letters in the Journal of Hospital Infection, in which half 
the country’s microbiologists more or less said this guidance was a waste of time, 
and by implication was written by London elitists, who knew nothing about 
165 See, for example, French et al. (2004). 
166 The British Broadcasting Corporation’s Panorama investigation, ‘Undercover hospital cleaner’, was 
broadcast on Wednesday, 13 July 2005, on BBC One. Health Secretary Alan Johnson announced that by 
January 2008: ‘Hospitals will adopt a new “bare below the elbows” dress code, i.e. short sleeves, no wrist 
watch, no jewellery and allied to this the avoidance of ties when carrying out clinical activity. The traditional 
doctors’ white coat will not be allowed. The new clothing guidance will ensure good hand and wrist washing.’ 
Press Release 2007/0269, 17 September 2007 [freely available at www.gnn.gov.uk/environment/fullDetail.a
sp?ReleaseID=314953&NewsAreaID=2&NavigatedFromDepartment=True (visited 7 February 2008).
167 Professor Gary French wrote: ‘Microbiologists were also split over the significance of MRSA. There was 
a widely held view, which is still common amongst some, that methicillin- and multi-resistant S. aureus are 
no more important than MSSA and that all the efforts expended on MRSA control are firstly ineffective 
and secondly took time and resources away from other, more important pathogens. It was strongly felt 
by some that microbiologists were chasing a marker (methicillin resistance) that had no relevance to 
clinical significance and that MSSA were equally important but largely ignored [Lacey (1987); Rahman 
et al. (2000)]. This argument continues, but there is now good evidence that MRSA infections have poor 
outcomes and that infection control – properly and strictly applied – can reduce MRSA infection rates. In 
my own view, microbiologists were remiss in not pursuing MRSA more actively in the early days of the 
epidemic when control was more possible.’ Note on draft transcript, 3 December 2007.
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infection control issues.168 There are still some microbiologists who believe that 
the importance of MRSA is overplayed, although I am not among them.
Microbiologists did not put their foot down about filthy and crowded wards. 
The public did, and that’s what got through to the politicians. MRSA became 
the focus for a growing understanding that infection control in hospitals 
was poor.
Duckworth: I would like to add to what Geoff [Scott] and Gary [French] have 
been saying about what gave MRSA the high profile for Government action. I 
think it was more than patients beginning to make a fuss. It was also the data 
itself, because that rise throughout the 1990s was very dramatic, and when we 
saw our data in the context of rates in countries on the continent, such as the 
Netherlands and Scandinavia, the situation became deeply embarrassing. That 
came to the attention of both the Department of Health and the National Audit 
Office (NAO), which undertook their first study of hospital-acquired infection 
and that report to the Commons’ Public Accounts Committee required a 
Government response, further raising the profile of the topic dramatically. In 
an unprecedented fashion, the NAO stayed on the topic for yet a second report, 
making a major impact.169 
Coming back to what Joe Selkon was saying, my role isn’t to defend the 
Department of Health. High bed occupancy must play a major part when we 
compare our situation with that in some countries on the continent, but despite 
all these difficulties, some trusts are making major inroads on their MRSA 
levels. I know Gary speaks about how they have made an impact in his trust. 
Despite all those pressures on beds, etc., some trusts have made a significant 
difference. What is quite interesting is that rates now appear to be coming down 
in acute specialist and teaching trusts, while it is in the District General Hospital 
(DGH)-type hospitals that levels are still rising.
Bud: One more on this and then I think we need to talk about the Staphylococcus 
Reference Laboratories.
Simmons: Why has the public attitude changed? It’s a good story. MRSA: it 
trips off the tongue; so does superbug. Even Professor Ayliffe used the word. 
168 British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection 
Control Nurses Association, Combined Working Party (1998).
169 National Audit Office (2000, 2004). House of Commons, Committee of Public Accounts (2000).
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It makes me want to puke; it’s an awful word; what’s super about it? It’s an 
awful word for a scientific meeting, it really is. It’s not super. But it trips off 
the tongue. Leslie Ash gets an ordinary staphylococcal infection.170 And, I got a 
magazine through my letterbox yesterday, which talks about MSSA, a variant 
of MRSA. Rubbish. 
Targets: I hate to tell you but the staphylococci aren’t frightened of the Prime 
Minister, they don’t take any notice of politicians – they don’t care who’s in No. 
10 – or even of the Chief Executive. Let me tell you, I spoke to someone, I had 
better not let you identify the person, who went to Russia at the request of the 
PHLS a number of years ago to assist the Russians in the control of post-operative 
infection. The Soviet government decreed that post-operative infection would 
not be more than 2 per cent, and the person said to me, ‘I learned of all the ways 
that government intervention could keep it below 2 per cent.’ Every time there 
was a report, someone went and visited the laboratory, and said: ‘Are you sure? 
Do you think taking all these swabs is a good thing?’ They want to penalize 
hospitals that have a high infection rate. The way to get this down is through 
the application of science. I am not all that convinced that the intervention of 
politicians is a good thing. Finally, the bed occupancy rate in the Netherlands is 
60 per cent, the occupancy in Britain is over 80 per cent. A paper has appeared 
recently showing a straight line correlation between occupancy and MRSA 
infection rate, or rather the MRSA bacteraemia rate.171 As far as I know, there 
is no published figure for post-operative infection after 1996, and that was ten 
years ago. All we know is about MRSA bacteraemia. We don’t know the post-
operative infection rate now. There might be thousands. We must draw our 
conclusions from the bacteraemia alone. I doubt if anyone would want to find 
the real figure, because that might really frighten Leslie Ash. So there are lots 
of reasons for public change. It’s a scare story and bad news which is good 
news if you are selling newspapers. My contact in the press said to me: ‘I have 
looked at what you have written about this, and I am now convinced we are 
just going to have to put up with it.’ And people will get used to it, and then it 
 
170 Actress Leslie Ash was admitted to Chelsea and Westminster Hospital, London, in April 2004 with a 
punctured lung and two broken ribs; she contracted MSSA during her treatment, leaving her partially 
paralyzed and unable to play active roles as an actress. The case against the hospital was due to be heard in 
April 2008, but was settled out of court in January 2008, with Chelsea and Westminster Hospital Trust 
admitting a breach of duty for ‘shortcomings in her care’, with total compensation of £5m to cover loss of 
earnings. Sanderson and Gibb (2008).
171 Cunningham et al. (2006). 
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will drift out of the news for a little while and then come back. I think it’s really 
press awareness that has driven the public concern.
Ayliffe: Briefly, I would like to say that 50 years ago our hospitals really weren’t 
so good. They were overcrowded, with beds along the centre of the wards; they 
were often not clean, and staff rarely washed their hands. And a house surgeon 
in a general hospital came in one morning and said to the consultant: ‘Welcome 
to Scutari’.172 
Bud: On that note, can we move to Dr Pitt, to introduce the Staph Reference 
Laboratories and also to Professor Gemmell.
Dr Tyrone Pitt: I am really only here as the link with the past; I have not made 
any contribution of any note to the staphylococcal lexicon. The Staphylococcus 
Reference Laboratory was formed in 1949 by R E O Williams. I joined the 
laboratory in 1968, seven years after Pat Jevons had described methicillin-
resistant strains.173 The main function of the lab over the years has been to 
support outbreak investigation by typing of isolates from hospitals and carry out 
limited surveillance of strain types at local regional and national levels. Today its 
best contribution is added-value characterization of strains. 
Originally it was a factory, a factory of ‘phage typing. All isolates of public 
health importance were referred (and some not so) and we had to type these at 
a rate of 100–200 strains a day.174 These were then read, I should stress, only by 
the senior staff, and often through a haze of cigarette or pipe smoke, which one 
just can’t imagine today. I remember Liz Asheshov and Pat Jevons used to have 
their ashtrays at their side as they read the ‘phage plates. 
172 Professor Graham Ayliffe wrote: ‘Scutari was the base hospital in Turkey for sick and wounded troops in 
the Crimean war. Florence Nightingale found hygienic standards were terrible and the mortality excessively 
high.’ E-mail to Mrs Lois Reynolds, 3 December 2007.
173 In a letter to the BMJ in 1961 [Jevons (1961)]. See page 12.
174 Dr Tyrone Pitt wrote: ‘Today this has expanded to the international arena owing to the spread of successful 
lineages, particularly the epidemic MRSA and less so, CA-MRSA [community-acquired or community-
associated multiply-resistant Staphylococcus aureus]. The early laboratory processed large numbers of isolates 
on a daily basis using standard methodology (‘phage typing and antimicrobial susceptibility screen), and 
results reported within 48–72 hours. These were subcultured, grown in broth, agar plates seeded and phages 
applied with the aid of a rather Heath Robinson invention of Dr Owen Lidwell [Figure 13], a derivative of 
which is still used to this day. Following incubation, the plates were read for ‘phage lysis patterns by senior 
staff.’ Note on draft manuscript, 14 August 2007. 
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The strength of the laboratory is that it provides an overview of the range of strain 
lineages circulating in hospitals, their prevalence and sometimes their patterns of 
spread. These data inform surveillance strategies and remain pivotal in the design 
of interventions to curtail spread of the organisms. A common criticism of these 
data is that only atypical or problem isolates are often sent by hospitals, so one 
could get a skewed view of the significance of these strains relative to others. On the 
other hand, we can be assured that the laboratory receives isolates of public health 
importance. Over the years, the emphasis has changed from the high-throughput 
ethic to more tailored investigations in support of hospital microbiologists. For 
example, today, in addition to traditional ‘phage typing, the service extends to 
DNA fingerprinting by pulsed-field gel electrophoresis, toxin gene profiling 
(enterotoxins, exfoliatins, TSST and PVL), staphylococcal cassette chromosome 
(SCC) mec type, and DNA typing by spa gene and multilocus sequence typing.175
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Lidwell ‘phage typing machine used in the Staphylococcus  
Reference Laboratory for almost 50 years.176  
Lidwell (1959). Photographed at the Colindale Staphylococcus Reference Laboratory, 2007.
175 See van Belkum et al. (2007).
176 Dr Tyrone Pitt wrote: ‘This machine is used to apply 25 phages to lawns of staphylococcal bacteria 
growing on an agar surface. The metal pins pick up volumes of the ‘phage and deposits them on to the agar 
surface. The arm revolves through a methylated spirit bath and then into a gas flame which sterilizes the pins 
ready for the next sample. You really have to see it in action and see the result it produces; it is simplicity 
itself. The tube [lower left-hand corner] is a gas lighter, the tweezers are used to straighten the pins when 
they are hot and the gas supply is controlled by the stopcock controls [at the back of the apparatus]. They 
don’t make them anymore and ‘phage typing is rapidly disappearing into the history books.’ E-mail to Mrs 
Lois Reynolds, 27 November 2007.
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The departure from simple ‘phage typing to the application of new technologies 
really started with the arrival of Dr Dick Marples in the mid-1970s. By the 
early 1980s the old guard of Jevons, Asheshov, Lidwell and, of course, Dr Tom 
Parker, who was the director from 1961 onwards, had already retired. Under the 
direction of Professor Mary Cooke in the 1980s there was an explosion in the 
application of new technologies, many based on electrophoretic separation of 
whole cell proteins and plasmid DNA. The introduction of restriction digestion 
of chromosomal DNA and the use of specific gene probes accelerated the 
definition of strain types and led to the nomenclature of the ‘epidemic strains’ 
of MRSA [see Appendix 1]. These now number 17 types [EMRSA-17], but 
recent genetic analysis shows that there was considerable duplication among 
them owing to excessive discrimination attributed to minor differences in 
‘phage typing patterns and genetic lineages, there are probably only five or six 
lineages there. Some EMRSA were not that ‘epidemic’ and never spread to 
more than two or three hospitals. However, the fact remains that today, about 
three-quarters of isolates are represented by two strain lineages EMRSA-15 and 
EMRSA-16.
At the turn of the millennium we were typing something like 50 000 isolates 
a year. Today, the number is under 10 000, although we have witnessed 
increased demand for toxin gene profiling given the public health impact of 
PVL-associated disease and the emergence of community-acquired MRSA and 
a renewed interest in MSSA. Angela Kearns, the current head of the service, is 
even contemplating abandoning ‘phage typing, like the Americans have done, 
and going to molecular-based typing, which might evoke a sharp intake of 
breath from the spirits of Williams, Jevons, Asheshov, Marples and Parker. 
I met Dr Parker last year a few months before he died.177 I had sent him the 
paper by Mark Enright and others in the Lancet, to which Brian Spratt has 
referred, on the re-emergence of ‘phage type 80/81 strains and he read it with 
interest. He commented, ‘If only we had then the tools they have today, we 
could have learnt so much more’. I think this is no doubt a common reflection 
of elderly scientists reminiscing.
Gemmell: If I could just give you a Scottish perspective on Reference Laboratories. 
We are much younger, infants compared with our English colleagues, we only 
started nine years ago in 1997. In fact we started off with about 2000 strains 
being sent to us, but very soon we actually reached 4000, 5000, and we are 
177 Dr Tom Parker died in 2006. See Biographical note on page 122.
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now running at 10 000 strains sent to us from laboratories serving Scottish 
hospitals. As our English colleagues know, I am sure, we actually stopped 
doing ‘phage typing in 2001, so we have already given up ‘phage typing as not 
being appropriate to our needs. We are doing all molecular tests – PFGE, PCR 
ribotyping, and mecA gene detection tests – as well as the toxin typing. But 
one thing we are trying to do, as well as trying to follow the epidemiology of 
MRSA in Scotland, and we have seen over the past nine years, this spectrum of 
75 per cent EMRSA-15s to 20–25 per cent EMRSA-16s and they are really not 
changing anything. But certainly what we are starting to do is something called 
snapshots, taking a short period of time in one particular hospital laboratory, 
and looking at all the MRSA strains, to try to see whether there are any trends 
year-on-year in the types of staphylococci [MRSA] that they are detecting. 
That’s where we are in Scotland.
Bud: I am aware that the evening is going on and the drinks are approaching, 
but I want to ask Bernard Dixon to continue a theme which we discussed earlier, 
about the public response in the 1990s. I think a lot of what we were talking 
about – the press response and the public, and the Government response – leads 
up to what Bernard might say.
Dr Bernard Dixon: I am aware that I am now all that stands between you 
and the drinks that have been mentioned. It helps me enormously that I have 
no data, unlike every other person who has spoken. I have been asked to talk 
about public attitudes. If you want to know about public attitudes to, say, GM 
food or animal experimentation, there are places you can go, for example, to 
the Eurobarometer, which is done regularly in all the EU countries, and it will 
tell you what people know about that subject, and what they think about it.178 
There are, as far as I know, no comparable data regarding antibiotic resistance. 
Maybe it would be a good idea if questions on that were included in the future 
Eurobarometer studies. 
Very briefly, what I can do is the next best thing, which is to talk about the 
media. There is a link with the media, which reflects the public at large, their 
views and their interests. The media also on occasions lead public opinion, 
178 The Eurobarometer study is sponsored by the European Commission in Brussels and the UK coordinator 
is Professor George Gaskell, London School of Economics. See the International Data Service (ESDS 
International) website, part of the wider Economic and Social Data Service (ESDS) and a national data 
service that came into operation in January 2003, jointly funded by the Economic and Social Research 
Council (ESRC) and the Joint Information Systems Committee (JISC), at www.esds.ac.uk/international/ 
support/I33089.asp (visited 10 December 2007).
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influence it certainly. I wanted to say a few things about that and give one 
brief story by way of analogy with the MRSA story. It is quite surprising that 
there has been comparatively little said about Staph. aureus resistance and more 
recently MRSA in the media until the past ten years. But, of course, over that 
period the problem itself has grown and there have been a number of occasions 
when the media have reflected that. The 1994 POST (Parliamentary Office of 
Science and Technology) Report, although primarily about TB, did get a lot of 
coverage on the general subject of drug resistance. In January 1996 the BBC’s 
Panorama did a very good programme on drug resistance, which was linked 
with the emergence of vancomycin resistance in enterococci.179 Then of course 
there was the House of Lords Select Committee in 1998, which was the lead 
item on at least three channels and, I think, possibly all of the BBC morning 
news bulletins.180 This clearly struck a chord with the gatekeepers in the media, 
the editors of programmes of that sort. Since then the subject has been pretty 
regularly in the news. The Government response to the Lords Report, the 
Advisory Committee being established and other points were all followed very 
closely by the media.
I must just add one point in defence of the slight criticism of the media that I heard 
earlier. I have seen very little sensationalism, very little exaggeration, in the media 
on this problem. I have two things here that don’t come from a tabloid newspaper. 
The first is from Nature, an article by Julian Davies, and the title is ‘Bacteria on 
the rampage’. The other is from the Lancet, the world’s major medical journal, 
on the occasion when vancomycin-resistant Staph. aureus first emerged and the 
title is ‘Apocalypse Now!’ These colourful headlines come from learned journals, 
not from the [popular] media. Let me go back to my chronology. There have 
been certainly lots of local stories, based on people with particular experiences 
which they took to their local newspapers, some of which got into the national 
newspapers. That, I think, has been an increasing trend. But then, of course, 
there was last year’s General Election [2005], when the whole question of MRSA 
became a political football between the two main parties. Michael Howard, 
whose mother-in-law’s death was apparently linked with MRSA, made a very 
strong attack on Labour’s record in hospital cleanliness.181 This was responded 
179 ‘Superbugs’, the BBC TV Panorama programme, was broadcast in 1996. A 40-minute videocassette is 
held as 771V in the Moving image and sound collections, Wellcome Library, London.
180 House of Lords, Select Committee on Science and Technology (1998).
181 See, for example, a BBC news item on Friday, 29 April 2005, at http://news.bbc.co.uk/1/hi/uk_politics/
vote_2005/wales/4497675.stm (visited 12 December 2007).
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to by John Reid, the Health Secretary, and he, of course, blamed the previous 
Tory government for not combating MRSA.182 Even more interesting than these 
exchanges was the great efflorescence of letters in the national newspapers, both 
the serious broadsheet newspapers like The Times, and also the tabloids – they 
all had letters from people about the problem, including experts.183 This was 
interesting because it was something of a cacophony, which I would have thought 
indicated to the average intelligent reader that there was no settled view as to what 
was the main problem, or certainly what was the most likely solution. There were 
letters about the organism itself, how it behaved, there were letters about the 
privatization of hospital cleaning services. There were articles and letters about 
the Netherlands and their policy of screening and isolating patients, and lots in 
the way of different ideas and suggestions, even from people who appeared to be 
experts. The average interested reader could simply conclude that there was no 
single view about this problem and certainly about the priorities for action, what 
needed to be done. Finally, I want to say one thing about a parallel case, which 
I think illustrates what hasn’t happened with MRSA in terms of influencing 
public attitudes. The example I have in mind is E S Anderson [Andy], whom 
Mark Richmond mentioned earlier.184 I want to contrast what he did way back in 
the late 1960s and early 1970s, with what has not happened with MRSA. Andy 
was one of the people who did a lot of early work on Salmonella typhimurium in 
particular, strains that were multiply resistant and he used ‘phage typing to trace 
the movement of these organisms from farm animals into humans. He was very 
concerned at what he saw as the abuse of antibiotics in animal husbandry posing 
a serious problem for human health. Looking back, and it may be that there are 
people in this room who share this view, the contribution that the agricultural 
misuse of antibiotics has made may not be as great as Andy believed it to be. 
None the less, it’s still interesting that he made it his business not only to write 
papers in Nature and elsewhere, but to lobby much more widely in order to 
influence public opinion and political action. He spoke to me as editor of the 
New Scientist, and we published quite a lot of articles by him and about his work, 
as well as editorials.185 He also talked to a man called Anthony (Phil) Tucker, who 
182 For details of Government guidance on healthcare-acquired infections, see Hansard (House of Commons, 
22 March 2005), cols 751–4.
183 See, for example, Naughton (2005). See also BMA summary of issues March-April 2005 at www.bma.
org.uk/ap.nsf/Content/hpd24marto15apr05#1Carvell (visited 6 March 2008).
184 See page 35.
185 See, for example, Anderson (1974a and b).
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was then the Science Editor of the Guardian newspaper, which devoted a lot of 
coverage to this whole question of the agricultural uses of antibiotics.186 All of this 
led to the setting up of the Swann Committee and restrictions that were placed 
on the inclusion of tetracyclines and penicillins in animal feed stuffs for growth 
promotion and prophylactic purposes.187 Now whatever you think about that, at 
this distance in time, it’s still interesting that Andy decided to give a substantial 
amount of his time and effort to lobbying in that sort of way. It was successful; it 
did result in government action. I now wonder whether there is, indeed, a settled 
view in the community of people concerned about MRSA as to how to combat 
the problem? Is there really a settled view upon which really vigorous lobbying 
could be conducted? I am not sure.
Stewart: I think we are winding up now, and in so doing I would like to follow 
through what Dr Dixon has said: credit where credit is due. This subject has 
been in need of critical attention for several years, especially since 1998, when 
the problem enlarged everywhere and especially in this country. In that year, 
the Wellcome Trust had a Witness Seminar on post-penicillin antibiotics, some 
of you were there.188 At that time it became obvious that problems like this 
needed more attention. Some of us did feel that action should be taken and 
the Wellcome Trust was more than willing to sponsor that. But these things 
don’t just happen easily, it’s much more difficult and I think this is where we 
must acknowledge the unique role of Robert Bud. Without his support and 
pressure, this would not have happened. What we have today is a free exchange 
of opinion by witnesses, by informed people who all know what they are talking 
about. That is comparatively rare nowadays. So I think we should end with a 
vote of thanks, not only to Robert and the Wellcome Trust, but to the History 
of Twentieth Century Medicine Group who have helped in this way, and we are 
very grateful to them.189
 
186 For example, see Tucker (1978, 1986). Anthony Tucker retired from the Guardian in 1988, died in 1998 
and his obituaries of well-known scientists continue to appear, such as Tucker (2006).
187 Agricultural Research Council and Medical Research Council, Joint Committee on Antibiotics in 
Animal Feeding (1969). The Committee was chaired by Professor Sir Michael Swann FRS (Lord Swann 
from 1981). See also Datta (1969).
188 Tansey and Reynolds (eds) (2000).
189 Professor Gordon Stewart provided additional material in January 2007, which will be deposited along 
with the tapes and other records of the meeting in GC/253 in Archives and Manuscripts of the Wellcome 
Library, London.
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Tansey: On behalf of the Wellcome Trust Centre, may I add our thanks to all 
of you for attending this meeting. The fact that we have gone over time and 
most people have remained is a very strong indicator of how important this 
has been and it has been a very great pleasure and privilege to listen to all your 
reminiscences and your comments. I would particularly like to thank Daphne, 
Wendy and Lois, my staff who organize and run these meetings.
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Appendix 1
Characteristics of Uk epidemic MRSA, 2007190
Epidemic MRSA ‘phage patternb Antibiotic resistance 
patternc
Toxin genesd
EMRSA-1a (84)/85/88A/(90)/932 P T E (K) (G) S A
EMRSA-2 80/85/90/932 P E A
EMRSA-3a 75/83A/(83C)/932 P E (K) (G) (N) (Cip) (S) -
EMRSA-4 85/(90)/932 P T E S A
EMRSA-5 29/6/42E/47/54/75/77/84/85/81 P T K G Rif A,B,C
EMRSA-6 90/932wk P T E K N Ba S A
EMRSA-7 85/932 P T E S A,C
EMRSA-8 83A/83C/932 P T S -
EMRSA-9 77/84/932 P T E K G S -
EMRSA-10 29/75/77/83A/85 P T E K G A,B
EMRSA-11 83A/84/85 P T E K G N Ba S A
EMRSA-12 75/83A/83C/932 P T E K N F S -
EMRSA-13 29/6/42E/47/54 P T K G N Ba F S -
EMRSA-14 29/6/47/54 P T K N F S -
EMRSA-15a 75wk P (E) Cip C
EMRSA-16a 29/52/75/77/83A/83C P E (K) (G) (N) Cip A, TSST-1
EMRSA-17a 29/77/932 P T (E) Rif F K G (N) S 
Tp Cip (Mup)
A
 
a Currently circulating UK Epidemic MRSA strains. 
b  ‘Phage patterns at 100 x RTD (routine test dilution); wk = weak reaction; ( ) = variable reaction. 
c Antibiotic resistance pattern: 
Ba, bacitracin; Cip, ciprofloxacin; E, erythromycin; F, fusidic acid; G, gentamicin; k, kanamycin 
(or tobramycin); Mup, mupirocin; N, neomycin; P, penicillin; Rif, rifampicin; S, streptomycin; T, 
tetracycline; Tp, teicoplanin borderline MIC [minimum inhibitory concentration] 4 - 8 mg/L; ( ), 
variable susceptibility among isolates. Neomycin resistance is difficult to detect by disc diffusion 
testing with some isolates. With gentamicin-susceptible isolates, tobramycin or kanamycin are 
more reliable indicators of the aadD gene responsible for neomycin resistance.
d Toxin genes: A,B,C Enterotoxins; TSST-1, Toxic Shock Syndrome Toxin-1.
190 Health Protection Agency, Evaluations and Standards Laboratory, Standards Unit (2007b). 
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Appendix 2
The bacteriophage groups of Staphylococcus aureus, after Parker (1962)
Bacteriophage 
group
Strains lysed by one or more ‘phages
I 29 52 52A 79 80 81
†
II 3A 3B 3C 55 71
III 6 7 42E 47 53 54 75 53 54 75 77 83A
IV 42D
Miscellaneous (a) (b)
† Strains lysed only by ‘phage 81 are placed in ‘phage group I.
(a) Strains lysed by ‘phages belonging to two or more lytic groups.
(b) Strains lysed by ‘phage 187.
Source: Williams et al. (1966): 25.
Superbugs and Superdrugs: A history of MRSA – References
83
References 
Abraham E P. (1983) Ernst Boris Chain. Biographical Memoirs of Fellows of the 
Royal Society 29: 43–91. 
Abraham E P, Chain E B. (1940) An enzyme from bacteria able to destroy 
penicillin. Nature 146: 837.
Abramson M A, Sexton D J. (1999) Nosocomial methicillin-resistant and 
methicillin-susceptible Staphylococcus aureus primary bacteraemias at what 
costs? Infection Control and Hospital Epidemiology 20: 408–11.
Agricultural Research Council and Medical Research Council, Joint Committee 
on Antibiotics in Animal Feeding. (1969) Report on the Use of Antibiotics in 
Animal Husbandry and Veterinary Medicine. Cmnd 4190. London: HMSO. 
Anderson E S. (1966) Letter: possible importance of transfer factors in bacterial 
evolution. Nature 209: 637–8.
Anderson E S. (1968) The ecology of transferable drug resistance in the 
enterobacteria. Annual Review of Microbiology 22: 131–80.
Anderson E S. (1974a) Nalidixic acid or if you can’t beat ‘em... New Scientist 
(21 March) 61: 750–1. 
Anderson E S. (1974b) How not to use data. New Scientist (31 October) 64: 
314–15.
Anderson E S, Armstrong J A, Niven J S F. (1959) Fluorescence microscopy: 
observation of virus growth with aminoacridines. In Isaacs A, Lacey B W. 
(eds) Virus Growth and Variation: Ninth symposium of the Society for 
General Microbiology held at the Sentate House, University of London, 
April 1959. Cambridge: Cambridge University Press, 224–55.
Annear D I. (1968) The effect of temperature on resistance of Staphylococcus 
aureus to methicillin and some other antibiotics. Medical Journal of Australia 
1: 444–6.
Anon. (1958a) The practical aspects of formaldehyde fumigation. Monthly 
Bulletin of the Ministry of Health and the Public Health Service Laboratory 
17: 270–3.
Anon. (1958b) Pencillin fallout. Time Magazine (17 November): 50–1.
Superbugs and Superdrugs: A history of MRSA – References
84
Anon. (1960) Editorial: a new penicillin. British Medical Journal ii: 720–1.
Anon. (1961) Editorial: ‘Celbenin’-resistant staphylococci. British Medical 
Journal i: 113–14. 
Anon. (1979) Obituary: Lawrence Paul Garrod. Lancet ii: 647.
Anon. (2006) Obituary: E S Anderson. The Times (27 March).
Avorn J L, Barrett J F, Davey P G, McEwen S A, O’Brien T F, Levy S B, Alliance 
for the Prudent Use of Antibiotics. (2001) Antibiotic Resistance: Synthesis of 
recommendations by expert policy groups. Geneva: WHO. Freely available at: 
http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_DRS_2001.10.pdf 
(visited 30 January 2008). 
Ayliffe G A J. (1973) Use of antibiotics and resistance. In Geddes A M, Williams 
J D. (eds) Current Antibiotic Therapy. Edinburgh: Churchill Livingstone; 
53–63.
Ayliffe G A J. (2007) Obituary: Edward Lowbury. Independent (14 August). 
Ayliffe G A J, English M P. (2003) Infection: From miasmas to MRSA. Cambridge: 
Cambridge University Press.
Ayliffe G A J, Lilly H A, Lowbury E J L. (1979a) Decline of the hospital 
staphylococcus: incidence of multiresistant Staphylococcus aureus in three 
Birmingham hospitals. Lancet i: 538–41.
Ayliffe G A J, Babb J R, Taylor L, Wise R. (1979b) A unit for source and 
protective isolation in a general hospital. British Medical Journal ii: 461–5.
Ayliffe G A J, Fraise A P, Geddes A M, Mitchell K. (eds) (2000) Control of 
Hospital Infection: A practical handbook, 4th edn. London: Arnold.
Ayliffe G A J, Green W, Livingston R, Lowbury E J L. (1977) Antibiotic-
resistant Staphylococcus aureus in dermatology and burn wards. Journal of 
Clinical Pathology 30: 40–4.
Ballio A, Chain E B, Dentice Di Accadia F, Rolinson G N, Batchelor F R. (1959) 
Penicillin derivatives of p-aminobenzylpenicillin. Nature 183: 180–1.
Barber M. (1947) Coagulase-positive staphylococci resistant to penicillin. 
Journal of Pathology and Bacteriology 59: 373–84.
Superbugs and Superdrugs: A history of MRSA – References
85
Barber M. (1948) Letter: sensitization of penicillin-resistant staphylococci. 
Lancet i: 730.
Barber M. (1961) Methicillin-resistant staphylococci. Journal of Clinical 
Pathology 14: 385–93.
Barber M. (1964a) Naturally occurring methicillin-resistant staphylococci. 
Journal of General Microbiology 35: 183–90.
Barber M. (1964b) Methicillin-resistant staphylococci and hospital infection. 
Postgraduate Medical Journal 40 (Suppl.): 178–81.
Barber M, Garrod L P. (1963) Antibiotic and Chemotherapy. Edinburgh: E & S 
Livingstone Ltd.
Barber M, Wildy P. (1958) A study of the antigenic specificity of staphylococcal 
coagulase in relation to bacteriophage group. Journal of General Microbiology 
18: 92–106. 
Barber M, Dutton A A, Beard M A, Elmes P C, Williams R. (1960) Reversal 
of antibiotic resistance in hospital staphylococcal infection. British Medical 
Journal i: 11–17.
Batchelor F R, Doyle F P, Nayler J H C, Rolinson G N. (1959) Syntheses of 
penicillin: 6-aminopenicillanic acid in penicillin fermentations. Nature 183: 
257–8.
Bates J. (1997) Epidemiology of vancomycin-resistant enterococci in the 
community and the relevance of farm animals to human infection. Journal 
of Hospital Infection 37: 89–101.
Beckman P S, Eickhoff T C. (eds) (1971) Proceedings of the International 
Conference on Nosocomial Infections. Chicago, IL: American Hospital 
Association.
van Belkum A, Tassios P T, Dijkshoorn L, Haeggman S, Cookson B, Fry N K, 
Fussing V, Green J, Feil E, Gerner-Smidt P, Brisse S, Struelens M.(2007) 
Guidelines for the validation and application of typing methods for use in 
bacterial epidemiology by the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) Study Group on Epidemiological Markers 
(ESGEM). Clinical Microbiology and Infection 13 (Suppl. 3): 1–46.
Bennison W H, Schwabacher H. (1948) Letter: sensitization of penicillin-
resistant bacteria. Lancet i: 885. 
Superbugs and Superdrugs: A history of MRSA – References
86
Blair J E, Williams R E O. (1961) ‘Phage typing of staphylococci. Bulletin of the 
World Health Organization 24: 771–84.
Borowski J. (1988a) Overview of current staphylococcal problems in Poland. 
Journal of Hospital Infection 11 (Suppl. A): 116–22. 
Borowski J. (1988b) Surveillance of MRSA in Poland. British Journal of Clinical 
Practice (Suppl.) 57: 72–3.
Borowski J, Kamieñska K, Rutecka I. (1964) Letter: Methicillin-resistant 
staphylococci. British Medical Journal i: 983. 
Borowski J, Jakubicz P, Jakoniuk P, Ziobro J. (1967) [Characteristics of 
Staphylococcus aureus strains isolated from the hospitals of Bialystok 
province] Polish. Roczniki Akademii Medycznej im. Juliana Marchlewskiego 
w Białymstoku 13: 189–98.
Brachman P. (ed.) Proceedings of the International Conference on Nosocomial 
Infections, 1970, Chicago, IL: American Hospital Association.
British Society for Antimicrobial Chemotherapy, Working Party. (1994) 
Hospital antibiotic control measures in the UK: Working Party Report. 
Journal of Antimicrobial Chemotherapy 34: 21–42.
British Society for Antimicrobial Chemotherapy and the Hospital Infection 
Society, Combined Working Party. (1995) Guidelines on the control of 
methicillin-resistant Staphylococcus aureus in the community. Report of a 
combined Working Party. Journal of Hospital Infection 31: 1–12.
British Society for Antimicrobial Chemotherapy, the Hospital Infection 
Society and the Infection Control Nurses Association, Combined Working 
Party. (1998) Revised guidelines for the control of methicillin-resistant 
Staphylococcus aureus infection in hospitals: report of a combined working 
party. Journal of Hospital Infection 39: 253–90.
British Society of Antimicrobial Chemotherapy, the Hospital Infection Society 
and the Infection Control Nurses Association, Joint Working Party. (2006) 
Guidelines for the control and prevention of meticillin-resistant Staphylococcus 
aureus (MRSA) in healthcare facilities. Journal of Hospital Infection 63 
(Suppl. 1): S1–44. Also cited as Coia et al. (2006).
Brown D F J, Reynolds P E. (1980) Intrinsic resistance to β-lactam antibiotics 
in Staphylococcus aureus. FEBS Letters 122: 275–8. 
Superbugs and Superdrugs: A history of MRSA – References
87
Brown D F, Edwards D I, Hawkey P M, Morrison D, Ridgway G L, Towner K 
J, Wren M W; Joint Working Party of the British Society for Antimicrobial 
Chemotherapy; Hospital Infection Society; Infection Control Nurses 
Association. (2005) Guidelines for the laboratory diagnosis and susceptibility 
testing of methicillin-resistant Staphylococcus aureus (MRSA). Journal of 
Antimicrobial Chemotherapy 56: 1000–18.
Brown K. (2004) Penicillin Man. Alexander Fleming and the antibiotic revolution. 
Stroud: Sutton Publishing.
Bud R. (2007) Penicillin: Triumph and tragedy. Oxford: Oxford University 
Press.
Budd W. (1984) On the Causes of Fever (1839): On the Causes and Mode of 
Propagation of the Common Continued Fevers of Great Britain and Ireland, 
Smith D C. (ed.). Baltimore, MD: Johns Hopkins University Press. 
Bulloch W. (1929) Alexander Ogston. Aberdeen University Review 16: 97–102.
Callaghan R P, Cohen S J, Stewart G T. (1961) Septicaemia due to colonization 
of Spitz-Holter valves by staphylococci. Five cases treated with methicillin. 
British Medical Journal i: 860–3.
Casewell M W. (1986). Epidemiology and control of the ‘modern’ methicillin-
resistant Staphylococcus aureus. Journal of Hospital Infection 7 (Suppl.): 
1–11. 
Casewell M W, Hill R L R. (1986) The carrier state: methicillin-resistant 
Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 18 (Suppl. A): 
1–12.
Casewell M W, Hill R L R. (1989) Mupirocin for eradication of nasal carriage 
of staphylococci. Lancet i: 154. 
Casewell M W, Hill R L R. (1991) Minimal dose requirements for nasal 
mupirocin and its role in the control of epidemic MRSA. Journal of Hospital 
Infection 19 (Suppl. B): 35–40.
Casewell M W, Hill R L R, Duckworth G J. (1984) The effect of mupirocin 
on the nasal carriage of Staphylococcus aureus. In Wilkinson D S, Price J 
D. (eds) Mupirocin – A novel antibiotic for the treatment of skin infection. 
Royal Society of Medicine Congress and Symposium series no. 80. 
London: RSM, 149–54.
Superbugs and Superdrugs: A history of MRSA – References
88
Centers for Disease Control (CDC). (1977) National Nosocomial Infections 
Study Report, Annual Summary 1975. Atlanta, GA: CDC, 13.
Chabbert Y A, Baudens J G. (1962) [Staphylococcus strains naturally resistant 
to methicillin and 5-methyl-3-phenyl-4-iso-oxazolyl-penicillin] French. 
Annales de l’Institut Pasteur 103: 222–30. 
Chabbert Y A, Baudens J G, Gerbaud G R. (1964) Variations sous l’influence 
de l’acriflavine et transduction de la resistance a la kanamcine et au 
chloramphenicol chez les staphylocoques] French. Annales de l’Institute 
Pasteur 107: 678–90.
Chain E B, Mellows G. (1977) Pseudomonic acid. Part 1. The structure of 
pseudomonic acid A, a novel antibiotic produced by Pseudomonas fluorescens. 
Journal of the Chemical Society, Perkin Transactions 1 (3): 294–309.
Clark A M, Colebrook L, Gibson T, Thomson M L, Foster A. (1943) Penicillin 
and propamidine in burns: elimination of haemolytic streptococci and 
staphylococci. Lancet 241: 605–9.
Coia J E, Duckworth G J, Edwards D I, Farrington M, Fry C, Humphreys H, 
Mallaghan C, Tucker D R. (2006) Guidelines for the control and prevention 
of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. 
Joint Working Party of the British Society of Antimicrobial Chemotherapy; 
Hospital Infection Society; Infection Control Nurses Association. Journal of 
Hospital Infection 63 (Suppl.) 1: S1–44.
Cooke E M, Marples R R. (1987) Letter: Methicillin-resistant Staphylococcus 
aureus. British Medical Journal 294: 371.
Cookson B, Phillips I. (1990) Methicillin-resistant staphylococci. Society for 
Applied Bacteriology Symposium Series 19: 55S–70S. 
Cooper B S, Stone S P, Kibbler C C, Cookson B D, Roberts J A, Medley 
G F, Duckworth G J, Lai R, Ebrahim S. (2003) Systematic review 
of isolation policies in the hospital management of methicillin-
resistant Staphylococcus aureus: a review of the literature with 
epidemiological and economic modelling. Health Technology Assessment 
7: 1–194. Freely available at: http://www.hta.ac.uk/execsumm/ 
summ739.htm (visited 5 December 2007).
Superbugs and Superdrugs: A history of MRSA – References
89
Cosgrove S E, Sakoulas G, Perencevich E N, Schwaber M J, Karchmer A W, 
Carmeli Y. (2003) Comparison of mortality associated with methicillin-
resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a 
meta-analysis. Clinical Infectious Diseases 36: 53–9.
Cox R A, Conquest C, Mallaghan C, Marples R R. (1995) A major outbreak 
of methicillin-resistant Staphylococcus aureus caused by a new ‘phage-type 
(EMRSA-16). Journal of Hospital Infection 29: 87–106. 
Cunningham J B, Kernohan W G, Rush T. (2006) Bed occupancy, turnover 
intervals and MRSA rates in English hospitals. British Journal of Nursing 
15: 656–60.
Daly J S, Eliopolous G M, Willey S, Moellering R C. (1988) Mechanism of 
action and in vitro and in vivo activities of S-6123, a new oxazolidinone 
compound. Antimicrobial Agents and Chemotherapy 32: 1341–6.
Dancer S J. (2008) Importance of the environment in meticillin-resistant 
Staphylococcus aureus acquisition: the case for hospital cleaning. Lancet 
Infectious Diseases 8: 101–13. 
Datta N. (1962) Transmissible drug resistance in an epidemic strain of Salmonella 
typhimurium. Journal of Hygiene 60: 301–10.
Datta N. (1969) Penicillin in poultry feed. British Medical Journal iv: 741.
Davies R R, Noble W C. (1962) Dispersal of bacteria on desquamated skin. 
Lancet ii: 1295–7.
Department of Health (DoH). (2000) All hospitals to monitor hospital-
acquired infection. Department of Health Press Release 2000/0584 [Monday, 
16 October 2000]. London: Department of Health. Freely available at: 
www.dh.gov.uk/en/Publicationsandstatistics/Pressreleases/DH_4007286 
(visited 5 December 2007).
DoH. (2001) Surveillance of healthcare-associated infections. CMO’s Update 30 
[21 May 2001]. London: Department of Health. Modified copy (9 February 
2007) freely available at: www.dh.gov.uk/en/Publicationsandstatistics/ 
Lettersandcirculars/CMOupdate/DH_4003623 (visited 5 December 2007).
Superbugs and Superdrugs: A history of MRSA – References
90
DoH. (2003) Winning ways: working together to reduce healthcare associated 
infection in England: Report of the Chief Medical Officer. London: Department 
of Health. Freely available at www.dh.gov.uk/en/Publicationsandstatistics/
Publ i ca t ions /Publ i ca t ionsPo l i cyAndGuidance/DH_4064682 
(visited 6 March 2008). 
DoH. (2004) Bloodborne MRSA infection rates to be halved by [March] 
2008 – Reid. Department of Health Press Release 2000 [Thursday, 5 
November 2004]. London: Department of Health. Freely available at: 
www.dh.gov.uk/en/Publicationsandstatistics/Pressreleases/DH_4093533 
(visited 5 December 2007).
DoH. (2008) Clean, Safe Care: Reducing infections and saving lives. 
London: Department of Health. Freely available at www.dh.gov.uk/ 
en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/
DH_081650 (visited 7 February 2008).
Douthwaite A H, Trafford J A P. (1960) A new synthetic penicillin. British 
Medical Journal ii: 687–90. 
Doyle P. (1993) John Nayler, 1927–93. Chemistry in Britain 29: 531.
Duckworth G J, Charlett A. (2005) Editorial: improving surveillance of MRSA 
bacteraemia. British Medical Journal 331: 976–7.
Duckworth G J, Lothian J L, Williams J D. (1988) Methicillin-resistant 
Staphylococcus aureus: report of an outbreak in a London teaching hospital. 
Journal of Hospital Infection 11: 1–15.
Dunstan E J, Main A N, Rowe J. (1995) In hot pursuit of MRSA. Lancet 
346: 1639.
Dyke K G. (1969) Penicillinase production and intrinsic resistance to penicillins 
in methicillin-resistant cultures of Staphylococcus aureus. Journal of Medical 
Microbiology 2: 261–78.
Dyke K G H, Parker M T, Richmond M H. (1970) Penicillinase production and 
metal-ion resistance in Staphylococcus aureus cultures isolated from hospital 
patients. Journal of Medical Microbiology 3: 125–36.
Elek S D. (1948a) Analysis of complex flocculating systems by means of diffusion 
gradients, PhD thesis, University of London.
Superbugs and Superdrugs: A history of MRSA – References
91
Elek S D. (1948b) The recognition of toxicogenic bacterial strains in vitro. 
British Medical Journal i: 493–6.
Elek S D, Conen P E. (1957) The virulence of Staphylococcus pyogenes for man: 
a study of the problems of wound infection. British Journal of Experimental 
Pathology 38: 573–86. 
Elek S D, Fleming P C. (1960) A new technique for the control of hospital 
cross-infection. Experience with BRL1241 in a maternity unit. Lancet ii: 
569–72. 
Engemann J J, Carmeli Y, Cosgrove S E, Fowler V G, Bronstein M Z, Trivette 
S L, Briggs J P, Sexton D J, Kaye K S. (2003) Adverse clinical and economic 
outcomes attributable to methicillin resistance among patients with 
Staphylococcus aureus surgical site infection. Clinical Infectious Diseases 36: 
592–8.
Enright M C, Robinson D A, Randle G, Feil E J, Grundmann H, Spratt B 
G. (2002) The evolutionary history of methicillin-resistant Staphylococcus 
aureus (MRSA). Proceedings of the National Academy of Sciences of the USA 
99: 7687–92. 
Eriksen K R. (1964) Methicillin-resistance in Staphylococcus aureus apparently 
developed during treatment with methicillin. Acta Pathologica et Microbiologica 
Scandinavica 61: 154–5.
European Society of Clinical Microbiology and Infectious Diseases (ESCMID), 
Study Group on Epidemiological Markers (ESGEM). (2007) Guidelines 
for the validation and application of typing methods for use in bacterial 
epidemiology. Clinical Microbiology and Infection 13 (Suppl. 3): 1–46. Also 
cited as van Belkum et al. (2007).
Eykyn S, Jenkins C, King A, Phillips I. (1973) Antibacterial activity of 
cefamandole, a new cephalosporin antibiotic, compared with that of 
cephaloridine, cephalothin, and cephalexin. Antimicrobial Agents and 
Chemotherapy 3: 657–61.
Faber V, Jessen O, Rosendal K, Eriksen K R. (1960) Staphylococcal bacteraemia: 
clinical and bacteriological observations in 201 cases. British Medical Journal 
ii: 1832–6.
Fairbrother R W, Williams B L. (1956) Two new antibiotics; antibacterial 
activity of novobiocin and vancomycin. Lancet 268: 1177–9.
Superbugs and Superdrugs: A history of MRSA – References
92
Filip S V, Cavelier F. (2004) A contribution to the nomenclature of depsipeptides. 
Journal of Peptide Science 10: 115–18.
Fisk R T. (1942) Studies on staphylococci. Occurrence of bacteriophage carriers 
amongst strains of Staphylococcus aureus. Identification of Staphylococcus 
aureus strains by means of bacteriophage. Journal of Infectious Diseases 71: 
153–60.
Ford C W, Hamel J C, Wilson D M, Moerman J K, Stapert D, Yancey R J Jr, 
Hutchinson D K, Barbachyn M R, Brickner S J. (1996) In vivo activities of 
U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against 
experimental bacterial infections. Antimicrobial Agents and Chemotherapy 
40: 1508–13.
French G L, Phillips I. (1997) Resistance. In O’Grady F, Lambert H P, Finch R G, 
Greenwood D. (eds) Antibiotics and Chemotherapy, 7th edn. New York, NY; 
Edinburgh: Churchill Livingstone, 23–43.
French G L, Otter J A, Shannon K P, Adams N M, Watling D, Parks M J. 
(2004) Tackling contamination of the hospital environment by methicillin-
resistant Staphylococcus aureus (MRSA): a comparison between conventional 
terminal cleaning and hydrogen peroxide vapour decontamination. Journal 
of Hospital Infection 57: 31–7.
Fuller A T, Mellows G, Woolford M, Banks G T, Barrow K D, Chain E B. 
(1971) Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. 
Nature 234: 416–7. 
Garrod L P. (1966) Mary Barber, 1911–65. Journal of Pathology and Bacteriology 
92: 603–10.
Gedney J, Lacey R W. (1982) Properties of methicillin-resistant staphylococci 
now endemic in Australia. Medical Journal of Australia 1: 448–50.
Gemmell C G, Edwards D I, Fraise A P, Gould F K, Ridgway G L, Warren R E; 
Joint Working Party of the British Society for Antimicrobial Chemotherapy, 
Hospital Infection Society and Infection Control Nurses Association. 
(2006) Guidelines for the prophylaxis and treatment of methicillin-resistant 
Staphylococcus aureus (MRSA) infections in the UK. Journal of Antimicrobial 
Chemotherapy 57: 589–608. 
Superbugs and Superdrugs: A history of MRSA – References
93
General Medical Council, Education Committee. (1993) Tomorrow’s Doctors: 
Recommendations on undergraduate medical education. Issued by the Education 
Committee of the General Medical Council in pursuance of section 5 of the 
Medical Act, 1983. London: General Medical Council. Rev. edn, 2002, available 
online at: www.gmc-uk.org/education/undergraduate/GMC_tomorrows_ 
doctors.pdf (visited 28 January 2008).
Gillespie W A, Alder V G. (1952) Production of opacity in egg yolk media by 
coagulase-positive staphylococcus. Journal of Pathology and Bacteriology 64: 
187–200. 
Gillespie W A, Alder V G, Ayliffe G A J, Powell D E B, Wypkema W. (1961) 
Control of staphylococcal cross-infection in surgical wards. Lancet i: 
1299–1303. 
Gillespie W J, Walenkamp G. (2001) Antibiotic prophylaxis for surgery for 
proximal femoral and other closed long bone fractures. Cochrane Database of 
Systematic Reviews 1: CD000244. DOI: 10.1002/14651858.CD000244.
Gould I M. (2005) Control of methicillin-resistant Staphylococcus aureus in 
the UK. European Journal of Clinical Microbiology and Infectious Diseases 
24: 789–93. Comment in: European Journal of Clinical Microbiology and 
Infectious Diseases (2005) 24: 777–9.
Gould I M. (ed.) (2007) MRSA in Practice. London: Royal Society of 
Medicine.
Gould I M, van der Meer J W M. (eds) (2005) Antibiotic Policies: Theory and 
practice. New York, NY; London: Kluwer Academic/Plenum.
Gould J C. (1958) Environmental penicillin and penicillin-resistant 
Staphylococcus aureus. Lancet i: 489–93. 
Greenwood D, O’Grady F. (1969) Antibiotic-induced surface changes in 
microorganisms demonstrated by scanning electron microscopy. Science 
163: 1076–8.
Gregory W A, Brittelli D R, Wang C L, Kezar H S 3rd, Carlson R K, Park C H, 
Corless P F, Miller S J, Rajagopalan P, Wuonola M A, McRipley R J, Eberly V 
S, See A M, Forbes M. (1990) Antibacterials: synthesis and structure-activity 
studies of 3-aryl-2-oxooxazolidines. 2. The A group. Journal of Medicinal 
Chemistry 33: 2569–78.
Superbugs and Superdrugs: A history of MRSA – References
94
Griffith R S. (1981) Introduction to vancomycin. Reviews of Infectious Diseases 
3 (Suppl.): 200–4.
Griffiths C, Lamagni T L, Crowcroft N S, Duckworth G J, Rooney C. (2004) 
Trends in MRSA in England and Wales: analysis of morbidity and mortality 
data for 1993–2002. Health Statistics Quarterly 21: 15–22.
Hakenbeck R, Tarpay M, Tomasz A. (1980) Multiple changes of penicillin-
binding proteins in penicillin-resistant clinical isolates of Streptococcus 
pneumoniae. Antimicrobial Agents and Chemotherapy 17: 364–71.
Hamilton-Miller J M T, Ramsay J. (1967) Stability of cephaloridine and 
cephalothin to staphylococcal penicillinase. Journal of General Microbiology 
49: 491–501.
Hanifah Y A, Hiramatsu K. (1994) Pulsed-field gel electrophoresis of 
chromosomal DNA of methicillin-resistant Staphylococcus aureus associated 
with nosocomial infections. Malaysian Journal of Pathology 16: 151–6.
Hardman J G, Limbird L E. (eds) (2001) Goodman & Gilman’s The Pharmacological 
Basis of Therapeutics, 10th edn. New York, NY: McGraw-Hill.
Hare R. (1983) The scientific activities of Alexander Fleming, other than the 
discovery of penicillin. Medical History 27: 347–72.
Hare R, Thomas C G. (1956) The transmission of Staphylococcus aureus. British 
Medical Journal ii: 840–4.
Hartman B J, Tomasz A. (1984) Low-affinity penicillin-binding protein 
associated with β-lactam resistance in Staphylococcus aureus. Journal of 
Bacteriology 158: 513–16.
Hartstein A I, Denny M A, Morthland V H, LeMonte A M, Pfaller M A. 
(1995) Control of methicillin-resistant Staphylococcus aureus in a hospital 
and an intensive care unit. Infection Control and Hospital Epidemiology 16: 
405–11.
Health Protection Agency (HPA). (2007) Third Report of the Mandatory 
Surveillance of Surgical Site Infection in Orthopaedic Surgery, April 2004 
to March 2007. London: Health Protection Agency. Freely available at: 
www.hpa.org.uk/infections/topics_az/surgical_site_infection/documents/
SSI3rdMandatory01-11-07.pdf (visited 5 December 2007).
Superbugs and Superdrugs: A history of MRSA – References
95
HPA, Evaluations and Standards Laboratory, Standards Unit. (2006) 
Susceptibility Testing. National Standard Method, BSOP 45, Issue 2 (Issue 
date: 30.10.06). Freely available from www.hpa-standardmethods.org.uk/ 
documents/bsop/pdf/bsop45.pdf (visited 14 February 2008).
HPA, Evaluations and Standards Laboratory, Standards Unit. (2007a) Staining 
Procedures. National Standard Method Issue 1. Freely available at www.hpa-
standardmethods.org.uk/pdf_sops.asp (visited 12 February 2008).
HPA, Evaluations and Standards Laboratory, Standards Unit. (2007b) Investigation 
of specimens for Screening for MRSA, Standard Operating Procedure, BSOP 
29, Issue 5. Freely available from www.hpa-standardmethods.org.uk/pdf_
sops.asp (visited 7 January 2008).
Hill A B. (1934) The Inheritance of Resistance to Bacterial Infection in Animal 
Species: A review of the published experimental data. Medical Research Council 
(Great Britain) Special report series no. 196. London: HMSO.
Hill R L R, Duckworth G J, Casewell M W. (1988) Elimination of nasal 
carriage of methicillin-resistant Staphylococcus aureus with mupirocin during 
a hospital outbreak. Journal of Antimicrobial Chemotherapy 22: 377–84.
Holt R J, Stewart G T. (1964) Penicillin amidase from coliforms: its extraction 
and some characteristics. Nature 201: 824.
Hookey J V, Richardson J F, Cookson B D. (1998) Molecular typing 
of Staphylococcus aureus based on PCR restriction fragment length 
polymorphism and DNA sequence analysis of the coagulase gene. Journal of 
Clinical Microbiology 36: 1083–9.
Hospital Infection Society and British Society for Antimicrobial Chemotherapy, 
Combined Working Party. (1986) Guidelines for the control of epidemic 
methicillin-resistant Staphylococcus aureus. Report. Journal of Hospital 
Infection 7: 193–201. Revised in 1990 [Journal of Hospital Infection 
16: 351–77]. 
Hospital Infection Society and the British Society for Antimicrobial 
Chemotherapy, Combined Working Party. (1990) Revised guidelines for 
the control of epidemic methicillin-resistant Staphylococcus aureus: report 
prepared by G Duckworth, Secretary to the working party. Journal of Hospital 
Infection 16: 351–77.
Superbugs and Superdrugs: A history of MRSA – References
96
House of Commons, Committee of Public Accounts. (2000) Forty-second Report: 
The management and control of hospital-acquired infection in acute NHS trusts in 
England. Session 1999/2000 [8 November 2000]. London: Stationery Office. 
Freely available at: www.publications.parliament.uk/pa/cm199900/cmselect/ 
cmpubacc/306/30603.htm#n1 (visited 5 December 2007).
House of Lords, Select Committee on Science and Technology. (1998) 
Resistance to Antibiotics and Other Antimicrobial Agents: Report of the House 
of Lords Select Committee on Science and Technology. House of Lords 
paper, 81-I, 7th report, Session 1997/8. London: The Stationery Office. 
See www.publications.parliament.uk/pa/ld199798/ldhansrd/vo981116/
text/81116-14.htm (visited 14 August 2007).
Hurlimann-Dalel R L, Ryffel C, Kayser FH, Berger-Bachi B. (1992) Survey of 
the methicillin resistance-associated genes mecA, mecR1-mecI, and femA-femB 
in clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrobial 
Agents and Chemotherapy 36: 2617–21.
Ingham H R. (2004) Letter: role of the isolation unit in MRSA control. Journal 
of Hospital Infection 58: 161.
Jevons M P. (1961) Letter: ‘Celbenin’-resistant staphylococci. British Medical 
Journal i: 124–5. 
Kagan B M, Martin E R, Stewart G T. (1964) L form induction of 
naturally occurring methicillin-resistant strains of Staphylococcus aureus. 
Nature 203: 1031–3.
Keith S T. (1981) Inventions, patents and commercial development from 
governmentally financed research in Great Britain: the origins of the National 
Research Development Corporation. Minerva 19: 92–122.
Kinmonth J B, Hare R, Tracy G D, Thomas C G, Marsh J D, Jantet G H. 
(1958) Studies of theatre ventilation and surgical wound infection. British 
Medical Journal ii: 407–11.
Kirby W M M. (1944) Extraction of a highly potent penicillin inactivator from 
penicillin-resistant staphylococci. Science 99: 452–3.
Kirst H A, Thompson D G, Nicas T I. (1998) Historical yearly usage of 
vancomycin. Antimicrobial Agents and Chemotherapy 42: 1303–4.
Knox R. (1960) A new penicillin (BRL 1241) active against penicillin-resistant 
staphylococci. British Medical Journal ii: 690–3.
Superbugs and Superdrugs: A history of MRSA – References
97
Knox R. (1961) Letter: ‘Celbenin’-resistant staphylococci. British Medical 
Journal i: 124–5.
Knox R. (1966) Professor Mary Barber. Nature 209: 559. 
Knox R, Smith J T. (1963) Stability of methicillin and cloxacillin to staphylococcal 
penicillinase. British Medical Journal ii: 205–7.
Knudsen E T, Rolinson G N. (1960) Absorption and excretion of a new 
antibiotic (BRL 1241). British Medical Journal ii: 700. 
Lacey R W. (1987) The primordial MRSA? Journal of Hospital Infection 9: 
89–90. 
Lamb H M, Figgitt D P, Faulds D. (1999) Quinupristin/dalfopristin: a review 
of its use in the management of serious Gram-positive infections. Drugs 58: 
1061–97.
Lambert H P. (1976) Birthday greeting to LPG[arrod]. Journal of Antimicrobial 
Chemotherapy 2: 1.
LaPlante K L, Rybak M J. (2004) Daptomycin – a novel antibiotic against 
Gram-positive pathogens. Expert Opinion on Pharmacotherapy 5: 2321–31.
Lazell H G. (1975) From Pills to Penicillin: The Beecham story, a personal account. 
London: Heinemann.
Lidwell O M. (1959) Apparatus for ‘phage typing of Staphylococcus aureus. 
Monthly Bulletin of the Ministry of Health and Public Health Laboratory 
Service 18: 49–52.
Lidwell O M, Davies J, Payne R W, Newman P, Williams R E O. (1971) Nasal 
acquisition of Staphylococcus aureus in partly divided wards Journal of Hygiene 
69: 113–23. 
Lidwell O M, Lowbury E J L, Whyte W, Blowers R, Stanley S J, Lowe D. (1982) 
Effect of ultraclean air in operating rooms on deep sepsis in the joint after 
total hip or knee replacement: a randomised study. British Medical Journal 
285: 10–14.
Lidwell OM, Lowbury E J L, Whyte W, Blowers R, Stanley SJ, Lowe D. (1984) 
Infection and sepsis after operations for total hip or knee joint replacement: 
influence of ultraclean air, prophylactic antibiotics and other factors. Journal 
of Hygiene 93: 505–29. 
Superbugs and Superdrugs: A history of MRSA – References
98
Lidwell O M, Polakoff S, Jevons M P, Parker M T, Shooter R A, French V I, 
Dunkerley D R. (1966). Staphylococcal infection in thoracic surgery: 
experience in a subdivided ward. Journal of Hygiene 64: 321–7.
Lidwell O M, Polakoff S, Davies J, Hewitt J H, Shooter R A, Walker K A, 
Gaya H, Taylor G W. (1970) Nasal acquisition of Staphylococcus aureus in a 
subdivided and mechanically ventilated ward: endemic prevalence of a single 
staphylococcal strain. Journal of Hygiene 68: 417–33.
Lilly H A, Lowbury E J L, Wilkins M D, Cason J S. (1979) Staphylococcal 
sepsis in a burns unit. Journal of Hygiene 83: 429–35. 
Lister J. (1867) On the antiseptic principle in the practice of surgery. Lancet ii: 
353–7, 668.
Loeb M, Main C, Walker-Dilks C, Eady A. (2003) Antimicrobial drugs for 
treating methicillin-resistant Staphylococcus aureus colonization. Cochrane 
Database of Systematic Reviews (4):CD003340.
Loveday H P, Pellowe C M, Jones S R, Pratt R J.(2006) A systematic review of 
the evidence for interventions for the prevention and control of meticillin-
resistant Staphylococcus aureus (1996–2004): report to the Joint MRSA 
Working Party (Subgroup A). Journal of Hospital Infection 63 (Suppl. 1): 
S45–70.
Lowbury E J L. (1983) Obituary: Leonard Colebrook (1883–1967). British 
Medical Journal 287: 1981–3. 
Lowbury E J L, Ayliffe G A J. (1974) Drug Resistance in Antimicrobial Therapy. 
Springfield, IL: Thomas. 
Lowbury E J L, Lilly H A, Kidson A. (1977) ‘Methicillin-resistant’ Staphylococcus 
aureus: reassessment by controlled trial in burns unit. British Medical Journal 
i: 1054–6.
Lowbury E J L, Ayliffe G A J, Geddes A M, Williams J D. (eds) (1975) Control 
of Hospital Infection: A practical handbook. London: Chapman and Hall for 
the Working Party on Control of Hospital Infection. Later editions edited 
by Professor Graham Ayliffe, for example, Ayliffe et al. (2000). 
Lyell A. (1989) Alexander Ogston, micrococci and Joseph Lister. Journal of the 
American Academy of Dermatology 20: 302–10.
Superbugs and Superdrugs: A history of MRSA – References
99
Maiden M C, Bygraves J A, Feil E, Morelli G, Russell J E, Urwin R, Zhang 
Q, Zhou J, Zurth K, Caugant D A, Feavers I M, Achtman M, Spratt B G. 
(1998) Multilocus sequence typing: a portable approach to the identification 
of clones within populations of pathogenic microorganisms. Proceedings of 
the National Academy of Sciences of the USA 95: 3140–5.
Maple P A, Hamilton-Miller J M, Brumfitt W. (1991) Differing activities of 
quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, 
methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and 
Chemotherapy 35: 345–50.
Marples R R. (1981) Taxonomic studies of staphylococci and micrococci. 
Zentralblattfuer Bakteriologie 10 (Suppl.): 9–13.
Marples R R, Cooke E M. (1988) Current problems with methicillin-resistant 
Staphylococcus aureus. Journal of Hospital Infection 11: 381–92.
Marples R R, Richardson J F. (1982) Evaluation of a micromethod gallery (API 
Staph) for the identification of staphylococci and micrococci. Journal of 
Clinical Pathology 35: 650–6. 
Medical Research Council (MRC), Cross Infection Committee. (1951) The 
Control of Cross-infection in Hospitals. London: HMSO. 
Ministry of Health. (1959) Staphylococcal Infections in Hospital: Report of the 
Subcommittee of the Central Health Services Council. London: HMSO.
Mitchison J M. (1991) Michael Meredith Swann, Baron Swann of Coln Denys. 
Biographical Memoirs of Fellows of the Royal Society 37: 446–60.
National Audit Office. (2000) Report by the Comptroller and Auditor General: 
The management and control of hospital acquired infection in acute NHS Trusts 
in England. HC 230, Session 1999/2000 [February 2000]. London: The 
Stationery Office. 
National Audit Office. (2004) Report by the Comptroller and Auditor General. 
Improving patient care by reducing the risk of hospital acquired infection: 
a progress report. HC 876, Session 2003/4 [14 July 2004]. London: The 
Stationery Office.
Naughton P. (2005) Tories dismiss MRSA figures as 'trickery', The Times 
Online, (7 March).
Superbugs and Superdrugs: A history of MRSA – References
100
Newsom S W B. (2004a) MRSA and its predecessor – a historical view. Part 
three: the rise of MRSA and EMRSA. British Journal of Infection Control 5: 
25–8.
Newsom S W B. (2004b) MRSA – past, present, future. Journal of the Royal 
Society of Medicine 97: 509–10.
Nightingale F. (1863) Notes on Hospitals, 3rd edn. London: Longman, Green, 
Longman, Roberts, and Green.
Nixon H H, O’Donnell B. (1961) The Essentials of Pædiatric Surgery. London: 
W. Heinemann (Medical).
Noble W C, Virani Z, Cree R G. (1992) Co-transfer of vancomycin and other 
resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus 
aureus. FEMS Microbiology Letters 72: 195–8.
Oeding P. (1952) Serological typing of staphylococci. Acta Pathologica et 
Microbiologica Scandinavic 93 (Suppl.): 356–63.
Oeding P, Williams R E O. (1958) The type classification of Staphylococcus 
aureus. A comparison of ‘phage typing with serological typing. Journal of 
Hygiene 56: 445–54.
Ogston A. (1881) Report upon micro-organisms in surgical diseases. British 
Medical Journal i: 369–74.
Ogston A. (1984) Classics in infectious diseases. On abscesses. Alexander 
Ogston (1844–1929). Reviews of Infectious Diseases 6: 122–8.
Ouchterlony O. (1948) In vitro method for testing toxin-producing capacity 
of diphtheria bacteria. Acta Pathologica et Microbiologica Scandinavica 25: 
186–91.
Pal S C, Ray B G. (1964) Methicillin-resistant staphylococci. Journal of the 
Indian Medical Association 42: 512–17.
Panton P N, Valentine F C O. (1932) Staphylococcal toxin. Lancet i: 506–8.
Parker M T. (1962) ‘Phage-typing and the epidemiology of Staphylococcus aureus 
infections. Journal of Applied Bacteriology 25: 389–402.
Parker M T. (1971) Methicillin-resistant staphylococci. In Brachman P S, 
Eickhoff T C. (eds) Proceedings of the International Conference on Nosocomial 
Infections 1970, Chicago, IL: American Hospital Association, 112–16.
Superbugs and Superdrugs: A history of MRSA – References
101
Parker M T, Jevons M P. (1963) Hospital strains of staphylococci. In Williams 
R E O, Shooter R A (eds) Infection in Hospitals, Epidemiology and Control. 
Oxford: Blackwell Scientific Publications, 5–66.
Parker M T, Ashehov E H, Hewitt J H, Nakhla L S, Brock B M. (1974) Endemic 
staphylococcal infection in hospitals. Annals of the New York Academy of 
Sciences 236: 466–84.
Peard M C, Fleck D G, Garrod L P, Waterworth P M. (1970) Combined 
rifampicin and erythromycin for bacterial endocarditis. British Medical 
Journal iv: 410–11. 
Phillips I. (1991) Epidemic potential and pathogenicity in outbreaks of infection 
with EMRSA and EMREC. Journal of Hospital Infection 18 (Suppl. A): 
197–201.
Phillips I. (2007) MRSA: a historical perspective. In Gould I. (ed.) MRSA in 
Practice. London: Royal Society of Medicine: 1–12.
Pirson M, Dramaix M, Struelens M, Riley T V, Leclercq P. (2005) Costs 
associated with hospital-acquired bacteraemia in a Belgian hospital. Journal 
of Hospital Infection 59: 33–40.
Pitt T. (2006) Obituary: Dr Tom Parker. Laboratory of HealthCare Associated 
Infection Newsletter 1: 3.
Pollock M R. (1965) Mary Barber. Journal of Clinical Pathology 18: 697–8.
Public Health Laboratory Service (PHLS). (1960) Incidence of surgical wound 
infection in England and Wales. Lancet ii: 659.
Radford T. (1998) Obituary: Anthony Tucker. Guardian (16 September): 20.
Rahman M, Sanderson P J, Bentley A H, Barrett S P, Karim Q N, Teare E L, 
Chaudhuri A, Alcock S R, Corcoran G D, Azadian B, Dance D A, Gaunt 
P N, Cunningham R, Ahmad F J, Garvey R J, Chattopadhyay B, Wiggins 
R J, Sheppard M, Wright E P, Moulsdale M, Falkiner F. (2000) Control of 
MRSA. Journal of Hospital Infection 44: 151–3.
Reeves D S, Phillips I, Williams J D, Wise R. (eds) (1978) Laboratory Methods 
in Antimicrobial Chemotherapy. Edinburgh: Churchill Livingstone.
Superbugs and Superdrugs: A history of MRSA – References
102
Reynolds L A, Tansey E M. (eds) (2007a) Early development of total hip 
replacement. Wellcome Witnesses to Twentieth Century Medicine, vol. 29. 
London: The Wellcome Trust Centre for the History of Medicine at UCL. 
Freely available online at www.ucl.ac.uk/histmed/publications/wellcome-
witnesses/index.html or following the links to Publications/Wellcome 
Witnesses from www.ucl.ac.uk/histmed.
Reynolds L A, Tansey E M. (eds) (2007b) Medical ethics education in Britain, 
1963–93. Wellcome Witnesses to Twentieth Century Medicine, vol. 31. London: 
The Wellcome Trust Centre for the History of Medicine at UCL.
Richards H C, Housley J R, Spooner D F. (1963) Quinacillin: a new penicillin 
with unusual properties. Nature 199: 354–6.
Richardson J F, Marples R R. (1982) Changing resistance to antimicrobial 
drugs and resistance typing in clinically significant strains of Staphylococcus 
epidermidis. Journal of Medical Microbiology 15: 475–84.
Ridgway G, Stokes E J. (2005) Pamela M Waterworth, August 1920–July 2004. 
British Society for Antimicrobial Chemotherapy Newsletter 5: 3.
Ritchie K, Bradbury I, Craig J, Eastgate J, Foster L, Kohli H, Iqbal K, MacPherson 
K, McCarthy T, McIntosh H, Nic Lochlainn E, Reid M, Taylor J. (2007) 
Health Technology Assessment Report 9: The clinical and cost effectiveness of 
screening for meticillin-resistant Staphylococcus aureus (MRSA). Glasgow; 
Edinburgh: NHS Quality Improvement Scotland. Freely available at: www.
nhshealthquality.org/nhsqis/files/PatientSafety_HTA9_MRSA_Oct07.pdf 
(visited 17 January 2008).
Roberts R B, de Lencastre A, Eisner W, Severina E P, Shopsin B, Kreiswirth 
B N, Tomasz A. (1998) Molecular epidemiology of methicillin-resistant 
Staphylococcus aureus in 12 New York hospitals. Journal of Infectious Diseases 
178: 164–71.
Roberts R B, Chung M, de Lencastre H, Hargrave J, Tomasz A, Nicolau D 
P, John J F, Korzeniowski O; Tri-State MRSA Collaborative Study Group. 
(2000) Distribution of methicillin-resistant Staphylococcus aureus clones 
among health care facilities in Connecticut, New Jersey, and Pennsylvania. 
Microbial Drug Resistance 6: 245–51.
Superbugs and Superdrugs: A history of MRSA – References
103
Robinson D A, Kearns A M, Holmes A, Morrison D, Grundmann H, Edwards 
G, O’Brien F G, Tenover F C, McDougal L K, Monk A B, Enright M 
C. (2005) Re-emergence of early pandemic Staphylococcus aureus as a 
community-acquired meticillin-resistant clone. Lancet 365: 1256–8.
Rolinson G N. (1961) ‘Celbenin’-resistant staphylococci. British Medical Journal 
i: 125–6.
Rolinson G N. (1998) Historical perspective: forty years of β-lactam research. 
Journal of Antimicrobial Chemotherapy 41: 589–603.
Rolinson G N, Geddes A M. (2007) The 50th anniversary of the discovery 
of 6-aminopenicillanic acid (6-APA). International Journal of Antimicrobial 
Agents 29: 3-8. Erratum in: International Journal of Antimicrobial Agents 
(2007) 29: 613.
Rolinson G N, Stevens S, Batchelor F R, Wood J C, Chain E B. (1960) 
Bacteriological studies on a new penicillin – BRL 1241. Lancet ii: 564–7. 
Rosenbach F J. (1884) Mikro-organismen bei den Wund-infektions-krankheiten 
des Menschen. Wiesbaden: J F Bergmann.
Rosendal K. (1971) Current national patterns – Denmark. In Beckman P S, 
Eickhoff T C. (eds) Proceedings of the International Conference on Nosocomial 
Infections. Chicago, IL: American Hospital Association, 11–16.
Rosendal K, Jessen O, Bentzon M W, Bülow P. (1977) Antibiotic policy and 
spread of Staphylococcus aureus strains in Danish hospitals, 1969–74. Acta 
Pathologica Microbiologica Scandinavica, Section B 85: 143–52.
Rountree P M, Barbour R G. (1950) Staphylococcus pyogenes in new-born babies 
in a maternity hospital. Medical Journal of Australia 1: 525–8. 
Rountree P M, Barbour R G. (1951) Incidence of penicillin-resistant and 
streptomycin-resistant staphylococci in a hospital. Lancet i: 435–6.
Rountree P M, Freeman B M. (1955) Infections caused by a particular ‘phage 
type of Staphylococcus aureus. Medical Journal of Australia 42: 157–61. 
Salgado C D, Farr B M, Calfee D P. (2003) Community-acquired methicillin-
resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. 
Clinical Infectious Diseases 36: 131–9.
Superbugs and Superdrugs: A history of MRSA – References
104
Sanderson D, Gibb F. (2008) Leslie Ash gets £5m payout from hospital where 
she caught MRSA. The Times (17 January).
Sato K, Shiratori O, Katagiri K. (1967) The mode of action of quinoxaline 
antibiotics. Interaction of quinomycin A with deoxyribonucleic acid. Journal 
of Antibiotics 20: 270–6. 
Selkon J B, Stokes E R, Ingham H R. (1980) The role of an isolation unit in the 
control of hospital infection with methicillin-resistant staphylococci. Journal 
of Hospital Infection 1: 41–6.
Shanson D C. (1981) Antibiotic-resistant Staphylococcus aureus. Journal of 
Hospital Infection 2: 11–36.
Shanson D C. (1982) Microbiology in Clinical Practice. Bristol: J Wright.
Shanson D C, McSwiggan D A. (1980) Operating theatre-acquired infection 
with a gentamicin-resistant, methicillin-resistant strain of Staphylococcus 
aureus: outbreaks in two hospitals attributable to one surgeon. Journal of 
Hospital Infection 1: 171–2.
Shanson D C, Johnstone D, Midgley J. (1985) Control of a hospital outbreak 
of methicillin-resistant Staphylococcus aureus infections: value of an isolation 
unit. Journal of Hospital Infection 6: 285–92.
Shanson D C, Kensit J G, Duke R. (1976) Outbreak of hospital infection with 
a strain of Staphylococcus aureus resistant to gentamicin and methicillin. 
Lancet ii: 1347–8.
Sheldrick G M, Heine A, Schmidt-Base K, Pohl E, Jones P G, Paulus E, Waring 
M J. (1995) Structures of quinoxaline antibiotics. Acta Crystallographica. 
Section B: Structural Crystallography and Crystal Chemistry 51: 987–99.
Shooter R A, Smith M A, Griffiths J D, Brown M E, Williams R E O, Rippon 
J E, Jevons M P. (1958) Spread of staphylococci in a surgical ward. British 
Medical Journal i: 607–13.
Shorr A F. (2007) Epidemiology of staphylococcal resistance. Clinical Infectious 
Diseases 45 (Suppl. 3): S171–6.
Superbugs and Superdrugs: A history of MRSA – References
105
Sievert D M, Boulton M L, Stoltman G, Johnson D, Stobierski M G, Downes 
F P, Somsel P A, Rudrik J T, Brown W, Hafeez W, Lundstrom T, Flanagan 
E, Johnson R, Mitchell J, Chang S. (2002) Staphylococcus aureus-resistant to 
vancomycin, US, 2002. Morbidity and Mortality Weekly Report (5 July 2002) 
51: 565–7.
Simpson E. (1988) Sir Peter Medawar 1915–1987. Immunology Today 9: 4–6.
Slee A M, Wuonola M A, McRipley R J, Zajac I, Zawada M J, Bartholomew 
P T, Gregory W A, Forbes M. (1987) Oxazolidinones, a new class of synthetic 
antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. 
Antimicrobial Agents and Chemotherapy 31: 1791–7.
Song M D, Wachi M, Doi M, Ishino F, Matsuhashi M. (1987) Evolution of 
an inducible penicillin-target protein in methicillin-resistant Staphylococcus 
aureus by gene fusion. FEBS Letters 221: 167–71.
Speller D C, Raghunath D, Stephens M, Viant A C, Reeves D S, Wilkinson 
P J, Broughall J M, Holt H A. (1976) Epidemic infection by a gentamicin-
resistant Staphylococcus aureus in three hospitals. Lancet i: 464–6.
Spicer W J. (1984) Three strategies in the control of staphylococci including 
methicillin-resistant Staphylococcus aureus. Journal of Hospital Infection 
5 (Suppl. A): 45–9. 
Spink W W. (1951) Clinical and biologic significance of penicillin-resistant 
staphylococci, including observations with streptomycin, aureomycin, 
chloramphenicol, and terramycin. Journal of Laboratory and Clinical Medicine 
37: 278–93.
Spink W W. (1962) Pathogenesis and therapy of shock due to infection, 
experimental and clinical studies. In Bock K D. (ed.) Shock: Pathogenesis 
and therapy: an international symposium. Berlin: Springer; New York, 
NY: Academic Press.
Spratt B G. (1975) Distinct penicillin-binding proteins involved in the division, 
elongation, and shape of Escherichia coli K12. Proceedings of the National 
Academy of Sciences of the USA 72: 2999–3003.
Spratt B G, Pardee A B. (1975) Penicillin-binding proteins and cell shape in 
E. coli. Nature 254: 516–17.
Stern H, Elek S D. (1955) Combined antibiotic therapy for the suppression of 
resistant variants in urinary infection. British Medical Journal ii: 1304–6.
Superbugs and Superdrugs: A history of MRSA – References
106
Stewart G T. (1946) The effect of penicillin upon Gram-negative bacteria. 
Journal of Hygiene 45: 282–8.
Stewart G T. (1965) The Penicillin Group of Drugs. Amsterdam; New York, NY: 
Elsevier.
Stewart G T. (1970) Epidemiological approach to assessment of health. Lancet 
ii: 115–19.
Stewart G T. (1992) Changing case-definition for AIDS. Lancet 340: 1414.
Stewart G T, Holt R J. (1963) Evolution of natural resistance to the newer 
penicillins. British Medical Journal i: 308–11.
Stewart G T, Coles H M T, Nixon H H, Holt R J. (1961) ‘Penbritin’: an oral 
penicillin with broad-spectrum activity. British Medical Journal ii: 200–6.
Stewart G T, Nixon H H, Coles H M, Kesson C W, Lawson D, Thomas R G, 
Mishra J N, Mitchell M E, Semmens J M, Wade T H. (1960) Report on 
clinical use of BRL 1241 in children with staphylococcal and streptococcal 
infections. British Medical Journal ii: 703–6.
Sutherland R, Rolinson G N. (1964) Characteristics of methicillin-resistant 
Staphylococci. Journal of Bacteriology 87: 887–99.
Tansey E M, Reynolds L A. (eds) (2000) Post penicillin antibiotics: From 
acceptance to resistance? Wellcome Witnesses to Twentieth Century Medicine, 
vol. 6. London: The Wellcome Trust. Freely available online at www.ucl.
ac.uk/histmed/publications/wellcome-witnesses/index.html or following the 
links to Publications/Wellcome Witnesses from www.ucl.ac.uk/histmed.
Tarr H A. (1958) Mechanical aids for the ‘phage-typing of Staphylococcus aureus. 
Monthly Bulletin of the Ministry of Health and the Public Health Service 
Laboratory 17: 64–72.
Tucker A. (1978) The brave new world of test tube babies: not all scientists 
welcome the advent of human embryos conceived in the laboratory. Guardian 
(27 July). Freely available at www.guardian.co.uk/environment/1986/
apr/29/energy.russia (visited 12 February 2008).
Tucker A. (1986) Radioactive Russian dust cloud escapes: major nuclear power 
accident reported at Chernobyl plant in the Soviet Union. Guardian (29 April). 
Freely available at www.guardian.co.uk/medicine/story/0,,1005345,00.html 
(visited 12 February 2008).
Superbugs and Superdrugs: A history of MRSA – References
107
Tucker A. (2006) Obituary: E S Anderson: brilliant bacteriologist who foresaw the 
public health dangers of genetic resistance to antibiotics. Guardian (22 March). 
Freely available at http://education.guardian.co.uk/higher/news/story/ 
0,,1736615,00.html (visited 12 February 2008).
US Department of Health Education and Welfare. (1958) On Hospital-acquired 
Staphylococcal Disease: Proceedings of the National Conference on Hospital-
acquired Staphylococcal Disease held at Atlanta, Georgia, 15–17 September 
1958, sponsored by the US Public Health Service, the Communicable 
Disease Center, the National Academy of Sciences and the National Research 
Council. Atlanta, GA: Communicable Disease Center.
Wasserman H H. (2006) Chemistry: synthesis with a twist. Nature 441: 
699–700.
Waterworth P M. (1978) Quantitative methods for bacterial sensitivity testing. 
In Reeves D S, Phillips I, Williams J D, Wise R. (eds) Laboratory Methods in 
Antimicrobial Chemotherapy. Edinburgh: Churchill Livingstone, 31–40.
Watts G. (2006) Obituary: Ephraim Saul Anderson. Lancet 367: 1392.
Whitby M, McLaws M L, Berry G. (2001) Risk of death from methicillin-
resistant Staphylococcus aureus bacteraemia: a meta-analysis. Medical Journal 
of Australia 175: 264–7. Comment in: Medical Journal of Australia (2002) 
176 : 188; author reply, 189. 
White L F, Dancer S J, Robertson C. (2007) A microbiological evaluation of 
hospital cleaning methods. International Journal of Environmental Health 
Research 17: 285–95.
White L F, Dancer S J, Robertson C, MacDonald J (2008) Are hygiene standards 
useful in assessing infection risk? American Journal of Infection Control 36: 
forthcoming. 
Williams R E O. (1959) Epidemic staphylococci. Lancet i: 190–5.
Williams R E O. (1963) Healthy carriage of Staphylococcus aureus: its prevalence 
and importance. Bacteriological Reviews 27: 56–71.
Williams R E O, Shooter R A. (eds) (1963) Infection in Hospitals, Epidemiology 
and Control. Oxford: Blackwell Scientific Publications.
Superbugs and Superdrugs: A history of MRSA – References
108
Williams R E O, Blowers R, Garrod L P, Shooter R A. (1960) Hospital 
Infection: Causes and prevention [2nd edn, 1966]. London: Lloyd-Luke 
Medical Books.
Wilson G S, Miles A A. (eds) (1964) Topley and Wilson’s Principles of Bacteriology 
and Immunity, 5th edn, 2 vols. London: Edward Arnold Publishers Ltd.
Wise R I, Cranny C, Spink W W. (1956) Epidemiologic studies on antibiotic-
resistant strains of Micrococcus pyogenes. American Journal of Medicine 20: 
176–84.
Witte W. (2000) Selective pressure by antibiotic use in livestock. International 
Journal of Antimicrobial Agents 16 (Suppl.): S19–24.
Woodford N, Johnson A P, Morrison D, Speller D C. (1995) Current perspectives 
on glycopeptide resistance. Clinical Microbiology Reviews 8: 585–615.
Wyllie D H, Crook D W, Peto T E. (2006) Mortality after Staphylococcus aureus 
bacteraemia in two hospitals in Oxfordshire, 1997–2003: cohort study. 
British Medical Journal 333: 281, Epub 2006 Jun 23. Erratum in: BMJ 
333: 468.
Superbugs and Superdrugs: A history of MRSA – Biographical Notes 
109
Professor Ephraim Saul (Andy) 
Anderson
CBE FRS (1911–2006) qualified 
at King’s College Medical School, 
Newcastle (then part of Durham 
University) and was in general 
practice until he joined the Royal 
Medical Corps in 1939 and served 
in Cairo. After further training in 
pathology and bacteriology at the 
Royal Postgraduate Medical School 
and studies of typhoid ‘phage types 
at the Lister Institute of Preventive 
Medicine, London, he joined the 
Enteric Reference Laboratory of 
the Public Health Laboratory 
Service, Colindale, in 1947, and 
was Director from 1954 until his 
retirement in 1978, as well as the 
International Reference Laboratory 
for Enteric ‘Phage Typing and the 
WHO Collaborating Centre on 
Drug Resistance in Enterobacteria 
from 1960, both at Colindale. 
His recognition of the health 
implications of multiple drug-
resistance in bacteria to antibiotics 
contributed to the formation of the 
Swann Committee [Agricultural 
Research Council and Medical 
Research Council, Joint Committee 
on Antibiotics in Animal Feeding 
(1969)], a risk acknowledged by 
doctors and governments in the 
1990s. Anderson (1968); Datta 
(1969); Tucker (2006); Anon. 
(2006); Watts (2006).
Professor Graham Ayliffe
MD FRCPath HonDipHIC  
(b. 1926) Developed an interest 
in hospital infection in Bristol 
with Professor William Gillespie 
(1956–59). In 1960 he joined 
Mary Barber at Hammersmith 
Hospital and was appointed Senior 
Scientific Officer (MRC) and Hon 
Consultant with Professor Edward 
Lowbury at the Hospital Infection 
Research Laboratory, Birmingham 
in 1964. He was then appointed 
Hon Director (1980–94), Director 
of the WHO Collaborating Centre 
for Hospital Infection (1985) and 
Professor of Medical Microbiology, 
University of Birmingham, 
1980–91. He was Chairman of 
the Combined Working Party on 
MRSA, 1996–98. See Lowbury  
et al. (eds) (1975).
Professor Mary Barber
MD FIBiol FRCPath (1911–65) 
was Professor in Clinical 
Bacteriology at the Postgraduate 
Medical School, Hammersmith 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources. 
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Hospital, London, from 1964 until 
her sudden death in 1965. She had 
been at the Hammersmith from 
1947–48 as lecturer and reader 
from 1957 to 1964. See Pollock 
(1965); Garrod (1966); Knox 
(1966). 
Dr Ralph Batchelor 
(b. 1931), a biochemist at Beecham 
Research Laboratories, Brockham 
Park, Betchworth, Surrey, from 
1956, worked his first year in 
Rome with Professor Sir Ernst 
Chain. He moved from research 
to general management in 1970 
and was a Director of Beecham 
Pharmaceuticals from 1978 until his 
retirement in 1989. He was awarded 
the Addingham Medal by the City 
of Leeds in 1966 and Mullard 
Medal of the Royal Society in 
1971. Some of the first crystals and 
early chromatograms showing the 
presence of 6-APA are in his original 
notebook, now on display in the 
Science Museum. See Batchelor  
et al. (1959). See Figure 1.
Dr Robert Blowers
FRCP FRCPath (1915–2004) 
qualified at the Middlesex Hospital, 
London, and trained in blood 
transfusion before taking command 
of No 4 Field Transfusion Unit, 
which served at D-Day. He was 
the first medical officer to enter  
concentration camps after their 
liberation. He trained in pathology 
after the war and was appointed 
to the Staphylococcus Reference 
Laboratory at the Central Public 
Health Laboratory, Colindale. 
In 1951 he became the director 
of the Middlesbrough public 
health laboratory and consultant 
microbiologist to the Teeside 
Hospital Group and the Newcastle 
Regional Hospital Board. He went 
to Uganda as Professor of Medical 
Microbiology at the Makerere 
University College, Kampala, 
Uganda, in 1967, returning to 
head the Division of Hospital 
Infection and Microbiology at the 
Medical Research Council’s Clinical 
Research Centre, Northwick Park 
Hospital, Harrow, in 1970 until his 
retirement in 1980. 
Dr Robert Bud
FRHS (b. 1952) took his doctorate 
at the University of Pennsylvania 
in the History and Sociology of 
Science. Since 1978 he has been 
at the Science Museum, where he 
is currently Principal Curator of 
Medicine. He was the Joint  
Winner of the Bunge Prize for the 
History of Scientific Instruments 
in 1998. He was responsible for 
the Science Museum temporary 
exhibition, ‘Penicillin: A Tale of 
Triumph and Tragedy’ (2007/08).  
See Bud (2007).
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Professor Mark Casewell
MD FRCP FRCPath (b. 1940) was 
Lecturer at St Thomas’ Hospital, 
London (1971–81) and Reader in 
Medical Microbiology at the Royal 
London Hospital (1981–84), until 
appointed Professor of Medical 
Microbiology at King’s College 
School of Medicine and Dentistry, 
London, and Head of the Dulwich 
Public Health Laboratory from 
1984 until his retirement in 1997, 
later Emeritus. He has a 30-year 
research interest in hospital 
infection and the epidemiology 
and control of infection caused 
by multiply antibiotic-resistant 
organisms, especially Klebsiella 
species and MRSA. He was the first 
to identify the activity of mupirocin 
against MRSA and its role in the 
control of epidemic MRSA. He was 
a founder member of the Hospital 
Infection Society and served as its 
Chairman (1988–91).
Dr Bilwanath (Bill) Chattopadhyay
DCP FRCPath (b. 1939) was 
Consultant Medical Microbiologist 
and Director of the Public Health 
Laboratory at Whipps Cross 
University Hospital, London, 
between 1974 and 2002. He was 
also Honorary Senior Lecturer in 
Medical Microbiology, University 
of London, during that period. 
Public health microbiology 
work covered eight boroughs 
of London in the North East 
Thames Region. He was appointed 
Consultant in Communicable 
Diseases Control (CCDC) by 
the borough of Waltham Forest, 
1991–93; the North East Thames 
Regional Adviser in Medical 
Microbiology for the Royal College 
of Pathologists during the 1990s. 
During the same time he was 
selected as a national inspector 
in Medical Microbiology for the 
Clinical Pathology Accreditation 
(CPA) Board (UK) Limited, which 
he held for 11 years, and was a 
Consultant Medical Microbiologist 
at North Middlesex University 
Hospital, London, 2002–06. He 
also worked for several years as a 
national Expert Witness in  
medical microbiology and 
infectious diseases.
Dr Stephanie Dancer
DTM&H MD FRCPath (b. 1959) 
is a consultant microbiologist at 
the Southern General Hospital in 
Glasgow, and the current editor of 
the Journal of Hospital Infection. 
She trained at St Bartholomew’s 
Hospital in London (1977–83), 
followed by postgraduate studies 
in Pathology at Guy’s Hospital, 
where she gained a thesis on the 
epidemiology of toxin-producing 
staphylococci. She has worked 
in various remote areas of the 
world, including Papua New 
Guinea, Thailand, Vietnam 
and the Canadian High Arctic, 
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and published her experiences, 
albeit with a microbiological 
slant. She spent six years as the 
Control of Infection Officer for 
Argyll before moving to Health 
Protection Scotland as its inaugural 
microbiologist (2002–05). At 
present, she balances clinical and 
editorial duties with research 
projects on the control of MRSA, 
specifically the role of cleaning.
Dr Bernard Dixon
OBE FIBiol (b. 1938) has been 
European Editor for the American 
Society for Microbiology since 
1997 and a columnist for Current 
Biology since 2000 and for Lancet 
Infectious Diseases since 2001. 
He was Editor of New Scientist 
from 1969 to 1979. He has 
run  media training and science 
communication courses for the 
University of Oxford and Cancer 
Research UK since 1991; and has 
been a member of the European 
Federation of Biotechnology’s 
Task Group on Public Perceptions 
of Biotechnology. He holds an 
honorary DSc from Edinburgh 
University for contributions to 
public debate on scientific issues 
and was appointed OBE for 
services to science journalism. He 
has received the Charter Award of 
the Institute of Biology for  
services to biology and in 2002 
shared (with Steven Rose) the 
Biochemical Society Award ‘for 
scientific communication in the 
public domain’.
Dr Peter Doyle
OBE CChem FRSC (1921–2004) 
was a chemist in industry after his 
graduation from the University of 
London in 1944. He joined the 
Beecham Research Laboratory at 
Brockham Park, Surrey, in 1952 
and was Director of Research of 
Beecham Pharmaceuticals from 
1962 until his retirement in 1983. 
His other honours include the 
Gold Medal in Therapeutics of the 
Worshipful Society of Apothecaries 
in 1964 awarded jointly with Dr 
G N Rolinson; and the Mullard 
Medal of the Royal Society in 1971 
jointly with Dr Ralph Batchelor, 
Dr J H C Nayler and Dr George 
Rolinson. He was made OBE for 
services to the pharmaceutical 
industry in 1977. See Figure 1.
Dr Georgia Duckworth
FRCP FRCPath (b. 1954) studied 
veterinary medicine at Churchill 
College in the first year of mixed 
colleges at Cambridge, later 
switching to human medicine 
and embarking on clinical studies 
in the first intake at Cambridge 
University School of Clinical 
Medicine, after a brief sojourn in 
Oxford to fill in her gaps on human 
anatomy and specialization in 
medical microbiology in Professor 
J D Williams’ department at the 
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London Hospital Medical College, 
London (1982–97). Her early 
research interest concentrated on 
MRSA and she was Honorary 
Secretary of various national 
working parties on its control 
and management. She was one 
of the first microbiologists to 
be appointed a Consultant in 
Communicable Disease Control, 
while also Senior Lecturer in 
Medical Microbiology at the 
London Hospital Medical 
College in 1989; later as 
Regional Epidemiologist for 
North Thames, then London 
(1997–2000). In 2001, she 
established the Department of 
Healthcare-associated Infection 
and Antimicrobial Resistance 
in the Communicable Disease 
Surveillance Centre, then part 
of the Public Health Laboratory 
Service, Colindale, London 
(now the Centre for Infections 
of the Health Protection Agency, 
Colindale). She is Deputy 
Chair of the Steering Group on 
Healthcare-associated Infection and 
Expert Adviser on the European 
Communicable Disease Centre 
Panel of Scientific Experts. She 
has served on the Council of the 
Hospital Infection Society twice.
Professor Brian Duerden
(b. 1948) is the Inspector of 
Microbiology and Infection 
Control at the Department of 
Health (DH) and Professor of 
Medical Microbiology at Cardiff 
University. He qualified at 
Edinburgh University (1972) and 
was a Lecturer in Bacteriology there 
and later at Sheffield University, 
becoming Professor of Medical 
Microbiology in 1983. He was 
Consultant Microbiologist to 
the Sheffield Children’s Hospital. 
In 1991 he became Professor of 
Medical Microbiology and Director 
of the Public Health Laboratory in 
Cardiff. He was Deputy Director 
and Medical Director of the PHLS 
in England and Wales from 1995 
and Director of the Service from 
August 2002 until it became part 
of the Health Protection Agency. 
He moved to the DH in 2004. 
His major interests are anaerobic 
microbiology, healthcare-associated 
infections and antibiotic resistance 
and he was Editor-in-Chief of the 
Journal of Medical Microbiology for 
20 years (1982–2002). 
Professor Michael Emmerson
OBE FRCPath FRCP FMedSci 
(b. 1937) received basic training in 
Microbiology at University College 
Hospital (UCH), London, under 
Dr Joan Stokes. He was appointed 
Professor of Clinical Bacteriology 
at Queen’s University of Belfast 
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(1984–89), later Professor of 
Microbiology at University of 
Leicester (1989–91); and Professor 
of Microbiology at University of 
Nottingham (1989–2000), later 
Emeritus. He co-founded and 
served as chairman of the Hospital 
Infection Society and was its 
President (2002–06). 
Sir Alexander Fleming
Kt FRCP FRS (1881–1955) 
discoverer of penicillin in 1929, 
was trained at St Mary’s Hospital 
Medical School (1906–08), 
entering with a scholarship in 
natural sciences, joining Sir 
Almroth Wright’s team there in 
1908, where he was Professor 
of Bacteriology from 1928 until 
his retirement in 1948, later 
Emeritus. He shared the Nobel 
Prize for Physiology or Medicine 
in 1945 for the discovery and 
development of penicillin 
with Lord Florey OM Kt FRS 
(1898–1968) and Sir Ernst Chain 
Kt FRS (1906–1979). Among 
many honors, he was President of 
the London Ayrshire Society and 
Pathological Comparative Medicine 
Sections, RSM; and the Society for 
General Microbiology and Rector 
of Edinburgh University, 1951–54. 
For a background to his work, see 
Hare (1983).
Professor Gary French
MD FRCPath DipHIC (b. 1945) 
qualified in medicine at St Thomas’ 
Hospital, London, and became a 
Senior Lecturer/Hon. Consultant 
in Microbiology in 1980. In 
1982 he was appointed to the 
Foundation Chair of Microbiology 
at the Chinese University of Hong 
Kong and the Prince of Wales 
Hospital and in 1990 was made 
Professor of Microbiology and 
Honorary Consultant at Guy’s 
and St Thomas’ Hospitals (merged 
into King’s College London in 
1998). He has been Chairman 
of the Hospital Infection Society 
(1999–2001) and Editor of 
the Journal of Hospital Infection 
(1995–99). He is a member of 
Government advisory committees 
on Antimicrobial Resistance 
and Healthcare Associated 
Infections (ARHAI) and the 
Rapid Review Panel (RRP) (on 
innovations in hospital infection 
control). His areas of specialist 
interest are the prevention and 
control of healthcare-associated 
infections, antibiotic therapy and 
antimicrobial resistance.
Professor Lawrence Paul Garrod
(1895–1979) was Professor of 
Bacteriology at St Bartholomew’s 
Hospital until 1961, moving to 
the Royal Postgraduate Medical 
School as Honorary Consultant in 
Chemotherapy from 1965 until 
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his retirement in 1971. He was co-
author of the first five editions of 
the influential textbook, Antibiotic 
and Chemotherapy (1963, with Mary 
Barber; later co-edited with Francis 
O’Grady and Harold P Lambert; 
and from the 4th edn, containing 
a chapter on laboratory methods 
by Pamela M Waterworth). See 
Lambert (1976): 1.
Professor Curtis Gemmell
FRCPath (b. 1941) graduated in 
Bacteriology, University of Glasgow 
in 1963, and completed his PhD 
there in 1968. He was appointed 
Lecturer at the University of 
Glasgow, later Senior Lecturer, 
Reader and Professor in Bacterial 
Infection and Epidemiology 
(2000–06). He was visiting 
Professor at the University of 
Minnesota, USA (1979/80) and 
Director of the Scottish Methicillin 
Resistant Staphylococcus aureus 
(MRSA) Reference Laboratory 
(1997–2006). 
Professor Alan Glynn
FRCP FRCPath (b. 1923) qualified 
at University College Hospital, 
London. He trained in clinical 
medicine but after two years as 
a senior registrar at St Mary’s 
Hospital, London, he converted to 
bacteriology becoming Professor 
there in 1971 and Head of the 
Department of Bacteriology in 
1974. In 1980 he became Director 
of the Central Public Health 
Laboratory at Colindale, London 
until his retirement in 1988.
Dr Ian Gould
PhD FRCP(E) FRCPath (b. 1953) 
qualified in medicine in 1976 and 
trained in clinical microbiology 
and infectious diseases in the UK, 
Canada and Africa. He has been 
Consultant Clinical Microbiologist 
at Aberdeen Royal Infirmary since 
1986, and Honorary Professor of 
Public Health, Epidemiology and 
Microbiology at the University of 
Trnava. He has been an adviser on 
antibiotic resistance and prescribing 
to the UK Department of Health, 
the Alliance for the Prudent Use 
of Antibiotics, the International 
Organisation for Epizoonosis, 
the European Commission, the 
European Centre for Disease 
Control and Government agencies 
abroad; and co-ordinator of the 
European projects ESAR and 
ARPAC. See Gould (2005).
Professor David Greenwood
(b. 1935) worked as a laboratory 
technician in various London 
hospitals, graduating in microbiology 
from UCL, London, in 1971, 
gaining a PhD in 1974. Later that 
year he moved to Nottingham as 
Lecturer in the new Medical School 
and was awarded a chair in 1989 as 
Professor of Antimicrobial Science 
at the University of Nottingham, 
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later Emeritus. His research interests 
encompassed various aspects of  
the response of bacteria to 
antimicrobial agents.
Professor Jeremy Hamilton-Miller
PhD DSc FRCPath (b. 1938) was 
a microbiologist at the Department 
of Medical Microbiology, The 
Royal College Free School 
of Medicine (Royal Free and 
University College Medical 
School after 1998) between 1972 
and 2003. He was appointed ad 
hominem Professor in 1987, later 
Emeritus. He had previously 
worked at medical schools at 
Guy’s Hospital and Charing Cross 
Hospital, and at The Sir William 
Dunn School of Pathology. 
His main research was done on 
assessment of novel antibiotics, 
antibiotic resistance, natural 
products and urinary infections. He 
retains an interest in probiotics.
Professor Ronald Hare
MD (1899–1986), a colleague of 
Fleming at St Mary’s Hospital, 
London, from 1925–30, was 
largely responsible for planning 
and building the penicillin plant at 
the University of Toronto funded 
by the Canadian Government. He 
returned to London as Professor of 
Bacteriology in the University of 
London at St Thomas’ Hospital, 
London, in 1946 until his 
retirement in 1964, later Emeritus. 
He was a member of the Council 
of the Wright-Fleming Institute 
(1952–60); the Nuffield Institute of 
Comparative Medicine (1960–68); 
President of the Pathology Section 
of the Royal Society of Medicine 
(1963/4) and member of the 
Council, Royal Society of Medicine 
(1965–68); as well as an Examiner 
in Universities of London, Malaya, 
Birmingham, West Indies and East 
Africa, Ibadan.
Dr Patricia Jevons
(1921–2005) found the first 
methicillin-resistant strain of 
Staphylococcus aureus at Colindale 
in 1960. See Jevons (1961). 
Dr Angela kearns
(b. 1959) trained as a 
microbiologist at the Public 
Health Laboratory in Newcastle 
General Hospital following her 
appointment in 1981. In the 
mid-1990s she set up a Regional 
Molecular Diagnostic Facility and 
played a key role in developing and 
implementing real-time molecular 
diagnostic techniques for a range of 
bacterial and viral pathogens now 
used throughout the PHLS. In June 
2002 she transferred to the Central 
Public Health Laboratory (now 
known as the Centre for Infections, 
Health Protection Agency) in 
Colindale, London where she 
heads the national Staphylococcus 
Reference Unit and takes a 
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keen interest in the evolution, 
epidemiology and pathogenicity of 
Staphylococcus aureus.
Dr Edward Lowbury
OBE FRSL (1913–2007) 
bacteriologist and poet, qualified 
in medicine at University College, 
Oxford, and trained at the Royal 
London Hospital, London. He 
served as pathologist in the RAMC 
(1943–46) and was a member of 
the scientific staff of the MRC 
Common Cold Research Unit, 
Salisbury, from 1947–49, moving 
to the MRC Burns Unit at the 
Birmingham Accident Hospital, 
as Head of Bacteriology, until his 
retirement in 1979. His particular 
interest was the prevention of 
infection; and the use of the 
mechanisms and the emergence 
of antibiotic resistance and its 
prevention. He was the first 
Honorary Director of the Hospital 
Infection Research Laboratory 
(HIRL) at Summerfield Hospital, 
Dudley Road (now the City 
Hospital), Birmingham, directed 
by Professor Graham Ayliffe. His 
work included Lowbury and Ayliffe 
(1974) and Lowbury et al. (eds) 
(1975). See also Ayliffe (2007); 
www.dudleyroad.org/History/ 
History.htm (visited 14 August 
2007). His reminiscences to Dr 
Tilli Tansey, dated 14 April 1998, 
have been deposited with the 
tapes, correspondence and other 
documentation from the 1998 
Witness Seminar, ‘Post penicillin 
Antibiotics’, in GC/253 in Archives 
and Manuscripts, Wellcome 
Library, London.
Dr John Nayler 
FRSC (1927–1993) joined 
the newly formed Chemistry 
Department at Beecham Research 
Laboratories in 1948, and was 
Head of the Department of 
Organic Chemistry there from 
c. 1960 to 1989. Nayler and his 
colleagues’ demonstration of the 
existence of the penicillin nucleus 
(6-aminopenicillanic acid) in 
certain penicillin fermentation 
solutions led to the synthesis of 
most of the commercially and 
clinically important semisynthetic 
penicillins marketed by Beecham 
from 1959 to 1972. Nayler’s name 
appears on the majority of the 
many patents and publications 
during this period. Doyle (1993). 
See also Batchelor et al. (1959). 
Dr Bill Newsom
MD FRCPath (b. 1932) was 
Consultant Microbiologist to 
Addenbrooke’s and Papworth 
Hospitals in Cambridge. He was on 
the editorial Board of the Journal 
of Antimicrobial Chemotherapy, and 
remains an Editor of the Journal 
of Hospital Infection. He has been 
President of the Hospital Infection 
Society and of the Institute of 
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Decontamination Sciences. He is 
currently the author of papers on 
medical history for the Journal of 
Hospital Infection and the British 
Journal of Infection Control.
Dr Marler Thomas Parker
FRCPath (1912–2006) qualified at 
Cambridge in 1937 and gained the 
Diploma of Bacteriology (London) 
with distinction in 1939 from 
the London School of Hygiene 
and Tropical Medicine under the 
tutelage of W W C Topley and 
G S Wilson. He served in the 
Royal Army Medical Corps as a 
pathologist, initially in the UK 
and then in India and Burma with 
the rank of Major. On his return 
to England he joined the newly 
formed Public Health Laboratory 
Service in 1946 and was Director 
of the Camarthen Laboratory 
until 1948 when he took over the 
directorship of the Manchester 
laboratory where he remained until 
he was appointed as Director of the 
PHLS Cross Infection Reference 
Laboratory (CIRL) from 1961 to 
1978. He brought together the 
Staphylococcus and Streptococcus 
Reference Laboratories and 
introduced work on Pseudomonas 
and other emerging opportunist 
Gram-negatives. He carried 
out a number of seminal 
studies on the epidemiology of 
Staphylococcus aureus, particularly 
the characterization of the 80/81 
epidemic strain and later with Dr 
Pat Jevons on the identification 
of ‘Celbenin’-resistant microarray 
technology strains which are 
today known as MRSA. He was 
a Founder Fellow of the Royal 
College of Pathologists in 1964 
and President of the Hospital 
Infection Society from 1984 to 
1988. See Pitt (2006). 
Professor Ian Phillips
(b. 1936) qualified in medicine at 
Cambridge in 1961 after studies 
at St John’s College and at St 
Thomas’ Hospital Medical School, 
London. His subsequent training 
was at St Thomas’ Hospital and 
at Makerere University, Uganda, 
and in 1974 he was appointed 
Professor of Microbiology at 
St Thomas’ Hospital Medical 
School. In later years he became 
Chairman of the British Society 
for Antimicrobial Chemotherapy, 
Chairman of the Association 
of Medical Microbiologists and 
finally, President of the European 
Society of Clinical Microbiology 
and Infectious Diseases. He 
became Emeritus Professor on his 
retirement in 1996.
Dr Tyrone Pitt
PhD (b. 1948) joined the Public 
Health Laboratory Service in 1965 
and served in the Staphylococcus 
Reference Laboratory from 1971 
to 1973. He was appointed Head 
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of the Gram Negative Unit in 
1981; this was combined with the 
staphylococcal service to form the 
Epidemiology Typing Unit and  
he has directed the joint service  
since 1994.
Dr Elizabeth Price
FRCPath (b. 1944) was appointed 
Senior Lecturer at the Institute 
of Child Health and Honorary 
Consultant Medical Microbiologist 
at the Queen Elizabeth Hospital for 
Children, London, in 1977. From 
1991 to 1997 she also worked at 
Great Ormond Street Hospital for 
Children NHS Trust. In 1997, she 
transferred to the Royal London 
Hospital and retired from routine 
clinical work in 2006.
Professor Sir Mark Richmond
Kt PhD DSc FRS (b. 1931) 
graduated in Biochemistry at 
Cambridge and did three years’ 
postgraduate work there under 
Professor Ernest Frederick Gale. 
His first postdoctoral position 
was at the National Institute of 
Medical Research, Mill Hill, and 
was followed by an appointment 
as Reader in Molecular Biology in 
the University of Edinburgh under 
Professors Martin Rivers Pollock 
and William Hayes. He moved 
to Bristol University in 1968 as 
Professor of Bacteriology, where 
most of his work on staphylococcal 
plasmids and antibiotic resistance 
was carried out. In 1981 he ceased 
active research in microbiology on 
appointment as Vice Chancellor 
of the University of Manchester, 
during which term he became 
Chairman of the Committee of 
Vice-Chancellors and Principals 
of the UK. From there he became 
Chairman of the Science and 
Engineering Research Council. 
In 1993 he moved into industry 
as Global Head of Research for 
Glaxo. On retirement from Glaxo 
Wellcome in 1996 he became an 
Honorary Fellow in the School 
of Public Policy at UCL. Since 
retirement from full-time work, he 
has been appointed Non-Executive 
Director of a number of companies, 
notably Genentech Inc. and OSI 
Pharmaceuticals in the US and 
Ark Therapeutics in the UK. He 
has been awarded the Robert Koch 
Medal of the Robert Koch Stiftung 
in Germany, the Colworth Medal 
of the Biochemical Society and the 
Garrod Medal of the Society for 
Antimicrobial Chemotherapy. 
Dr George Rolinson
(b. 1926) was Associate Director of 
Research and Senior Microbiologist 
at Beecham Pharmaceuticals at 
Brockham Park, Betchworth, 
Surrey, from 1955 to 1988. See 
Rolinson (1998).
Dr Geoff Scott
(b. 1948) has been Consultant 
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Clinical Microbiologist at 
University College London 
Hospitals since 1986. He was the 
first Press Officer for the Hospital 
Infection Society in 1987. He has 
an interest in hospital-acquired 
infections and manages patients 
with tuberculosis.
Dr Joseph Selkon 
TD FRCPath (b. 1928) graduated 
MBChB in 1950 from Cape 
Town and DCP from London 
in 1954. He was Consultant 
Microbiologist and Director of 
the Newcastle Regional Public 
Health Laboratory from 1977 and 
then the Oxford Regional Public 
Health Laboratory from 1982. He 
has been an Honorary Lecturer at 
Newcastle and Oxford Universities 
and is a Past President of the British 
Thoracic Society (1988–93).
Dr David Shanson
FRCPath (b. 1944) was Senior 
Lecturer and Consultant 
Microbiologist at the London 
Hospital (1974–76), St Stephen’s 
and Westminster, Charing Cross 
and Chelsea and Westminster 
Hospitals (1977–94) and was 
recently Microbiologist at 
Great Ormond Street Hospital 
for Children, London. He has 
been President of the Section of 
Pathology at the Royal Society of 
Medicine. In 1979 he chaired a 
steering group that founded the 
Hospital Infection Society and 
became its first Secretary in 1980, 
and later its Chairman (1984–87). 
In 1987 he chaired the organizing 
committee of the first International 
Conference of the Hospital 
Infection Society when MRSA 
was discussed as a major topic. He 
has been a member of all the UK 
joint working parties producing 
guidelines for the control of 
MRSA. See Shanson (1982).
Professor Reginald A Shooter
(b. 1916) formerly Professor of 
Bacteriology at St Bartholomew’s 
Hospital, London, and an expert 
on hospital infection.
Dr Norman Simmons
CBE FRCPath FIFST (b. 1933) 
was consultant and clinical tutor 
at the Enfield Group of Hospitals 
for six years before being appointed 
Consultant Clinical Microbiologist 
and head of the Department of 
Clinical Bacteriology and Virology 
at Guy’s Hospital London in 
1972. He was responsible for the 
diagnostic and infection control 
services at that hospital until he 
left in 1994, but he continued in 
clinical practice until 2006. His 
special interests were endocarditis 
and food safety and he was a 
member of the government’s 
Advisory Committee on the 
Microbiological Safety of Food 
from 1990 to 2001. He was 
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appointed CBE in 2000. He retains 
his interests in hospital-acquired 
infection and food safety and still 
contributes to the literature on 
these subjects. 
Professor Dale Smith
PhD (b. 1951) received his 
doctorate in the history of medicine 
from the University of Minnesota 
in 1979 under the direction of 
Professor Leonard G Wilson and 
was then appointed to the faculty 
there. He has been at the F Edward 
Hébert School of Medicine, 
Uniformed Services University 
of the Health Sciences, Bethesda, 
Maryland since 1982, Professor and 
Chairman of the Department of 
Medical History since 1997. He is 
the author of numerous papers on 
medical history. His professional 
interests include the history of 
graduate medical education, 
infectious diseases, surgery and  
the problems of patient evacuation 
in military operations. See  
Budd (1984).
Professor Brian Spratt
FMedSci FRS (b. 1947) was 
a postdoctoral fellow with Art 
Pardee at Princeton University in 
the 1970s where he discovered 
bacterial penicillin-binding 
proteins (PBPs) [Spratt and Pardee 
(1975)] and determined their role 
in the killing action of penicillin. 
He subsequently worked on 
the mechanisms of resistance to 
penicillin mediated by alterations 
of PBPs and developed multilocus 
sequence typing (MLST) for the 
precise characterization of strains 
of bacterial pathogens. With Mark 
Enright he used MLST to identify 
and discern the evolutionary origins 
of the major lineages of MRSA. 
He was Professor of Biology at 
Oxford (1997–2001) and Sussex 
Universities (1989–97) and has 
been Professor of Molecular 
Microbiology and Head of the 
Department of Infectious Disease 
Epidemiology at Imperial College 
London since 2001. 
Professor Gordon Stewart
(b. 1919) began his long 
professional interest in the control 
of communicable diseases with 
trials of domestic penicillins 
at the Royal Navy’s Medical 
School, Clevedon, Somerset, in 
the combined Services Hospital, 
Trincomalee, Sri Lanka, and, 
from 1946, at St Mary’s Hospital, 
London, other centres in the 
UK and the University of North 
Carolina at Chapel Hill, NC, 
from 1963 to 1972. He held the 
Mechan Chair of Public Health 
at the University of Glasgow from 
1972 until his retirement in 1984, 
later Emeritus. He was particularly 
interested in the molecular aspects 
of antimicrobial and allergenic 
properties of penicillins, and 
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contributed to efforts to widen 
activity and identify hazards in 
other antimicrobials and from other 
pathogens, like MRSA and Gram-
negative bacteria. See, for example, 
Stewart (1965, 1992).
Dr Robert Sutherland
DSc (b. 1930) graduated in 
chemistry and microbiology 
in 1950 from the University 
of Edinburgh and joined the 
Chemotherapy Department of May 
& Baker in 1955 to evaluate novel 
macrolide antibiotics, including 
spiramycin. He later became head 
of the Bacteriology Laboratory of 
Beecham Research Laboratories 
at Brockham Park, Betchworth, 
Surrey, in 1962, involved primarily 
in research and development 
of semi-synthetic penicillins, 
resistance to β-lactam antibiotics 
and β-lactamase inhibitors.
Professor Sir Michael Swann
FRS (Lord Swann from 1981) 
(1920–90), Principal and Vice-
Chancellor of the University 
of Edinburgh, 1965–73. See 
Mitchison (1991); Datta (1969).
Dr Tilli Tansey
HonFRCP FMedSci (b. 1953) 
is Convenor of the History of 
Twentieth Century Medicine 
Group and Reader in the History 
of Modern Medical Sciences at 
the Wellcome Trust Centre for the 
History of Medicine at UCL.
Mr Anthony (Phil) Tucker
(1924–98) graduated in fine 
art from Manchester College of 
Art and joined the Guardian’s 
Manchester offices in 1953, 
becoming a sub-editor in 1957, a 
founder member of the features 
department and followed John 
Maddox as Science correspondent 
in 1964, where he was an articulate 
science writer, winning the Glaxo 
prize for science journalism several 
times, until his retirement in 1988. 
He continued until his death to 
write obituaries, such as Tucker 
(2006). See Radford (1998). 
Miss Pamela Waterworth
(1920–2004) was a trainee nurse 
during the Second World War 
when deafness changed her career. 
She worked with Professor L P  
Garrod at St Bartholomew’s 
Hospital, London, as a technician 
from penicillin’s introduction in 
1944 until Garrod’s retirement 
in 1961. She was to join Mary 
Barber at the Royal Postgraduate 
Medical School, Hammersmith 
Hospital, London, but Barber’s 
sudden death in a car accident 
prevented this. In 1971 she moved 
to the Department of Microbiology 
at University College Hospital, 
London, where she worked with 
Dr Joan Stokes until her retirement 
in 1981. Between 1955 and her 
retirement she published 69 peer-
reviewed articles. Along with Joan 
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Stokes, she developed a method 
of qualitative antimicrobial 
susceptibility testing. See Ridgway 
and Stokes (2005).
Professor John West
MD FRCP (b. 1928) received 
his medical training in Adelaide, 
Australia, and then moved to the 
Royal Postgraduate Medical School, 
Hammersmith Hospital, London, 
where he spent 15 years. He has 
been Professor of Medicine and 
Physiology at the University of 
California, San Diego since 1969. 
Sir Robert Evan Owen Williams
Kt (1916–2003), bacteriologist, 
trained at University College 
Hospital, London, and qualified in 
1940. In 1942 he was appointed 
pathologist in the MRC Burns 
Research Unit at the Birmingham 
Accident Hospital and his interest 
in the spread of wound infections 
began. He joined the Public Health 
Laboratory Service in Colindale 
in 1946 and was Director of the 
Streptococcus, Staphylococcus 
and Air Hygiene Laboratory from 
1949 until 1960. He returned to 
the clinical field as Professor of 
Bacteriology and Director of the 
Wright-Fleming Institute at St 
Mary’s Hospital Medical School, 
London, in 1967 becoming the first 
full-time academic to be Dean of the 
Medical School. He was appointed 
Director of the Public Health 
Laboratory Service from 1973 until 
his retirement in 1981. He was a 
member of the Medical Research 
Council and President of the Royal 
College of Pathologists (1975–78). 
See Figure 3. 
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automated laboratory techniques 
for detecting antimicrobial 
resistance 
Standardized laboratory 
techniques on bacterial isolates 
were implemented in the 1950s, 
followed by clinical and economic 
pressures to find rapid test methods 
requiring less skilled labour input, 
which led to the development of 
semi-automated and automated 
antimicrobial susceptibility tests 
(AST) in the 1970s. Three routine 
ASTs are found in the UK: the 
disc diffusion test, the breakpoint 
test, and the polymerase chain 
reaction (PCR) test. Tests vary 
by typability, reproducibility, the 
ability to discriminate between 
strains, stability, cost-effectiveness 
and turnaround time. 
bacteriophage type, group III 
MRSA and other members of 
this group are often resistant 
to penicillin, streptomycin and 
tetracycline (PST). See Appendix 2, 
page 82.
bacteriophage typing 
A biological typing method based 
on the susceptibility of different 
strains of Staph. aureus to different 
bacteriophages (bacterial viruses). 
Standard drops of a number 
of different ‘phages are placed 
on a nutrient agar plate already 
inoculated with the bacterial isolate 
to establish the strain. ‘Phage typing 
used in the 1950s was set out by 
Fisk [(1942)], who showed that 
many strains of Staph. aureus carried 
bacteriophages that could lyse or 
destroy some strains, but not all. 
See Williams et al. (1960): 26; Tarr 
(1958), see also Figures 2 and 13.
chlorhexidine 
A dermal antiseptic used in gel and 
powder form to treat nasal carriers 
of MRSA, but with limited success.
cloxacillin (Orbenin®, Beecham 
Pharmaceuticals)
An oral penicillinase-resistant 
penicillin, a variant of oxacillin 
with an extra chlorine atom, 
introduced in 1962; it is used to 
treat infections with staphylococci 
resistance to penicillin.
colonization by MRSA 
The spread of bacteria from one 
location, such as the nose, to the 
skin and from there to surfaces 
and other people. Colonization 
becomes a serious problem in a 
hospital setting with plastic devices 
and textiles to which the bacteria 
can easily spread. The majority of 
patients from whom MRSA strains 
Glossary*
* Terms in bold appear in the Glossary as separate entries
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are isolated are already colonized by 
the bacteria. See HPA (2007b): 6.
commensal 
Normal flora; a harmless microbial 
association with a healthy host, 
who is asymptomatic.
daptomycin (Cubicin®; Novartis 
Europharm Ltd) 
An acid lipopeptide antibiotic 
derived from Streptomyces roseosporus, 
a class of antimicrobial agents 
known as the peptolides, active 
against MRSA and vancomycin-
resistant Gram-positive bacteria, 
including enterococci. European 
Union approval was received in 
2006. The antibiotic has been 
available in the UK for treatment of 
bacteraemia and right-sided infective 
endocarditis since 2007. See www.
nelm.nhs.uk/Record%20Viewing/
vR.aspx?id=584977 (visited 8 
October 2007). For nomenclature, 
see Filip and Cavelier (2004).
electrophoresis 
A technique using an electrical field 
to separate a mixture of molecules 
by their differential migration 
through a gel or on specially 
prepared paper.
epidemic MRSA (EMRSA) 
Strains with mecA genes 
and a property described as 
‘epidemigenicity’ or ‘epidemicity’. 
See pages 24 and 34.
 
epimers 
Variants of a molecule with the 
same chemical structure but in a 
different steric arrangement, for 
example, differing only in the 
relative position of hydrogen and 
hydroxyl groups.
episomal or extrachromosomal 
Refers to a genetic element separate 
from the chromosome.
European Antimicrobial 
Resistance Surveillance System 
(EARSS) 
A European epidemiological 
network devoted to antibiotic-
resistant pathogens. It provides 
reference data on antimicrobial 
resistance and is funded by 
the European Commission’s 
Directorate-General for Health and 
Consumer Affairs (DG SANCO). 
See www.rivm.nl/earss/ (visited 15 
January 2008). See also Figure 7.
flucloxacillin (Floxapen®, Beecham 
Pharmaceuticals) 
A semi-synthetic penicillin, a 
derivative of 6-APA, containing one 
chlorine and one fluorine atom, 
better absorbed from the gut. It 
replaced cloxacillin in 1970 and 
is used to treat penicillin-resistant 
staphylococci.
glycopeptides 
Antimicrobials, such as vancomycin 
and teicoplanin, that inhibit the 
synthesis of the bacterial wall and 
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are used to treat Gram-positive 
infections including multi-resistant 
staphylococci.
Gram-positive bacteria 
An organism that stains purple 
when treated with Gram’s stain.
The Gram-negatives stain red, a 
property thought to be associated 
with possession of a second, outer 
membrane in addition to the 
normal cytoplasmic membrane. See 
Health Protection Agency (2007a). 
Health Protection Agency (HPA) 
A non-departmental public 
body, independent of the UK 
Department of Health, created to 
provide support and advice to the 
NHS, local authorities, emergency 
services, and other agencies, as well 
as the Department of Health and 
the Devolved Administrations. 
Radiation protection became 
part of the HPA remit in 2005, 
replacing the National Radiological 
Protection Board. Its three 
major centres are the Centre for 
Infections at Colindale, the base for 
communicable disease surveillance 
and specialist microbiology; the 
Centre for Radiation, Chemical 
and Environmental Hazards, 
based at Chilton; and the Centre 
for Emergency Preparedness and 
Response at Porton, focusing on 
applied microbiological research 
and emergency response. For details 
of their current structure, see  
www.hpa.org.uk/default.htm 
(visited 11 February 2008).
infection, MRSA 
A minority of patients from whom 
MRSA strains are isolated are 
infected by the MRSA, although 
the proportion of colonized 
patients who later become infected 
varies between 5 and 60 per cent, 
depending on the population 
studied. See HPA (2007b): 6.
linezolid (Zyvox®, Pharmacia) 
An oxazolidinone antimicrobial 
approved by the UK MHRA 
[Medicines and Healthcare 
Products Regulatory Agency] in 
January 2001, sometimes used 
for the treatment of MRSA and 
vancomycin-resistant enterococci.
mecA gene 
The gene that confers methicillin 
resistance to Staphylococcus 
aureus. It can be detected by the 
polymerase chain reaction (PCR) 
method.
methicillin (BRL 1241; Celbenin®, 
Beecham Pharmaceuticals) 
A β-lactam antibiotic first 
introduced by the Beecham 
Research Laboratories in 1960 
and discontinued in 1993. It was 
suitable for treating infections 
caused by penicillin-resistant 
staphylococci because it was resistant 
to staphylococcal β-lactamase, but 
not to acid, and thus could not be 
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given orally. See Barber (1961): 
385. The trade name, Celbenin, was 
formed from the name of C E L 
Bencard. See Tansey and Reynolds 
(eds) (2000): 31.
molecular methods for typing 
Staph. aureus strains 
Molecular typing methods include 
pulsed field gel electrophoresis 
(PFGE) and PCR ribotyping. For 
an evaluation of these methods 
on UK strains, see Hookey et al. 
(1998).
MRSA (methicillin-resistant/
multidrug-resistant  
Staphylococcus aureus) 
Penicillin-resistant staphylococci 
were isolated with increasing 
frequency in the 1950s following 
widespread clinical usage of 
penicillin G [benzyl penicillin] and 
resistance was shown to be due 
to the production of β-lactamase, 
an enzyme that inactivates the 
β-lactam molecule. Methicillin is 
stable to staphylococcal β-lactamase 
and shows marked activity against 
most β-lactamase-producing 
staphylococci, but methicillin-
resistant strains (MRSA) possess 
a modified penicillin-binding 
protein (PBP2a or PBP2´) with 
reduced affinity to methicillin or 
other β-lactams. The modified PBP 
is synthesized by a chromosomally 
acquired gene (mecA), located on a 
transposon, which enables spread 
between staphylococcal species.
The transition from ‘methicillin-
resistant’ to ‘multi-resistant’ has 
been gradual and is still incomplete. 
This term has continued to be 
widely used since methicillin 
became obsolete.
MRSA test 
See automated laboratory 
techniques for detecting 
antimicrobial resistance
mupirocin (pseudomonic 
acid; Bactroban®; Beecham 
Pharmaceuticals) 
An antibacterial preparation 
that received a UK marketing 
authorization (product licence) 
in 2001 and has been found to 
have remarkable activity as a 
topical treatment suitable for nasal 
carriage and skin infections due 
to staphylococci, as it is unrelated 
to other antibiotics and thus has 
no cross-resistance. See Hill et al. 
(1988); Casewell and Hill (1991).
neomycin 
An aminoglycoside widely used 
during the 1950s, now considered 
too toxic for systemic use and 
restricted to topical application. 
nosocomial infection
A hospital-acquired infection.
Panton–Valentine leuc[k]ocidin 
(PVL) 
A major virulence factor of 
Staphylococcus aureus, whose 
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action impairs the respiratory 
activity of leucocytes, leading to 
their destruction. First described by  
P N Panton, Director of the Hale 
Clinical Laboratories, London 
Hospital, and F C O Valentine his 
Assistant Director. See Panton and 
Valentine (1932).
penicillinase-resistant penicillins 
Penicillins, such as methicillin 
and cloxacillin, that are resistant 
to hydrolysis by staphylococcal 
penicillinase. 
penicillin-binding proteins (PBPs) 
The enzymes that carry out 
the final stages of cell wall 
(peptidoglycan) synthesis are 
inhibited by penicillin, resulting 
in a number of effects, including 
cell lysis and death. They 
were identified in 1975 as the 
physiological targets of penicillin 
and other lactam antibiotics. 
MRSA strains make an additional 
PBP that allows the bacteria to 
evade the action of β-lactam 
antibiotics. See Spratt (1975). 
penicillins, isoxazolyl 
Derivatives of 6-APA, including 
oxacillin (the first of the isoxazolyls), 
cloxacillin, dicloxacillin and 
flucloxacillin.
penicillins, quinoline-associated 
For example, quinacillin (Boots), 
approved in 1961 and never used 
therapeutically.
‘phage typing 
See bacteriophage typing.
polymerase chain reaction (PCR) 
A fast technique for making an 
unlimited number of copies of 
any piece of DNA and used as a 
procedure to detect the mecA gene 
in the chromosomal DNA of an 
MRSA sample. For the background 
to this 1986 discovery for which 
Kary Mullis shared the 1993 
Nobel Prize for Chemistry, see 
http://nobelprize.org/chemistry/
laureates/1993/mullis-lecture.html 
(visited 19 February 2008).
pre-admission screening 
Some hospitals have introduced a 
clinic for patients with a planned 
admission to attend in advance 
for blood tests, an ECG and a 
chest X-ray, as well as an MRSA 
test, which involves a nose and 
sometimes a perineal swab, the 
results of which are available after 
24–48 hours. Patients testing 
positive with MRSA are given 
antibacterial soap and an ointment 
to reduce nasal carriage for use at 
home and are screened again before 
admission. Emergency patients are 
assumed to be carriers and tested on 
admission, automatically given the 
treatment and isolated from planned 
admissions. For a description of 
NHS patient screening and national 
targets, see Department of Health 
(2008): 10–13. 
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quinupristin-dalfopristin (Synercid®; 
May & Baker) 
An expensive injectible combination 
of two streptogramin agents (30:70 
ratio) that received a product 
licence in 1999 for the treatment of 
nosocomial pneumonia, skin and 
soft tissue infections when there 
are no other antibacterial agents 
active against the organisms. It is a 
derivative of Pristinamycin.  
See Lamb et al. (1999). 
resistance, multiple drug 
Some MRSA strains demonstrate 
resistance to as many as 20 
antimicrobial compounds, 
including antiseptics and 
disinfectants. See HPA (2007): 6.
scalded skin syndrome 
A staphylococcal disease caused 
by strains that produce an 
epidermolytic toxin, one that 
necroses the skin. 
staphylococcal bacteriophages 
Viruses that lyse (destroy) specific 
strains of Staphylococcus aureus. 
A set of different bacteriophages 
(see Appendix 2) is applied to 
strains of staphylococci and varying 
patterns of lyses are obtained with 
different strains, for example 
80/81, 6/7/53/75/77. ‘Phage type 
80/81 is a particularly virulent 
penicillin-resistant clone of Staph. 
aureus that has caused serious 
hospital-acquired and community-
acquired infections, which was 
largely eliminated by the use of 
penicillinase-resistant β-lactamase 
antibiotics.
Staphylococcus aureus 
A bacterium that may be found 
in nasal membranes, skin, hair 
follicles and perineum of healthy 
people and can cause superficial 
skin infections, boils and 
wound infection, but also, more 
rarely, pneumonia, meningitis, 
endocarditis and septicaemia. 
Its resistance to penicillin was 
described by Kirby in 1944. 
Staphylococcus Reference 
Laboratory 
Formed in 1949 as the 
Staphylococcus and Streptococcus 
Reference Laboratory by Dr R E 
O Williams. Currently it is part 
of the Laboratory of Healthcare 
Associated Infection, Centre for 
Infections, Colindale, London, of 
the Health Protection Agency. For 
a manual of services, see www.hpa.
org.uk/cfi/dhcaiar/DHCAIAR_
User_Manual.pdf (visited 19 
February 2008).
strain 
A characterized pure culture of 
bacteria descended from a single 
isolate.
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vancomycin (Vancocin®; Lilly)
A bactericidal antibiotic, whose 
name was derived from the verb ‘to 
vanquish’, isolated in the Eli Lilly 
Company laboratories in the US 
from a Streptomyces species found 
in soils obtained from Borneo and 
India, became available in 1956. 
Lilly were sole suppliers of the drug 
until 1983. Vancomycin-resistant 
Staphylococcus aureus (VRSA) 
have been described since 1995. 
See Fairbrother and Williams 
(1956); Kirst et al. (1998): 1303, 
Table 1 and Figure 1. See also the 
Supplement to Reviews of Infectious 
Diseases [(1981) 3: S199–300] 
entitled ‘Reassessments of 
vancomycin – a potentially  
useful antibiotic’; Griffith (1981); 
Figure 11. 
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abscesses, xxi, 8
adverse effects, 10, 50, 54, 60
aerosolized methicillin, 29, 33–4
airborne microbial transmission,  
22, 31
6-aminopenicillanic acid (6-APA), 13, 
46, 47
ampicillin (BRL1060, Beecham),  
13, 57
animal husbandry, 54, 77–8
antibiotic resistance , xxi, xxii, 6, 9, 
12–13, 15, 17–20, 23, 29, 36, 
37–9, 43, 47–8, 53–6. 69, 75, 
76, 125–31; see also β-lactamase 
resistance; cadmium resistance; 
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